U.S. patent application number 15/669219 was filed with the patent office on 2017-11-23 for novel anti-inflammatory agents.
The applicant listed for this patent is Resverlogix Corp.. Invention is credited to Sarah C. Attwell, Henrik C. Hansen, Ewelina B. Kulikowski, Kevin G. Mclure, Gregory S. Wagner.
Application Number | 20170333419 15/669219 |
Document ID | / |
Family ID | 42236704 |
Filed Date | 2017-11-23 |
United States Patent
Application |
20170333419 |
Kind Code |
A1 |
Hansen; Henrik C. ; et
al. |
November 23, 2017 |
NOVEL ANTI-INFLAMMATORY AGENTS
Abstract
Disclosed are methods of regulating interleukin-6 (IL-6) and/or
vascular cell adhesion molecule-1 (VCAM-1) and methods of treating
and/or preventing cardiovascular and inflammatory diseases and
related disease states, such as, for example, atherosclerosis,
asthma, arthritis, cancer, multiple sclerosis, psoriasis, and
inflammatory bowel diseases, and autoimmune disease(s) by
administering a naturally occurring or synthetic quinazolone
derivative. The invention provides novel synthetic quinazolone
compounds, as well as pharmaceutical compositions comprising those
compounds.
Inventors: |
Hansen; Henrik C.; (Calgary,
CA) ; Wagner; Gregory S.; (Foster City, CA) ;
Attwell; Sarah C.; (Calgary, CA) ; Mclure; Kevin
G.; (Calgary, CA) ; Kulikowski; Ewelina B.;
(Calgary, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Resverlogix Corp. |
Calgary |
|
CA |
|
|
Family ID: |
42236704 |
Appl. No.: |
15/669219 |
Filed: |
August 4, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13265060 |
Nov 22, 2011 |
9757368 |
|
|
PCT/US2010/031870 |
Apr 21, 2010 |
|
|
|
15669219 |
|
|
|
|
61171620 |
Apr 22, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 401/12 20130101;
C07D 215/36 20130101; A61P 9/00 20180101; A61P 7/00 20180101; A61P
11/02 20180101; A61K 31/47 20130101; A61P 11/06 20180101; C07D
403/12 20130101; A61P 29/02 20180101; A61P 17/06 20180101; A61P
1/00 20180101; A61P 19/02 20180101; A61P 35/00 20180101; A61P 3/00
20180101; A61P 13/12 20180101; A61P 35/02 20180101; A61P 21/00
20180101; A61P 37/02 20180101; A61K 9/4833 20130101; C07D 239/91
20130101; A61P 3/04 20180101; C07D 405/04 20130101; A61P 3/10
20180101; C07D 413/12 20130101; A61P 9/12 20180101; A61P 17/00
20180101; A61P 9/10 20180101; A61P 25/16 20180101; A61P 11/00
20180101; A61P 25/00 20180101; A61P 37/08 20180101; C07D 403/04
20130101; C07D 239/93 20130101; A61P 25/28 20180101; A61P 3/06
20180101; C07D 215/22 20130101; C07D 401/02 20130101; A61P 37/06
20180101; A61K 31/5025 20130101; A61P 27/02 20180101; A61P 29/00
20180101; A61K 31/517 20130101; A61P 43/00 20180101; A61P 9/04
20180101; C07D 487/04 20130101 |
International
Class: |
A61K 31/47 20060101
A61K031/47; C07D 405/04 20060101 C07D405/04; C07D 403/12 20060101
C07D403/12; C07D 403/04 20060101 C07D403/04; C07D 401/12 20060101
C07D401/12; C07D 413/12 20060101 C07D413/12; C07D 239/91 20060101
C07D239/91 |
Claims
1-46. (canceled)
47. A compound selected from
2-(4-(2-(benzyloxy)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]-
pyrimidin-4(3H)-one;
N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxy]-ethyl}-acetamide;
N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-di-
methyl-benzyl]-acetamide;
N-{2-[4-(6,8-dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxy]-ethyl}-formamide;
2-(2-hydroxymethyl-benzofuran-5-yl)-5,7-dimethoxy-3H-quinazolin-4-one;
7-(2-benzyloxy-ethoxy)-2-(2-hydroxymethyl-benzofuran-5-yl)-5-methoxy-3H-q-
uinazolin-4-one;
2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one;
2-[4-(2-hydroxy-ethoxy)-naphthalen-1-yl]-5,7-dimethoxy-3H-quinazolin-4-on-
e; and
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylpyrido[2,3-d-
]pyrimidin-4(3H)-one, or a pharmaceutically acceptable salt
thereof.
48. A compound selected from
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-morpholinoquinazolin-4(3H)-o-
ne;
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)-
methyl)quinazolin-4(3H)-one;
5,7-Dimethoxy-2-{3-methyl-4-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylamino)-eth-
oxy]-phenyl}-3H-quinazolin-4-one;
N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylbenzyl)-
acetamide;
2-[4-(2-hydroxyethoxy)-3,5-dimethyl-phenyl]-6-morpholin-4-ylmet-
hyl-3H-quinazolin-4-one;
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one hydrochloride;
2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-methylacetamide;
2-[4-(5,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-(4-methoxy-phenyl)-acetamide;
N-benzyl-2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimeth-
ylphenoxy]acetamide;
2-{3,5-Dimethyl-4-[2-(3-methyl-[1,2,4]oxadiazol-5-ylamino)-ethoxy]-phenyl-
}-5,7-dimethoxy-3H-quinazolin-4-one;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)acetamide;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)dimethylamino-N-sulfonamide;
2-(3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)phenyl)-5,7-dimet-
hoxyquinazolin-4(3H)-one;
2-(3,5-dimethyl-4-(2-(pyrimidin-2-ylamino)ethoxy)phenyl)-5,7-dimethoxyqui-
nazolin-4(3H)-one;
2-(4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquin-
azolin-4(3H)-one;
2-(4-(2-(4,6-dimethoxypyrimidin-2-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-
-dimethoxyquinazolin-4(3H)-one;
2-[4-(3-hydroxy-propyl)-3-methoxy-phenyl]-5,7-dimethoxy-3H-quinazolin-4-o-
ne; and
2-[4-(3-hydroxy-propyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-3H-quin-
azolin-4-one, or a pharmaceutically acceptable salt thereof.
49. A compound selected from
2-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinaz-
olin-4-one;
7-(2-benzyloxy-ethoxy)-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-met-
hoxy-3H-quinazolin-4-one;
2-{3,5-dimethyl-4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-phenyl}-5,7-dim-
ethoxy-3H-quinazolin-4-one;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)propane-2-sulfonamide;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylacetamide;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)formamide;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylformamide;
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)cyanamide;
7-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;
8-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-8-methoxyquinazolin-4(3H)-one;
5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;
5,7-difluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-o-
ne;
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3H-quina-
zolin-4-one;
2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;
2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin--
4-one;
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H-
)-one;
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquina-
zolin-4(3H)-one;
2-(4-(2-(isopropylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazol-
in-4(3H)-one;
2-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazoli-
n-4(3H)-one, or a pharmaceutically acceptable salt thereof.
50. A pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt thereof of claim 47 and a
pharmaceutically acceptable carrier.
51. A pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt thereof of claim 48 and a
pharmaceutically acceptable carrier.
52. A pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt thereof of claim 49 and a
pharmaceutically acceptable carrier.
53. A method for treating and/or preventing cardiovascular disease,
inflammatory disease, or cancer, characterized by altered
expression of IL-6 and/or VCAM-1, comprising administering a
therapeutically effective amount of at least one compound or
pharmaceutically acceptable salt thereof of claim 47.
54. A method for treating and/or preventing cardiovascular disease,
inflammatory disease, or cancer, characterized by altered
expression of IL-6 and/or VCAM-1, comprising administering a
therapeutically effective amount of at least one compound or
pharmaceutically acceptable salt thereof of claim 48.
55. A method for treating and/or preventing cardiovascular disease,
inflammatory disease, or cancer, characterized by altered
expression of IL-6 and/or VCAM-1, comprising administering a
therapeutically effective amount of at least one compound or
pharmaceutically acceptable salt thereof of claim 49.
56. The method of claim 53, wherein the cardiovascular disease is
selected from acute coronary syndrome, angina, arteriosclerosis,
atherosclerosis, carotid atherosclerosis, cerebrovascular disease,
cerebral infarction, congestive heart failure, congenital heart
disease, coronary heart disease, coronary artery disease, coronary
plaque stabilization, dyslipidemias, dyslipoproteinemias,
endothelium dysfunctions, familial hypercholeasterolemia, familial
combined hyperlipidemia, hypoalphalipoproteinemia,
hypertriglyceridemia, hyperbetalipoproteinemia,
hypercholesterolemia, hypertension, hyperlipidemia, intermittent
claudication, ischemia, ischemia reperfusion injury, ischemic heart
diseases, cardiac ischemia, metabolic syndrome, multi-infarct
dementia, myocardial infarction, obesity, peripheral vascular
disease, reperfusion injury, restenosis, renal artery
atherosclerosis, rheumatic heart disease, stroke, thrombotic
disorder, transitory ischemic attacks, and lipoprotein
abnormalities associated with Alzheimer's disease, obesity,
diabetes mellitus, syndrome X, impotence, multiple sclerosis, and
Parkinson's disease.
57. The method of claim 54, wherein the cardiovascular disease is
selected from acute coronary syndrome, angina, arteriosclerosis,
atherosclerosis, carotid atherosclerosis, cerebrovascular disease,
cerebral infarction, congestive heart failure, congenital heart
disease, coronary heart disease, coronary artery disease, coronary
plaque stabilization, dyslipidemias, dyslipoproteinemias,
endothelium dysfunctions, familial hypercholeasterolemia, familial
combined hyperlipidemia, hypoalphalipoproteinemia,
hypertriglyceridemia, hyperbetalipoproteinemia,
hypercholesterolemia, hypertension, hyperlipidemia, intermittent
claudication, ischemia, ischemia reperfusion injury, ischemic heart
diseases, cardiac ischemia, metabolic syndrome, multi-infarct
dementia, myocardial infarction, obesity, peripheral vascular
disease, reperfusion injury, restenosis, renal artery
atherosclerosis, rheumatic heart disease, stroke, thrombotic
disorder, transitory ischemic attacks, and lipoprotein
abnormalities associated with Alzheimer's disease, obesity,
diabetes mellitus, syndrome X, impotence, multiple sclerosis, and
Parkinson's disease.
58. The method of claim 55, wherein the cardiovascular disease is
selected from acute coronary syndrome, angina, arteriosclerosis,
atherosclerosis, carotid atherosclerosis, cerebrovascular disease,
cerebral infarction, congestive heart failure, congenital heart
disease, coronary heart disease, coronary artery disease, coronary
plaque stabilization, dyslipidemias, dyslipoproteinemias,
endothelium dysfunctions, familial hypercholeasterolemia, familial
combined hyperlipidemia, hypoalphalipoproteinemia,
hypertriglyceridemia, hyperbetalipoproteinemia,
hypercholesterolemia, hypertension, hyperlipidemia, intermittent
claudication, ischemia, ischemia reperfusion injury, ischemic heart
diseases, cardiac ischemia, metabolic syndrome, multi-infarct
dementia, myocardial infarction, obesity, peripheral vascular
disease, reperfusion injury, restenosis, renal artery
atherosclerosis, rheumatic heart disease, stroke, thrombotic
disorder, transitory ischemic attacks, and lipoprotein
abnormalities associated with Alzheimer's disease, obesity,
diabetes mellitus, syndrome X, impotence, multiple sclerosis, and
Parkinson's disease.
59. The method of claim 53, wherein the inflammatory disease is
selected from arthritis, asthma, dermatitis, psoriasis, cystic
fibrosis, post transplantation late and chronic solid organ
rejection, multiple sclerosis, systemic lupus erythematosus,
inflammatory bowel diseases, autoimmune diabetes, diabetic
retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular
inflammation, uveitis, rhinitis, ischemia-reperfusion injury,
post-angioplasty restenosis, chronic obstructive pulmonary disease
(COPD), glomerulonephritis, Graves disease, gastrointestinal
allergies, conjunctivitis, atherosclerosis, coronary artery
disease, angina, and small artery disease.
60. The method of claim 54, wherein the inflammatory disease is
selected from arthritis, asthma, dermatitis, psoriasis, cystic
fibrosis, post transplantation late and chronic solid organ
rejection, multiple sclerosis, systemic lupus erythematosus,
inflammatory bowel diseases, autoimmune diabetes, diabetic
retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular
inflammation, uveitis, rhinitis, ischemia-reperfusion injury,
post-angioplasty restenosis, chronic obstructive pulmonary disease
(COPD), glomerulonephritis, Graves disease, gastrointestinal
allergies, conjunctivitis, atherosclerosis, coronary artery
disease, angina, and small artery disease.
61. The method of claim 55, wherein the inflammatory disease is
selected from arthritis, asthma, dermatitis, psoriasis, cystic
fibrosis, post transplantation late and chronic solid organ
rejection, multiple sclerosis, systemic lupus erythematosus,
inflammatory bowel diseases, autoimmune diabetes, diabetic
retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular
inflammation, uveitis, rhinitis, ischemia-reperfusion injury,
post-angioplasty restenosis, chronic obstructive pulmonary disease
(COPD), glomerulonephritis, Graves disease, gastrointestinal
allergies, conjunctivitis, atherosclerosis, coronary artery
disease, angina, and small artery disease.
62. The method of claim 53, wherein the cancer is selected from
uterine cancer, multiple myeloma, histiocytomas, plasmacytoma,
hormone-independent prostate cancer, cancer induced cachexia, B
cell lymphoma, and metastatic renal cell carcinoma.
63. The method of claim 54, wherein the cancer is selected from
uterine cancer, multiple myeloma, histiocytomas, plasmacytoma,
hormone-independent prostate cancer, cancer induced cachexia, B
cell lymphoma, and metastatic renal cell carcinoma.
64. The method of claim 55, wherein the cancer is selected from
uterine cancer, multiple myeloma, histiocytomas, plasmacytoma,
hormone-independent prostate cancer, cancer induced cachexia, B
cell lymphoma, and metastatic renal cell carcinoma.
Description
[0001] This application claims the benefit of U.S. Provisional
Application No. 61/171,620, filed Apr. 22, 2009, which is
incorporated herein by reference in its entirety.
[0002] The present invention relates to methods of regulating
interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1
(VCAM-1) and to methods of treating and/or preventing
cardiovascular and inflammatory diseases and related disease
states, such as, for example, atherosclerosis, asthma, arthritis,
cancer, multiple sclerosis, psoriasis, and inflammatory bowel
diseases, and autoimmune disease(s) by administering a naturally
occurring or synthetic quinazolone derivative. The invention
provides novel synthetic quinazolone compounds, as well as
pharmaceutical compositions comprising those compounds.
[0003] Coronary heart disease (CHD) remains a leading cause of
death in industrialized nations. A primary cause of CHD is
atherosclerosis, a disease characterized by the deposition of
lipids in the arterial vessel wall, resulting in a narrowing of the
vessel passages and, ultimately, hardening of the vascular
system.
[0004] It is generally accepted that atherosclerosis can begin with
local injury to the arterial endothelium, followed by monocyte
recruitment and maturation, and smooth muscle cell proliferation in
the intimal arterial layer, along with the deposition of lipids and
the accumulation of foam cells in the lesion. As the
atherosclerotic plaque develops, it progressively occludes more of
the affected blood vessel and can eventually lead to ischemia or
infarction. Thus, it continues to be desirable to develop
treatments to inhibit or prevent the progression of atherosclerosis
in patients in need thereof.
[0005] Cardiovascular disease has been linked to several causative
factors, including hypercholesterolemia, hyperlipidemia, and
vascular cell adhesion molecule-1 (VCAM-1) in vascular endothelial
cells. VCAM-1 promotes the adhesion of lymphocytes, monocytes,
eosinophils, and basophils. Certain melanoma cells can use VCAM-1
to adhere to the endothelium, and VCAM-1 may participate in
monocyte recruitment to atherosclerotic sites. As a result, VCAM-1
is of interest as a drug target.
[0006] The VCAM-1 gene is a member of the immunoglobulin (Ig)
superfamily and encodes a cell-surface sialoglycoprotein expressed
by cytokine-activated endothelial cells. This type-1 membrane
protein mediates leukocyte-endothelial cell adhesion and signal
transduction, and may play a role in the development of
artherosclerosis and rheumatoid arthritis. VCAM-1, also known as
CD106, has several roles in the immune system. The VCAM-1 protein
contains six or seven immunoglobulin domains, and is expressed in
both large and small vessels only after endothelial cells are
stimulated by cytokines.
[0007] Adhesion of leukocytes to the endothelium represents a
fundamental, early event in many inflammatory conditions, including
atherosclerosis, autoimmune disorders, and bacterial and viral
infections. Leukocyte recruitment to the endothelium begins when
inducible adhesion molecule receptors on the surface of endothelial
cells interact with their counter-receptors on immune cells.
Vascular endothelial cells determine which type(s) of leukocyte(s)
(e.g., monocytes, lymphocytes, neutrophils) are recruited, by
selectively expressing specific adhesion molecules, such as VCAM-1,
intracellular adhesion molecule-1 (ICAM-1), and E-selectin.
[0008] In the early stage of the atherosclerotic lesion, there is
localized endothelial expression of VCAM-1 and selective
recruitment of mononuclear leukocytes that express the integrin
counter-receptor VLA-4. Because of the selective expression of
VLA-4 on monocytes and lymphocytes, but not neutrophils, VCAM-1 is
important in mediating the selective adhesion of mononuclear
leukocytes. Subsequent conversion of leucocytes to foamy
macrophages results in the synthesis of a wide variety of
inflammatory cytokines, growth factors, and chemoattractants that
help expand leukocyte and platelet recruitment, smooth muscle cell
proliferation, endothelial cell activation, and the extracellular
matrix synthesis characteristic of maturing atherosclerotic
plaques.
[0009] VCAM-1 is a mediator in chronic inflammatory disorders, such
as asthma, rheumatoid arthritis, and diabetes. For example, it is
known that VCAM-1 and ICAM-1 is increased in asthmatics (Pilewski
et al. (1995) Am. J. Respir. Cell Mol. Biol. 12, 1-3; Ohkawara et
al. (1995) Am J. Respir. Cell Mol. Biol. 12, 4-12). Further
examples of non-cardiovascular inflammatory diseases mediated by
VCAM-1 include rheumatoid and osteoartitis, asthma, dermatitis, and
multiple sclerosis. Blocking the integrin receptors for VCAM-1 and
ICAM-1 (VLA-4 and LFA-1, respectively) suppresses both early- and
late-phase responses in an ovalbumin-sensitized rat model of
allergic airway responses (Rabb et al. (1994) Am. J. Respir. Care
Med. 149, 1186-1191). There is also increased expression of
endothelial adhesion molecules, including VCAM-1, in the
microvasculature of rheumatoid synovium (Koch et al. (1991) Lab.
Invest. 64, 313-322; Morales-Ducret et al. (1992) Immunol. 149,
1421-31).
[0010] Neutralizing antibodies directed against VCAM-1 or its
counter receptor, VLA-4, can delay the onset of diabetes in a mouse
model (NOD mice) which spontaneously develop the disease (Yang et
al. (1993) Proc. Natl. Acad. Sci. USA 90, 10494-10498; Burkly et
al. (1994) Diabetes 43, 523-534; Baron et al. (1994) J. Clin.
Invest. 93, 1700-1708). Monoclonal antibodies to VCAM-1 can also
have beneficial effects in animal models of allograft rejection,
suggesting that inhibitors of VCAM-1 expression may also have
utility in preventing transplant rejection (Oroez et al. (1992)
Immunol. Lett. 32, 7-12).
[0011] VCAM-1 is expressed by cells both in a membrane-bound form
and a soluble form. The soluble form has been shown to induce
chemotaxis of vascular endothelial cells in vitro and to stimulate
an angiogenic response in rat cornea (Koch et al. (1995) Nature
376, 517-519). Inhibitors of VCAM-1 have potential therapeutic
value in treating diseases with an angiogenic component, including
tumor growth and metastasis (Folkman & Shing (1992) Biol. Chem.
10931-10934).
[0012] Because cardiovascular disease is currently a leading cause
of death and disability in the developed world, there is a strong
need to identify new methods and pharmaceutical agents for its
treatment. Thus, there is a need to identify and manipulate
synthetic compounds that can affect mediators of the inflammatory
process, such as, for example, VCAM-1.
[0013] Interleukin-6 (IL-6) is a 22-27-kDa secreted glycoprotein
that exhibits growth stimulatory and pro-inflammatory activities.
IL-6 has also been called interferon-.beta.2 (IFN-.beta.2),
IL-1-inducible 26-kDa protein, hepatocyte-stimulating factor,
cytotoxic T-cell differentiation factor, and B-cell stimulatory
factor (Trikha et al. (2003) Clin. Cancer Res. 9, 4653-4665). IL-6
was originally identified in monocytes/macrophages, fibroblasts,
and endothelial cells.
[0014] IL-6 is secreted by various cell types and exerts its
activities by binding to a high-affinity receptor complex,
consisting of two membrane glycoproteins, an 80-kDa component
receptor that binds IL-6 with low affinity (IL-6R) and a
signal-transducing component of 130 kDa (also known as gp130) that
does not bind IL-6 itself, but is required for high-affinity
binding of IL-6 by the complex. The IL-6R can be cleaved by a
transmembrane metalloproteinase to yield a soluble IL-6R.
[0015] IL-6 levels are rapidly elevated in the circulation in
numerous infectious, inflammatory, and autoimmune diseases, and in
some cancers, in association with increased synthesis of other
cytokines, stimulated by infection, trauma, and immunological
challenge. (Trikha et al. (2003) Clin. Cancer Res. 9, 4653-4665).
IL-6 has been implicated in various diseases and disorders,
including multiple myeloma (Rossi et al. (2005) Bone Marrow
Transplantation 36, 771-779), lymphomas (Emilie et al. (1994) Blood
84, 2472-2479), neurological disorders, such as neurodegeneration,
astrocytosis, and cerebral angiogenesis (Campbell et al. (1993)
Proc. Natl. Acad. Sci. USA 90, 10061-10065), autoimmune disorders
(such as, e.g., rheumatoid arthritis), inflammatory diseases,
Alzheimer's disease, myocardial infarction, Paget's disease,
osteoporosis, solid tumors, prostate and bladder cancers (Trikha et
al. (2003) Clin. Cancer Res. 9, 4653-4665), septic shock,
transplants, acute infections of the central nervous system,
cardiac myxoma (Wijdenes et al. (1991) Mol. Immunol. 28,
1183-1192), tumor-induced cachexia (Cahlin et al. (2000) Cancer
Res. 60, 5488-5489), cancer-associated depression, and cerebral
edema secondary to brain tumors (Musselman et al. (2001) Am. J.
Psychiatry 158, 1252-1257). Inflammation and IL-6 are now
specifically thought to be linked to heart attacks (Taubes (2002)
Science 296, 242).
[0016] Generally, it is known that IL-6 is abnormally produced in
some inflammatory, autoimmune, and neoplastic diseases; further, it
has been proposed that abnormal production of IL-6 is an aspect of
the mechanisms of these diseases (Hirano et al. (1990) Immunol.
Today, 11, 443-449; Sehgal (1990) Proc. Soc. Exp. Biol. Med. 195,
183-191; Grau (1990) Eur. Cytokine Net 1, 203-210; Bauer et al.
(1991) Ann. Hematol. 62, 203-210; Campbell et al. (1991) J. Clin.
Invest. 7, 739-742; Roodman et al. (1992) J. Clin. Invest. 89,
46-52). In particular, it is known that IL-6 is associated with
neuropathological processes, and its level in blood is increased in
diseases invading the central nervous system. It has been found
that IL-6 increases the level of tau epitope, by stimulating the
dementia-associated phosphorylation of the tau protein in neuronal
cells (Quintanilla et al. (2004) Exp. Cell Res. 295, 245-257), and
mice lacking IL-6 have enhanced resistance to glutamate toxicity
and increased viability of neuronal cells (Fisher et al. (2001) J.
Neuroimmunol. 119, 1-9). It has also been found that IL-6 amplifies
a calcium influx signal for the neurotransmitter
N-methyl-D-aspartate (NMDA), through voltage-sensitive calcium
channels, which provides a clue that the increased IL-6 level may
have a role in inducing pathological changes in central nervous
system diseases (Qiu et al. (1998) 18, 10445-10456). It has also
been reported that the abnormal levels of IL-6 is a pathogenic
mechanism in other diseases, including cardiac myxoma, uterine
cancer (Kishimoto et al. (1988) Ann. Rev. Immunol. 6, 485; multiple
myeloma; histiocytomas (Taga et al. (1987) J. Exp. Med. 166, 967),
plasmacytoma, hematological diseases, including plasma cell
dyscrasias, leukemia, and lymphoma (Kishimoto (1989) Blood 74, 1;
Taga et al. (1987) J. Exp. Med. 166, 967; Klein et al. (1991) Blood
78, 1198-1204); proliferative glomerulonephritis; activated
multiclonal B-cell (types I-IV) allergic diseases, rheumatoid
arthritis (Hirano et al. (1988) Eur. J. Immunol. 18, 1797),
diabetes (Campbell et al. (1991) J. Clin. Invest. 87, 739-742),
multiple sclerosis, SLE, septic shock, bacterial infections, viral
infections, osteoporosis (Roodman et al. (1992) J. Clin. Invest.
89, 46-52; Jilka et al. (1992) Science 257, 88-91); chronic
immunodeficiency syndrome and autoimmune immunodeficiency
syndromes, including AIDS (Med. Immunol. 15, 195-201 (1988)), and
inflammatory diseases, including inflammatory bowel diseases (such
as Crohn's disease and ulcerative colitis) (WO99/47170). It is
known that IL-6 is associated with some central nervous system
diseases (Frei et al. (1991) J. Neuroimmunol. 31, 147).
[0017] Interleukin-6 is secreted by many advanced cancers, such as
hormone-independent prostate cancer, and is believed to be a growth
factor for such cancers. Additionally, the secretion of IL-6 by
cancer cells is believed to cause cachexia, the wasting syndrome
characteristic of advanced cancers. Thus, reducing the level of
IL-6 would be useful in treating such cancers. IL-6 also plays a
key role in B cell development. Autoimmune diseases with a
significant antibody component, such as rheumatoid arthritis, could
be treated by decreasing IL-6 levels. Disorders involving B cell
proliferation, such as multiple myeloma and B cell lymphoma, could
also be treated by reducing IL-6 activity. Additionally, IL-6 plays
an important role in bone remodeling by promoting bone resorption.
Reducing IL-6 activity would have the effect of reducing bone
resorption and could be used to treat osteoporosis.
[0018] Accordingly, there have been various attempts to reduce the
levels of IL-6, which are believed to be associated with the
pathogenic mechanisms of these various diseases and conditions. A
steroid formulation has been used for suppressing the cytokines in
the art, but such medicines may causes severe side-effects, such as
peptic ulcers, if administered for an extended period.
[0019] Anti-IL-6 antibodies have been shown to be effective in
treating several diseases and disorders. For example, anti-IL-6
monoclonal antibodies have been shown to block the proliferation of
myeloma cells both in vivo and in vitro (Rossi et al. (2005) Bone
Marrow Transplantation 36, 771-779). Administration of anti-IL-6
antibodies to chronic rheumatoid arthritis patients was found to
alleviate the symptoms of the disease (Wendling et al. (1993) J.
Rheumatol. 20, 259-262). Anti-IL-6 antibodies have also been shown
to be effective in treating AIDS-associated lymphoma (Emilie et al.
(1994) Blood 84, 2472-2479), and metastatic renal cell carcinoma
(Blay et al. (1997) Int. J. Cancer 72, 424-430). Clinical results
involving the administration of anti-IL-6 antibodies to treat
various other diseases and disorders are summarized in Trikha et
al. (2003) Clin. Cancer Res. 9, 4653-4665.
[0020] Thus, the present invention provides methods of regulating
interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1)
in a mammal by administering one or more compounds of Formula I or
Formula II to the mammal. The invention also provides methods of
treating and/or preventing cardiovascular and inflammatory
diseases, such as, for example, atherosclerosis, asthma, arthritis,
cancer, multiple sclerosis, psoriasis, and inflammatory bowel
diseases, and autoimmune disease(s) in a mammal by administering
one or more compounds of Formula I or Formula II to the mammal. The
invention further provides novel compounds, pharmaceutical
compositions comprising those compounds, and methods of preparing
those compounds.
[0021] Without wishing to be bound by theory, it is believed that
the compounds of Formula I and II act by inhibiting expression of
IL-6 and/or VCAM-1 in the subject receiving the compound. However,
regardless of the mechanism of action, administration of one or
more compounds of Formula I and/or Formula II will reduce the
levels of IL-6 and/or VCAM-1 in the subject and as a result treat
or reduce the incidence of cardiovascular and/or inflammatory
diseases.
[0022] One aspect of the invention provides a method for reducing
IL-6 and/or VCAM-1 in a subject comprising administering to the
subject in need thereof, a therapeutically effective amount of at
least one compound of Formula I:
##STR00001##
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or
hydrate thereof, wherein:
[0023] Q is selected from N and CRa.sub.3;
[0024] V is selected from N and CRa.sub.4;
[0025] W is selected from N and CH;
[0026] U is selected from C.dbd.O, C.dbd.S, SO.sub.2, S.dbd.O, and
SR.sub.1;
[0027] X is selected from OH, SH, NH.sub.2, S(O)H, S(O).sub.2H,
S(O).sub.2NH.sub.2, S(O)NH.sub.2, NHAc, and NHSO.sub.2Me;
[0028] Ra.sub.1, Ra.sub.3, and Ra.sub.4 are independently selected
from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.3-C.sub.6 cycloalkyl, and halogen;
[0029] Ra.sub.2 is selected from hydrogen, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl, amino, amide,
and halogen;
[0030] Rb.sub.2 and Rb.sub.6 are independently selected from
hydrogen, methyl and fluorine;
[0031] Rb.sub.3 and Rb.sub.5 are independently selected from
hydrogen, halogen, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6
cycloalkyl, and C.sub.1-C.sub.6 alkoxy; and
[0032] Rb.sub.2 and Rb.sub.3 and/or Rb.sub.5 and Rb.sub.6 may be
connected to form a cycloalkyl or a heterocycle,
[0033] provided that at least one of Ra.sub.1, Ra.sub.2, Ra.sub.3,
and Ra.sub.4 is not hydrogen.
[0034] In certain embodiments, the method for reducing IL-6 and/or
VCAM-1 in a subject, comprises administering a therapeutically
effective amount of at least one compound of Formula II:
##STR00002##
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or
hydrate thereof, wherein:
[0035] P is selected from N and CRa.sub.1;
[0036] V is selected from N and CRa.sub.4;
[0037] W is selected from N and CH;
[0038] U is selected from C.dbd.O, C.dbd.S, SO.sub.2, S.dbd.O, and
SR.sub.1;
[0039] X is selected from O, S, CH.sub.2, and NH;
[0040] Ra.sub.1, Ra.sub.3, and Ra.sub.4 are independently selected
from hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.3-C.sub.6 cycloalkyl, and halogen;
[0041] Ra.sub.2 is selected from hydrogen, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, heterocycle, amide, amino, fluoro, and
bromo;
[0042] Rb.sub.2 and Rb.sub.6 are independently selected from
hydrogen, methyl, and fluoride;
[0043] Rb.sub.3 and Rb.sub.5 are independently selected from
hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, halogen, and amino;
[0044] Rb.sub.2 and Rb.sub.3 and/or Rb.sub.5 and Rb.sub.6 may be
connected to form a cycloalkyl, phenyl, or heterocycle; and
[0045] Rd is selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy, and C.sub.3-C.sub.6 cycloalkyl, wherein Rd may be connected
to Rb.sub.3 or Rb.sub.5 to form a heterocycle,
[0046] provided that
[0047] at least one of Ra.sub.1, Ra.sub.2, Ra.sub.3, and Ra.sub.4
is not hydrogen;
[0048] if --XRd is --OCH.sub.2CH.sub.2OH, then Rb.sub.3 is not
pyrrolidine; and
[0049] if --XRd is --OMe, then Ra.sub.2 is not
--CH.sub.2morpholino.
Definitions
[0050] As used in the present specification, the following words,
phrases and symbols are generally intended to have the meanings as
set forth below, except to the extent that the context in which
they are used indicates otherwise. The following abbreviations and
terms have the indicated meanings throughout:
[0051] The terms "compound of Formula I" and "compound of Formula
II" are intended to include any stereoisomer, tautomer, and/or
pharmaceutically acceptable salt as defined herein. Compounds of
Formula I and Formula II also include crystalline and amorphous
forms of those compounds, including, for example, polymorphs,
pseudopolymorphs, solvates, hydrates, unsolvated polymorphs
(including anhydrates), conformational polymorphs, and amorphous
forms of the compounds, as well as mixtures thereof. "Crystalline
form," "polymorph," and "novel form" may be used interchangeably
herein, and are meant to include all crystalline and amorphous
forms of the compound, including, for example, polymorphs,
pseudopolymorphs, solvates, hydrates, unsolvated polymorphs
(including anhydrates), conformational polymorphs, and amorphous
forms, as well as mixtures thereof, unless a particular crystalline
or amorphous form is referred to. Compounds of Formula I and
compounds of Formula II also included pharmaceutically acceptable
forms of the recited compounds, including chelates, non-covalent
complexes, prodrugs, and mixtures thereof.
[0052] As noted above, prodrugs also fall within the scope of
compounds of Formula I and compounds of Formula II. In some
embodiments, the "prodrugs" described herein include any compound
that becomes a compound of Formula I and/or Formula II when
administered to a patient, e.g., upon metabolic processing of the
prodrug. Examples of prodrugs include derivatives of functional
groups, such as a carboxylic acid group, in the compounds of
Formula I and/or Formula II. Exemplary prodrugs of a carboxylic
acid group include, but are not limited to, carboxylic acid esters
such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, and
aryloxyalkyl esters.
[0053] A "solvate" is formed by the interaction of a solvent and a
compound. The terms "compound of Formula I" and "compounds of
Formula II" are intended to include solvates of compounds.
Similarly, "salts" includes solvates of salts. Suitable solvates
are pharmaceutically acceptable solvates, such as hydrates,
including monohydrates and hemi-hydrates.
[0054] A "chelate" is formed by the coordination of a compound to a
metal ion at two (or more) points. The term "compound" is intended
to include chelates of compounds. Similarly, "salts" includes
chelates of salts.
[0055] A "non-covalent complex" is formed by the interaction of a
compound and another molecule wherein a covalent bond is not formed
between the compound and the molecule. For example, complexation
can occur through van der Waals interactions, hydrogen bonding, and
electrostatic interactions (also called ionic bonding). Such
non-covalent complexes are included in the term "compound".
[0056] As used herein, "cardiovascular disease" refers to diseases,
disorders and conditions of the heart and circulatory system that
are mediated by VCAM-1 and/or IL-6. Exemplary cardiovascular
diseases, including cholesterol- or lipid-related disorders,
include, but are not limited to, acute coronary syndrome, angina,
arteriosclerosis, atherosclerosis, carotid atherosclerosis,
cerebrovascular disease, cerebral infarction, congestive heart
failure, congenital heart disease, coronary heart disease, coronary
artery disease, coronary plaque stabilization, dyslipidemias,
dyslipoproteinemias, endothelium dysfunctions, familial
hypercholeasterolemia, familial combined hyperlipidemia,
hypoalphalipoproteinemia, hypertriglyceridemia,
hyperbetalipoproteinemia, hypercholesterolemia, hypertension,
hyperlipidemia, intermittent claudication, ischemia, ischemia
reperfusion injury, ischemic heart diseases, cardiac ischemia,
metabolic syndrome, multi-infarct dementia, myocardial infarction,
obesity, peripheral vascular disease, reperfusion injury,
restenosis, renal artery atherosclerosis, rheumatic heart disease,
stroke, thrombotic disorder, transitory ischemic attacks, and
lipoprotein abnormalities associated with Alzheimer's disease,
obesity, diabetes mellitus, syndrome X, impotence, multiple
sclerosis, Parkinson's diseases and an inflammatory diseases.
[0057] As used herein, "inflammatory diseases" includes refers to
diseases, disorders and conditions, that are mediated by VCAM-1
and/or IL-6. Exemplary inflammatory diseases, include, but are not
limited to, arthritis, asthma, dermatitis, psoriasis, cystic
fibrosis, post transplantation late and chronic solid organ
rejection, multiple sclerosis, systemic lupus erythematosus,
inflammatory bowel diseases, autoimmune diabetes, diabetic
retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular
inflammation, uveitis, rhinitis, ischemia-reperfusion injury,
post-angioplasty restenosis, chronic obstructive pulmonary disease
(COPD), glomerulonephritis, Graves disease, gastrointestinal
allergies, conjunctivitis, atherosclerosis, coronary artery
disease, angina, and small artery disease.
[0058] "Subject" refers to an animal, such as a mammal, that has
been or will be the object of treatment, observation, or
experiment. The methods described herein may be useful for both
human therapy and veterinary applications. In one embodiment, the
subject is a human.
[0059] As used herein, "treatment" or "treating" refers to an
amelioration of a disease or disorder, or at least one discernible
symptom thereof. In another embodiment, "treatment" or "treating"
refers to an amelioration of at least one measurable physical
parameter, not necessarily discernible by the patient. In yet
another embodiment, "treatment" or "treating" refers to reducing
the progression of a disease or disorder, either physically, e.g.,
stabilization of a discernible symptom, physiologically, e.g.,
stabilization of a physical parameter, or both. In yet another
embodiment, "treatment" or "treating" refers to delaying the onset
of a disease or disorder. For example, treating a cholesterol
disorder may comprise decreasing blood cholesterol levels.
[0060] As used herein, "prevention" or "preventing" refers to a
reduction of the risk of acquiring a given disease or disorder.
[0061] A dash ("-") that is not between two letters or symbols is
used to indicate a point of attachment for a substituent. For
example, --CONH.sub.2 is attached through the carbon atom.
[0062] By "optional" or "optionally" is meant that the subsequently
described event or circumstance may or may not occur, and that the
description includes instances where the event or circumstance
occurs and instances in which is does not. For example, "optionally
substituted aryl" encompasses both "aryl" and "substituted aryl" as
defined below. It will be understood by those skilled in the art,
with respect to any group containing one or more substituents, that
such groups are not intended to introduce any substitution or
substitution patterns that are sterically impractical,
synthetically non-feasible and/or inherently unstable.
[0063] The term "acyl" term as used herein refers to a carbonyl
radical attached to an alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycyl, aryl, or heteroaryl. Exemplary acyl groups include,
but are not limited to, acetyl, formyl, propionyl, benzoyl, and the
like.
[0064] The term "aldehyde" or "formyl" as used herein refers to
--CHO.
[0065] The term "alkenyl" as used herein refers to an unsaturated
straight or branched hydrocarbon having at least one carbon-carbon
double bond, such as a straight or branched group of 2-22, 2-8, or
2-6 carbon atoms, referred to herein as (C.sub.2-C.sub.22)alkenyl,
(C.sub.2-C.sub.8)alkenyl, and (C.sub.2-C.sub.6)alkenyl,
respectively. Exemplary alkenyl groups include, but are not limited
to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl,
pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, and
4-(2-methyl-3-butene)-pentenyl.
[0066] The term "alkoxy" as used herein refers to an alkyl group
attached to an oxygen (--O-alkyl-). "Alkoxy" groups also include an
alkenyl group attached to an oxygen ("alkenyloxy") or an alkynyl
group attached to an oxygen ("alkynyloxy") groups. Exemplary alkoxy
groups include, but are not limited to, groups with an alkyl,
alkenyl or alkynyl group of 1-22, 1-8, or 1-6 carbon atoms,
referred to herein as (C.sub.1-C.sub.22)alkoxy,
(C.sub.1-C.sub.8)alkoxy, and (C.sub.1-C.sub.6)alkoxy, respectively.
Exemplary alkoxy groups include, but are not limited to methoxy and
ethoxy.
[0067] The term "alkyl" as used herein refers to a saturated
straight or branched hydrocarbon, such as a straight or branched
group of 1-22, 1-8, or 1-6 carbon atoms, referred to herein as
(C.sub.1-C.sub.22)alkyl, (C.sub.1-C.sub.8)alkyl, and
(C.sub.1-C.sub.6)alkyl, respectively. Exemplary alkyl groups
include, but are not limited to, methyl, ethyl, propyl, isopropyl,
2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,
3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl,
2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,
2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,
2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl,
isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and
octyl.
[0068] The term "alkynyl" as used herein refers to an unsaturated
straight or branched hydrocarbon having at least one carbon-carbon
triple bond, such as a straight or branched group of 2-22, 2-8, or
2-6 carbon atoms, referred to herein as (C.sub.2-C.sub.22)alkynyl,
(C.sub.2-C.sub.8)alkynyl, and (C.sub.2-C.sub.6)alkynyl,
respectively. Exemplary alkynyl groups include, but are not limited
to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl,
4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl.
[0069] The term "amide" as used herein refers to the form
--NR.sub.aC(O)(R.sub.b)-- or --C(O)NR.sub.bR.sub.c, wherein
R.sub.a, R.sub.b and R.sub.c are each independently selected from
alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl,
heteroaryl, heterocyclyl, and hydrogen. The amide can be attached
to another group through the carbon, the nitrogen, R.sub.b, or
R.sub.c. The amide also may be cyclic, for example R.sub.b and
R.sub.c, may be joined to form a 3- to 12-membered ring, such as a
3- to 10-membered ring or a 5- or 6-membered ring. The term "amide"
encompasses groups such as sulfonamide, urea, ureido, carbamate,
carbamic acid, and cyclic versions thereof. The term "amide" also
encompasses an amide group attached to a carboxy group, e.g.,
-amide-COOH or salts such as -amide-COONa, an amino group attached
to a carboxy group (e.g., -amino-COOH or salts such as
-amino-COONa).
[0070] The term "amine" or "amino" as used herein refers to the
form --NR.sub.dR.sub.e or --N(R.sub.d)R.sub.e--, where R.sub.d and
R.sub.e are independently selected from alkyl, alkenyl, alkynyl,
aryl, arylalkyl, carbamate, cycloalkyl, haloalkyl, heteroaryl,
heterocyclyl, and hydrogen. The amino can be attached to the parent
molecular group through the nitrogen. The amino also may be cyclic,
for example any two of R.sub.d and R.sub.e may be joined together
or with the N to form a 3- to 12-membered ring (e.g., morpholino or
piperidinyl). The term amino also includes the corresponding
quaternary ammonium salt of any amino group. Exemplary amino groups
include alkylamino groups, wherein at least one of R.sub.d or
R.sub.e is an alkyl group.
[0071] The term "aryl" as used herein refers to a mono-, bi-, or
other multi-carbocyclic, aromatic ring system. The aryl group can
optionally be fused to one or more rings selected from aryls,
cycloalkyls, and heterocyclyls. The aryl groups of this invention
can be substituted with groups selected from alkoxy, aryloxy,
alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate,
carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen,
haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro,
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide,
and thioketone. Exemplary aryl groups include, but are not limited
to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and
naphthyl, as well as benzo-fused carbocyclic moieties such as
5,6,7,8-tetrahydronaphthyl. Exemplary aryl groups also include, but
are not limited to a monocyclic aromatic ring system, wherein the
ring comprises 6 carbon atoms, referred to herein as
"(C.sub.6)aryl."
[0072] The term "arylalkyl" as used herein refers to an alkyl group
having at least one aryl substituent (e.g., -aryl-alkyl-).
Exemplary arylalkyl groups include, but are not limited to,
arylalkyls having a monocyclic aromatic ring system, wherein the
ring comprises 6 carbon atoms, referred to herein as
"(C.sub.6)arylalkyl."
[0073] The term "aryloxy" as used herein refers to an aryl group
attached to an oxygen atom. Exemplary aryloxy groups include, but
are not limited to, aryloxys having a monocyclic aromatic ring
system, wherein the ring comprises 6 carbon atoms, referred to
herein as "(C.sub.6)aryloxy."
[0074] The term "arylthio" as used herein refers to an aryl group
attached to an sulfur atom. Exemplary arylthio groups include, but
are not limited to, arylthios having a monocyclic aromatic ring
system, wherein the ring comprises 6 carbon atoms, referred to
herein as "(C.sub.6)arylthio."
[0075] The term "arylsulfonyl" as used herein refers to an aryl
group attached to a sulfonyl group, e.g., --S(O).sub.2-aryl-.
Exemplary arylsulfonyl groups include, but are not limited to,
arylsulfonyls having a monocyclic aromatic ring system, wherein the
ring comprises 6 carbon atoms, referred to herein as
"(C.sub.6)arylsulfonyl."
[0076] The term "benzyl" as used herein refers to the group
--CH.sub.2-phenyl.
[0077] The term "bicyclic aryl" as used herein refers to an aryl
group fused to another aromatic or non-aromatic carbocylic or
heterocyclic ring. Exemplary bicyclic aryl groups include, but are
not limited to, naphthyl or partly reduced forms thereof, such as
di-, tetra-, or hexahydronaphthyl.
[0078] The term "bicyclic heteroaryl" as used herein refers to a
heteroaryl group fused to another aromatic or non-aromatic
carbocylic or heterocyclic ring. Exemplary bicyclic heteroaryls
include, but are not limited to 5,6- or 6,6-fused systems, wherein
one or both rings contain heteroatoms. The term "bicyclic
heteroaryl" also encompasses reduced or partly reduced forms of
fused aromatic system wherein one or both rings contain ring
heteroatoms. The ring system may contain up to three heteroatoms,
independently selected from oxygen, nitrogen, and sulfur. The
bicyclic system may be optionally substituted with one or more
groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl,
amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl,
heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide,
sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
Exemplary bicyclic heteroaryl's include, but are not limited to,
quinazolinyl, benzothiophenyl, benzoxazolyl, benzimidazolyl,
benzothiazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl,
phthalazinyl, benzotriazolyl, benzopyridinyl, and benzofuranyl.
[0079] The term "carbamate" as used herein refers to the form
--R.sub.gOC(O)N(R.sub.h)--, --R.sub.gOC(O)N(R.sub.h)R.sub.i--, or
--OC(O)NR.sub.hR.sub.i, wherein R.sub.g, R.sub.h and R.sub.i are
each independently selected from alkyl, alkenyl, alkynyl, aryl,
arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and
hydrogen. Exemplary carbamates include, but are not limited to,
arylcarbamates or heteroaryl carbamates (e.g., wherein at least one
of R.sub.g, R.sub.h and R.sub.i are independently selected from
aryl or heteroaryl, such as pyridine, pyridazine, pyrimidine, and
pyrazine).
[0080] The term "carbonyl" as used herein refers to --C(O)--.
[0081] The term "carboxy" as used herein refers to --COOH or its
corresponding carboxylate salts (e.g., --COONa). The term carboxy
also includes "carboxycarbonyl," e.g. a carboxy group attached to a
carbonyl group, e.g., --C(O)--COOH or salts, such as
--C(O)--COONa.
[0082] The term "cyano" as used herein refers to --CN.
[0083] The term "cycloalkoxy" as used herein refers to a cycloalkyl
group attached to an oxygen.
[0084] The term "cycloalkyl" as used herein refers to a saturated
or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon
group of 3-12 carbons, or 3-8 carbons, referred to herein as
"(C.sub.3-C.sub.8)cycloalkyl," derived from a cycloalkane.
Exemplary cycloalkyl groups include, but are not limited to,
cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes.
Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl,
alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate,
carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen,
haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro,
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide
and thioketone. Cycloalkyl groups can be fused to other cycloalkyl
saturated or unsaturated, aryl, or heterocyclyl groups.
[0085] The term "dicarboxylic acid" as used herein refers to a
group containing at least two carboxylic acid groups such as
saturated and unsaturated hydrocarbon dicarboxylic acids and salts
thereof. Exemplary dicarboxylic acids include alkyl dicarboxylic
acids. Dicarboxylic acids may be substituted with alkoxy, aryloxy,
alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate,
carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen,
haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone,
nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid,
sulfonamide and thioketone. Dicarboxylic acids include, but are not
limited to succinic acid, glutaric acid, adipic acid, suberic acid,
sebacic acid, azelaic acid, maleic acid, phthalic acid, aspartic
acid, glutamic acid, malonic acid, fumaric acid, (+)/(-)-malic
acid, (+)/(-) tartaric acid, isophthalic acid, and terephthalic
acid. Dicarboxylic acids further include carboxylic acid
derivatives thereof, such as anhydrides, imides, hydrazides (for
example, succinic anhydride and succinimide).
[0086] The term "ester" refers to the structure --C(O)O--,
--C(O)O--R.sub.j--, --R.sub.kC(O)O--R.sub.j--, or --R.sub.kC(O)O--,
where O is not bound to hydrogen, and R.sub.j and R.sub.k can
independently be selected from alkoxy, aryloxy, alkyl, alkenyl,
alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl, ether,
haloalkyl, heteroaryl, and heterocyclyl. R.sub.k can be a hydrogen,
but R.sub.j cannot be hydrogen. The ester may be cyclic, for
example the carbon atom and R.sub.j, the oxygen atom and R.sub.k,
or R.sub.j and R.sub.k may be joined to form a 3- to 12-membered
ring. Exemplary esters include, but are not limited to, alkyl
esters wherein at least one of R.sub.j or R.sub.k is alkyl, such as
--O--C(O)-alkyl, --C(O)--O-alkyl-, and -alkyl-C(O)--O-alkyl-.
Exemplary esters also include aryl or heteoraryl esters, e.g.
wherein at least one of R.sub.j or R.sub.k is a heteroaryl group
such as pyridine, pyridazine, pyrmidine and pyrazine, such as a
nicotinate ester. Exemplary esters also include reverse esters
having the structure --R.sub.kC(O)O--, where the oxygen is bound to
the parent molecule. Exemplary reverse esters include succinate,
D-argininate, L-argininate, L-lysinate and D-lysinate. Esters also
include carboxylic acid anhydrides and acid halides.
[0087] The term "ether" refers to the structure
--R.sub.lO--R.sub.m--, where R.sub.l and R.sub.m can independently
be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and
ether. The ether can be attached to the parent molecular group
through R.sub.l or R.sub.m. Exemplary ethers include, but are not
limited to, alkoxyalkyl and alkoxyaryl groups. Ethers also includes
polyethers, e.g., where one or both of R.sub.l and R.sub.m are
ethers.
[0088] The terms "halo" or "halogen" or "Hal" as used herein refer
to F, Cl, Br, or I.
[0089] The term "haloalkyl" as used herein refers to an alkyl group
substituted with one or more halogen atoms. "Haloalkyls" also
encompass alkenyl or alkynyl groups substituted with one or more
halogen atoms.
[0090] The term "heteroaryl" as used herein refers to a mono-, bi-,
or multi-cyclic, aromatic ring system containing one or more
heteroatoms, for example 1-3 heteroatoms, such as nitrogen, oxygen,
and sulfur. Heteroaryls can be substituted with one or more
substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl,
amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl,
heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide,
sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
Heteroaryls can also be fused to non-aromatic rings. Illustrative
examples of heteroaryl groups include, but are not limited to,
pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl,
pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl,
pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,
furyl, phenyl, isoxazolyl, and oxazolyl. Exemplary heteroaryl
groups include, but are not limited to, a monocyclic aromatic ring,
wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms,
referred to herein as "(C.sub.2-C.sub.5)heteroaryl."
[0091] The terms "heterocycle," "heterocyclyl," or "heterocyclic"
as used herein refer to a saturated or unsaturated 3-, 4-, 5-, 6-
or 7-membered ring containing one, two, or three heteroatoms
independently selected from nitrogen, oxygen, and sulfur.
Heterocycles can be aromatic (heteroaryls) or non-aromatic.
Heterocycles can be substituted with one or more substituents
including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester,
ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl,
hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl,
sulfonic acid, sulfonamide and thioketone. Heterocycles also
include bicyclic, tricyclic, and tetracyclic groups in which any of
the above heterocyclic rings is fused to one or two rings
independently selected from aryls, cycloalkyls, and heterocycles.
Exemplary heterocycles include acridinyl, benzimidazolyl,
benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl,
cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl,
dihydrothienyl, dithiazolyl, furyl, homopiperidinyl,
imidazolidinyl, imidazolinyl, imidazolyl, indolyl, isoquinolyl,
isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl,
morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl,
piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl,
pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl,
pyrrolidinyl, onyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxaloyl,
tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydropyranyl,
tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl,
thiazolyl, thienyl, thiomorpholinyl, thiopyranyl, and
triazolyl.
[0092] The terms "hydroxy" and "hydroxyl" as used herein refers to
--OH.
[0093] The term "hydroxyalkyl" as used herein refers to a hydroxy
attached to an alkyl group.
[0094] The term "hydroxyaryl" as used herein refers to a hydroxy
attached to an aryl group.
[0095] The term "ketone" as used herein refers to the structure
--C(O)--Rn (such as acetyl, --C(O)CH.sub.3 or
--R.sub.n--C(O)--R.sub.o--. The ketone can be attached to another
group through R.sub.n or R.sub.o. R.sub.n or R.sub.o can be alkyl,
alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl, or R.sub.n or
R.sub.o can be joined to form a 3- to 12-membered ring.
[0096] The term "monoester" as used herein refers to an analogue of
a dicarboxylic acid wherein one of the carboxylic acids is
functionalized as an ester and the other carboxylic acid is a free
carboxylic acid or salt of a carboxylic acid. Examples of
monoesters include, but are not limited to, to monoesters of
succinic acid, glutaric acid, adipic acid, suberic acid, sebacic
acid, azelaic acid, oxalic and maleic acid.
[0097] The term "nitro" as used herein refers to --NO.sub.2.
[0098] The term "perfluoroalkoxy" as used herein refers to an
alkoxy group in which all of the hydrogen atoms have been replaced
by fluorine atoms.
[0099] The term "perfluoroalkyl" as used herein refers to an alkyl
group in which all of the hydrogen atoms have been replaced by
fluorine atoms. Exemplary perfluroalkyl groups include, but are not
limited to, C.sub.1-C.sub.5 perfluoroalkyl, such as
trifluoromethyl.
[0100] The term "perfluorocycloalkyl" as used herein refers to a
cycloalkyl group in which all of the hydrogen atoms have been
replaced by fluorine atoms.
[0101] The term "phenyl" as used herein refers to a 6-membered
carbocyclic aromatic ring. The phenyl group can also be fused to a
cyclohexane or cyclopentane ring. Phenyl can be substituted with
one or more substituents including alkoxy, aryloxy, alkyl, alkenyl,
alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl,
heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide,
sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
[0102] The term "phosphate" as used herein refers to the structure
--OP(O)O.sub.2--, --R.sub.xOP(O)O.sub.2--, --OP(O)O.sub.2R.sub.y--,
or --R.sub.xOP(O)O.sub.2R.sub.y--, wherein R.sub.x and R.sub.y can
be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl,
hydrogen.
[0103] The term "sulfide" as used herein refers to the structure
--R.sub.zS--, where R.sub.z can be alkyl, alkenyl, alkynyl, aryl,
arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl. The
sulfide may be cyclic, forming a 3 to 12-membered ring. The term
"alkylsulfide" as used herein refers to an alkyl group attached to
a sulfur atom.
[0104] The term "sulfinyl" as used herein refers to the structure
--S(O)O--, --R.sub.pS(O)O--, --R.sub.pS(O)OR.sub.q--, or
--S(O)OR.sub.q--, wherein R.sub.p and R.sub.q can be alkyl,
alkenyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl,
heterocyclyl, hydroxyl. Exemplary sulfinyl groups include, but are
not limited to, alkylsulfinyls wherein at least one of R.sub.p or
R.sub.q is alkyl, alkenyl, or alkynyl.
[0105] The term "sulfonamide" as used herein refers to the
structure --(R.sub.r)--N--S(O).sub.2--R.sub.5-- or
--R.sub.t(R.sub.r)--N--S(O).sub.2--R.sub.s, where R.sub.t, R.sub.r,
and R.sub.s can be, for example, hydrogen, alkyl, alkenyl, alkynyl,
aryl, cycloalkyl, and heterocyclyl. Exemplary sulfonamides include
alkylsulfonamides (e.g., where R.sub.s is alkyl), arylsulfonamides
(e.g., where R.sub.s is aryl), cycloalkyl sulfonamides (e.g., where
R.sub.s is cycloalkyl), and heterocyclyl sulfonamides (e.g., where
R.sub.s is heterocyclyl).
[0106] The term "sulfonate" as used herein refers to --OSO.sub.3--.
Sulfonate includes salts such as --OSO.sub.3Na, --OSO.sub.3K and
the acid --OSO.sub.3H.
[0107] The term "sulfonic acid" refers to --SO.sub.3H-- and its
corresponding salts (e.g., --SO.sub.3K-- and --SO.sub.3Na--).
[0108] The term "sulfonyl" as used herein refers to the structure
R.sub.uSO.sub.2--, where R.sub.u can be alkyl, alkenyl, alkynyl,
aryl, cycloalkyl, and heterocyclyl (e.g., alkylsulfonyl). The term
"alkylsulfonyl" as used herein refers to an alkyl group attached to
a sulfonyl group. "Alkylsulfonyl" groups can optionally contain
alkenyl or alkynyl groups.
[0109] The term "thioketone" refers to the structure
--R.sub.v--C(S)--R.sub.w--. The ketone can be attached to another
group through R.sub.v or R.sub.w. R.sub.v or R.sub.w can be alkyl,
alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl, or R.sub.v or
R.sub.w can be joined to form a 3- to 12-membered ring.
[0110] "Alkyl" groups can be substituted with or interrupted by or
branched with at least one group selected from alkoxy, aryloxy,
alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate,
carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen,
haloalkyl, ketone, heteroaryl, heterocyclyl, hydroxyl, nitro,
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide,
thioketone, ureido and N. The substituents may be branched to form
a substituted or unsubstituted heterocycle or cycloalkyl.
[0111] "Alkenyl," "alkynyl", "alkoxy", "amino" and "amide" groups
can be substituted with or interrupted by or branched with at least
one group selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl,
amide, amino, aryl, arylalkyl, carbamate, carbonyl, carboxy, cyano,
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl,
heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide,
sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thioketone, ureido
and N. The substituents may be branched to form a substituted or
unsubstituted heterocycle or cycloalkyl.
[0112] As used herein, a "suitable substituent" refers to a group
that does not nullify the synthetic or pharmaceutical utility of
the compounds of the invention or the intermediates useful for
preparing them. Examples of suitable substituents include, but are
not limited to: C.sub.1-22, C.sub.1-8, and C.sub.1-6 alkyl, alkenyl
or alkynyl; C.sub.1-6 aryl, C.sub.2-5 heteroaryl; C.sub.3-7
cycloalkyl; C.sub.1-22, C.sub.1-8, and C.sub.1-6 alkoxy; C.sub.6
aryloxy; --CN; --OH; oxo; halo, carboxy; amino, such as
--NH(C.sub.1-22, C.sub.1-8, or C.sub.1-6 alkyl), --N(C.sub.1-22,
C.sub.1-8, and C.sub.1-6 alkyl).sub.2, --NH((C.sub.6)aryl), or
--N((C.sub.6)aryl).sub.2; formyl; ketones, such as --CO(C.sub.1-22,
C.sub.1-8, and C.sub.1-6 alkyl), --CO((C.sub.6 aryl) esters, such
as --CO.sub.2(C.sub.1-22, C.sub.1-8, and C.sub.1-6 alkyl) and
--CO.sub.2 (C.sub.6 aryl). One of skill in art can readily choose a
suitable substituent based on the stability and pharmacological and
synthetic activity of the compound of the invention.
[0113] The term "pharmaceutically acceptable carrier" as used
herein refers to any and all solvents, dispersion media, coatings,
isotonic and absorption delaying agents, and the like, that are
compatible with pharmaceutical administration. The use of such
media and agents for pharmaceutically active substances is well
known in the art. The compositions may also contain other active
compounds providing supplemental, additional, or enhanced
therapeutic functions.
[0114] The term "pharmaceutically acceptable composition" as used
herein refers to a composition comprising at least one compound as
disclosed herein formulated together with one or more
pharmaceutically acceptable carriers.
[0115] The term "pharmaceutically acceptable prodrugs" as used
herein represents those prodrugs of the compounds of the present
invention that are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response,
commensurate with a reasonable benefit/risk ratio, and effective
for their intended use, as well as the zwitterionic forms, where
possible, of the compounds of the invention. A discussion is
provided in Higuchi et al., "Prodrugs as Novel Delivery Systems,"
ACS Symposium Series, Vol. 14, and in Roche, E. B., ed.
Bioreversible Carriers in Drug Design, American Pharmaceutical
Association and Pergamon Press, 1987, both of which are
incorporated herein by reference.
[0116] The term "pharmaceutically acceptable salt(s)" refers to
salts of acidic or basic groups that may be present in compounds
used in the present compositions. Compounds included in the present
compositions that are basic in nature are capable of forming a wide
variety of salts with various inorganic and organic acids. The
acids that may be used to prepare pharmaceutically acceptable acid
addition salts of such basic compounds are those that form
non-toxic acid addition salts, i.e., salts containing
pharmacologically acceptable anions, including but not limited to
sulfate, citrate, matate, acetate, oxalate, chloride, bromide,
iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate,
isonicotinate, acetate, lactate, salicylate, citrate, tartrate,
oleate, tannate, pantothenate, bitartrate, ascorbate, succinate,
maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate,
formate, benzoate, glutamate, methanesulfonate, ethanesulfonate,
benzenesulfonate, p-toluenesulfonate and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds
included in the present compositions that include an amino moiety
may form pharmaceutically acceptable salts with various amino
acids, in addition to the acids mentioned above. Compounds included
in the present compositions, that are acidic in nature are capable
of forming base salts with various pharmacologically acceptable
cations. Examples of such salts include alkali metal or alkaline
earth metal salts and, particularly, calcium, magnesium, sodium,
lithium, zinc, potassium, and iron salts.
[0117] In addition, if the compounds described herein are obtained
as an acid addition salt, the free base can be obtained by
basifying a solution of the acid salt Conversely, if the product is
a free base, an addition salt, particularly a pharmaceutically
acceptable addition salt, may be produced by dissolving the free
base in a suitable organic solvent and treating the solution with
an acid, in accordance with conventional procedures for preparing
acid addition salts from base compounds. Those skilled in the art
will recognize various synthetic methodologies that may be used to
prepare non-toxic pharmaceutically acceptable addition salts.
[0118] The compounds of the disclosure may contain one or more
chiral centers and/or double bonds and, therefore, exist as
stereoisomers, such as geometric isomers, enantiomers or
diastereomers. The term "stereoisomers" when used herein consist of
all geometric isomers, enantiomers or diastereomers. These
compounds may be designated by the symbols "R" or "S," depending on
the configuration of substituents around the stereogenic carbon
atom. The present invention encompasses various stereoisomers of
these compounds and mixtures thereof. Stereoisomers include
enantiomers and diastereomers. Mixtures of enantiomers or
diastereomers may be designated "(.+-.)" in nomenclature, but the
skilled artisan will recognize that a structure may denote a chiral
center implicitly.
[0119] Individual stereoisomers of compounds of the present
invention can be prepared synthetically from commercially available
starting materials that contain asymmetric or stereogenic centers,
or by preparation of racemic mixtures followed by resolution
methods well known to those of ordinary skill in the art. These
methods of resolution are exemplified by (1) attachment of a
mixture of enantiomers to a chiral auxiliary, separation of the
resulting mixture of diastereomers by recrystallization or
chromatography and liberation of the optically pure product from
the auxiliary, (2) salt formation employing an optically active
resolving agent, or (3) direct separation of the mixture of optical
enantiomers on chiral chromatographic columns. Stereoisomeric
mixtures can also be resolved into their component stereoisomers by
well known methods, such as chiral-phase gas chromatography,
chiral-phase high performance liquid chromatography, crystallizing
the compound as a chiral salt complex, or crystallizing the
compound in a chiral solvent. Stereoisomers can also be obtained
from stereomerically-pure intermediates, reagents, and catalysts by
well known asymmetric synthetic methods.
[0120] Geometric isomers can also exist in the compounds of the
present invention. The present invention encompasses the various
geometric isomers and mixtures thereof resulting from the
arrangement of substituents around a carbon-carbon double bond or
arrangement of substituents around a carbocyclic ring. Substituents
around a carbon-carbon double bond are designated as being in the
"Z" or "E" configuration wherein the terms "Z" and "E" are used in
accordance with IUPAC standards. Unless otherwise specified,
structures depicting double bonds encompass both the E and Z
isomers.
[0121] Substituents around a carbon-carbon double bond
alternatively can be referred to as "cis" or "trans," where "cis"
represents substituents on the same side of the double bond and
"trans" represents substituents on opposite sides of the double
bond. The arrangements of substituents around a carbocyclic ring
are designated as "cis" or "trans." The term "cis" represents
substituents on the same side of the plane of the ring and the term
"trans" represents substituents on opposite sides of the plane of
the ring. Mixtures of compounds wherein the substituents are
disposed on both the same and opposite sides of plane of the ring
are designated "cis/trans."
[0122] The compounds disclosed herein may exist as tautomers and
both tautomeric forms are intended to be emcompassed by the scope
of the invention, even though only one tautomeric structure is
depicted. For example, any claim to compound A below is understood
to include tautomeric structure B, and vice versa, as well as
mixtures thereof.
##STR00003##
EXEMPLARY EMBODIMENTS
[0123] Formula I Methods and Compounds
[0124] In certain embodiments, the method for reducing IL-6 and/or
VCAM-1 in a subject and the method for treating an inflammatory or
cardiovascular disease comprise administering a therapeutically
effective amount of at least one compound of Formula I or a
stereoisomer, tautomer, pharmaceutically acceptable salt, or
hydrate thereof, wherein:
[0125] Q is selected from CRa.sub.3
[0126] V is selected from N and CRa.sub.4;
[0127] W is selected from N and CH;
[0128] U is C.dbd.O;
[0129] X is selected from OH, NH.sub.2, S(O).sub.2NH.sub.2, NHAc,
and NHSO.sub.2Me;
[0130] Ra.sub.1 is selected from hydrogen and C.sub.1-C.sub.6
alkoxy;
[0131] Ra.sub.2 is selected from hydrogen, C.sub.1-C.sub.6 alkoxy,
amino, amide, and C.sub.1-C.sub.6 alkyl;
[0132] Ra.sub.3 and Ra.sub.4 are independently selected from
hydrogen and C.sub.1-C.sub.6 alkoxy;
[0133] Rb.sub.2 and Rb.sub.6 are both hydrogen; and
[0134] Rb.sub.3 and Rb.sub.5 are independently selected from
C.sub.1-C.sub.6 alkyl and halogen.
[0135] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0136] U is C=0;
[0137] Q is selected from CRa.sub.3;
[0138] Ra.sub.3 is selected from hydrogen, methoxy,
##STR00004##
wherein
[0139] n is 0, 1, or 3;
[0140] R.sub.1, R.sub.1', R.sub.2, and R.sub.2' are independently
selected from hydrogen, C.sub.1-C.sub.3 alkyl, cyclopropyl, and
halogen wherein if n is 1, then R.sub.2 and R.sub.2', R.sub.1 and
R.sub.1', R.sub.1 and R.sub.2', or R.sub.2 and R.sub.1' may form a
double bond, wherein said double bond can be cis, trans, or a
mixture thereof;
[0141] Rx is selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6
cycloalkyl, and aryl;
[0142] Rn.sub.1 and Rn.sub.2 are independently selected from
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, and aryl;
and
[0143] V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.4, Rb.sub.2, Rb.sub.3,
Rb.sub.5, and Rb.sub.6 are as defined in paragraph [021].
[0144] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0145] U is C.dbd.O;
[0146] Ra.sub.3 is selected from hydrogen, methoxy,
##STR00005##
wherein
[0147] n is 1, 2, or 3;
[0148] R.sub.5 is selected from C.sub.1-C.sub.6 alkyl substituted
with one or more groups selected from methyl, phenyl, and
pyridinyl;
[0149] R.sub.6 and R.sub.7 are independently selected from
unsubstituted C.sub.1-C.sub.6 alkyl; and
[0150] Q, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0151] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0152] U is C.dbd.O;
[0153] Ra.sub.3 is selected from hydrogen, methoxy,
2-methoxy-ethoxy, 2-dimethylamino-ethoxy, 2-benzyloxy-ethoxy, and
2-(pyridin-3-ylmethoxy)ethoxy; and
[0154] Q, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0155] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0156] U is C.dbd.O;
[0157] V is selected from N and CRa.sub.4;
[0158] Ra.sub.4 is selected from hydrogen and unsubstituted
C.sub.1-C.sub.6 alkoxy; and
[0159] Q, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Rb.sub.2, Rb.sub.3,
Rb.sub.5, and Rb.sub.6 are as defined in paragraph [021].
[0160] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0161] U is C.dbd.O;
[0162] Ra.sub.4 is selected from hydrogen and methoxy; and
[0163] Q, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0164] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0165] U is C.dbd.O;
[0166] X is OH; and
[0167] Q, V, W, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0168] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0169] U is C.dbd.O;
[0170] Ra.sub.1 is selected from hydrogen, methoxy,
##STR00006##
wherein
[0171] n is 0, 1, or 3;
[0172] R.sub.1, R.sub.1', R.sub.2, and R.sub.2' are independently
selected from hydrogen, C.sub.1-C.sub.3 alkyl, cyclopropyl, and
halogen wherein if n is 1, then R.sub.2 and R.sub.2', R.sub.1 and
R.sub.1', R.sub.1 and R.sub.2', or R.sub.2 and R.sub.1' may form a
double bond, wherein said double bond can be cis, trans, or a
mixture thereof;
[0173] Rx is selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6
cycloalkyl, and aryl;
[0174] Rn.sub.1 and Rn.sub.2 are independently selected from
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, and aryl;
and
[0175] Q, V, W, X, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0176] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0177] U is C.dbd.O;
[0178] Ra.sub.1 is selected from hydrogen, methoxy,
##STR00007##
[0179] n is 1, 2, or 3;
[0180] R.sub.5, R.sub.6, and R.sub.7 are independently selected
from unsubstituted C.sub.1-C.sub.6 alkyl; and
[0181] Q, V, W, X, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0182] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0183] U is C.dbd.O;
[0184] Ra.sub.1 is selected from hydrogen, methoxy,
2-methoxy-ethoxy, and 2-dimethylamino-ethoxy; and
[0185] Q, V, W, X, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0186] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0187] U is C.dbd.O;
[0188] Ra.sub.2 is selected from hydrogen, unsubstituted
C.sub.1-C.sub.6 alkoxy, NHR.sub.9, and C.sub.1-C.sub.6 alkyl
substituted with heterocycle or amino;
[0189] R.sub.9 is selected from acyl, and heteroaryl; and
[0190] Q, V, W, X, Ra.sub.1, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0191] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0192] U is C.dbd.O;
[0193] Ra.sub.2 is selected from hydrogen, methoxy, acetamido,
morpholin-4-ylmethyl, pyridin-2-ylamino,
(4-methylpiperazin-1-yl)methyl, and methanesulfonamido; and
[0194] Q, V, W, X, Ra.sub.1, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in paragraph
[021].
[0195] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0196] U is C=0;
[0197] Rb.sub.3 and Rb.sub.5 are independently selected from
unsubstituted C.sub.1-C.sub.6 alkyl and halogen; and
[0198] Q, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, and Rb.sub.6 are as defined in paragraph [021].
[0199] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula I, wherein:
[0200] U is C=0;
[0201] Rb.sub.3 and Rb.sub.5 are independently selected from
methyl, tert-butyl, fluorine, and chlorine; and
[0202] Q, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, and Rb.sub.6 are as defined in paragraph [021].
[0203] In certain embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound selected
from: [0204]
3-(3-fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one; [0205]
3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;
[0206]
2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one-
; [0207]
7-(4-hydroxy-3,5-dimethylphenyl)-2,4-dimethoxy-1,6-naphthyridin-5-
(6H)-one; [0208]
2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
[0209]
2-(3-chloro-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
[0210]
2-(4-hydroxy-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one-
; [0211]
N-(2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-
-yl)acetamide; [0212]
2-(4-hydroxy-3,5-dimethylphenyl)-6-(morpholinomethyl)quinazolin-4(3H)-one-
; [0213]
2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimi-
din-4(3H)-one; [0214]
2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-6-(morpholinomethyl)quinaz-
olin-4(3H)-one; [0215]
5-(2-dimethylamino-ethoxy)-2(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-q-
uinazolin-4-one; [0216]
2-(4-hydroxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one; [0217]
7-(2-amino-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quinazo-
lin-4-one; [0218]
2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one; [0219]
7-(2-benzyloxy-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-qui-
nazolin-4-one; [0220]
2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)etho-
xy]-3H-quinazolin-4-one; [0221]
7-(2-dimethylamino-ethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-
-4-one; [0222]
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-o-
ne; [0223]
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-2-ylamino)-3H-quin-
azolin-4-one; [0224]
2-(4-hydroxy-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)methyl)quinaz-
olin-4(3H)-one; and [0225]
N-((2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)met-
hyl)methanesulfonamide, or a tatutomer, stereoisomer,
pharmaceutically acceptable salt, or hydrate thereof.
[0226] Another aspect of the invention provides compounds of
Formula I selected from: [0227]
5-(2-dimethylamino-ethoxy)-2(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-q-
uinazolin-4-one; [0228]
2-(4-hydroxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one; [0229]
7-(2-amino-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quinazo-
lin-4-one; [0230]
2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one; [0231]
7-(2-benzyloxy-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-qui-
nazolin-4-one; [0232]
2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)etho-
xy]-3H-quinazolin-4-one; [0233]
7-(2-dimethylamino-ethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-
-4-one; [0234]
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-o-
ne; [0235]
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-2-ylamino)-3H-quin-
azolin-4-one; [0236]
2-(4-hydroxy-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)methyl)quinaz-
olin-4(3H)-one; and [0237]
N-((2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)met-
hyl)methanesulfonamide, and tautomers, stereoisomers,
pharmaceutically acceptable salts, and hydrates thereof.
[0238] Formula II Methods and Compounds
[0239] In certain embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II or a stereoisomer, tautomer, pharmaceutically acceptable
salt, or hydrate thereof, wherein:
[0240] P is CRa.sub.1;
[0241] V is selected from N and CRa.sub.4;
[0242] W is selected from N and CH;
[0243] U is C.dbd.O;
[0244] X is selected from O, S, CH.sub.2, and NH;
[0245] Ra.sub.1 is selected from hydrogen, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, and halogen;
[0246] Ra.sub.3 is selected from hydrogen, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, heterocycle, amide, and amino;
[0247] Ra.sub.3 and Ra.sub.4 are independently selected from
hydrogen, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, and
halogen;
[0248] Rb.sub.2 and Rb.sub.6 are independently selected from
hydrogen, methyl, and fluoride;
[0249] Rb.sub.3 and Rb.sub.5 are independently selected from
hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, halogen, and amino, wherein Rb.sub.2 and
Rb.sub.3 and/or Rb.sub.5 and Rb.sub.6 may be connected to form a
phenyl ring; and
[0250] Rd is selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy, and C.sub.3-C.sub.6 cycloalkyl, wherein Rd may be connected
to Rb.sub.3 or Rb.sub.5 to form a heterocycle.
[0251] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0252] U is C=0;
[0253] Ra.sub.1 is selected from hydrogen, unsubstituted
C.sub.1-C.sub.6 alkyl, unsubstituted C.sub.1-C.sub.6 alkoxy, and
halogen; and
[0254] P, V, W, X, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0255] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0256] U is C.dbd.O; and
[0257] Ra.sub.1 is selected from hydrogen, methyl, methoxy,
chlorine, and fluorine; and
[0258] P, V, W, X, Ra.sub.2, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0259] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0260] U is C=0;
[0261] Ra.sub.2 is selected from hydrogen, C.sub.1-C.sub.6 alkyl
substituted with heterocyclyl, unsubstituted C.sub.1-C.sub.6
alkoxy, amino, and heterocycle; and
[0262] P, V, W, X, Ra.sub.1, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0263] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0264] U is C.dbd.O; and
[0265] Ra.sub.2 is selected from hydrogen, methoxy, acetamido,
morpholino, morpholin-4-ylmethyl, and
(4-methylpiperazin-1-yl)methyl; and
[0266] P, V, W, X, Ra.sub.1, Ra.sub.3, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0267] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0268] U is C.dbd.O;
[0269] Ra.sub.3 is selected from selected from hydrogen, methoxy,
unsubstituted C.sub.1-C.sub.6 alkyl, halogen, and
##STR00008##
[0270] n is 1, 2, or 3;
[0271] R.sub.5 is C.sub.1-C.sub.6 alkyl substituted with phenyl or
heteroaryl; and
[0272] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0273] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0274] U is C.dbd.O;
[0275] Ra.sub.3 is selected from selected from hydrogen, methoxy,
chlorine, fluorine, isopropoxy, methyl, 2-benzyloxy-ethoxy, and
2-(pyridin-3-ylmethoxy)ethoxy; and
[0276] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.4, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0277] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0278] U is C=0;
[0279] Ra.sub.4 is selected from hydrogen, unsubstituted
C.sub.1-C.sub.6 alkoxy, and halogen;
[0280] and
[0281] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Rb.sub.2,
Rb.sub.3, Rb.sub.5, Rb.sub.6, and Rd are as defined in paragraph
[022].
[0282] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0283] U is C.dbd.O;
[0284] Ra.sub.4 is hydrogen, methoxy, and chlorine; and P, V, W, X,
Ra.sub.1, Ra.sub.2, Ra.sub.3, Rb.sub.2, Rb.sub.3, Rb.sub.5,
Rb.sub.6, and Rd are as defined in paragraph [022].
[0285] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0286] U is C=0;
[0287] Rb.sub.3 and Rb.sub.5 are independently selected from
hydrogen, methyl, C.sub.1-C.sub.6 alkyl substituted with
heterocyclyl, and unsubstituted C.sub.1-C.sub.6 alkoxy wherein
Rb.sub.2 and Rb.sub.3 and/or Rb.sub.5 and Rb.sub.6 may be connected
to form a phenyl ring; and
[0288] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.6, and Rd are as defined in paragraph [022].
[0289] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0290] U is C.dbd.O;
[0291] Rb.sub.3 and Rb.sub.5 are independently selected from
hydrogen, methyl, methoxy, and morpholinomethyl, and wherein
Rb.sub.2 and Rb.sub.3 and/or Rb.sub.5 and Rb.sub.6 may be connected
to form a phenyl ring; and
[0292] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.6, and Rd are as defined in paragraph [022].
[0293] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0294] U is C.dbd.O;
[0295] Rd is selected from C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl,
##STR00009##
[0296] m is selected from 1, 2, or 3;
[0297] R.sub.1, R.sub.1', R.sub.2, and R.sub.2' are independently
selected from hydrogen, fluorine, C.sub.1-C.sub.6 alkyl, hydroxyl,
--NH.sub.2, and C.sub.1-C.sub.6 alkoxy wherein R.sub.2 and R.sub.2'
may be eliminated to form a double bond;
[0298] Y is selected from OH, SH, NH.sub.2, --Oalkyl, --Oaryl,
--CH.sub.2aryl, --C(O)NHalkyl, --C(O)N(alkyl).sub.2, --C(O)NHaryl,
--NHacyl, --NHalkyl, --NHS(O).sub.2alkyl, --N(alkyl).sub.2,
--NHS(O).sub.2N(alkyl).sub.2, --NHCN, and --NHC(O)N(alkyl).sub.2,
--NHheterocyclyl, and heterocyclyl;
[0299] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in
paragraph [022]; and
[0300] Rd may be connected to Rb.sub.3 or Rb.sub.5 to form a
heterocycle,
[0301] provided that for --N(alkyl).sub.2 the alkyl chains cannot
be joined to form an aryl or heterocyclic ring.
[0302] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0303] U is C=0;
[0304] Rd is connected to Rb.sub.3 or Rb.sub.5 to form a
heterocycle selected from substituted furanyl or substituted
pyrrolyl; and
[0305] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in
paragraph [022].
[0306] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0307] U is C.dbd.O;
[0308] Rd is connected to Rb.sub.3 or Rb.sub.5 to form a
heterocycle selected from 2-hydroxymethyl-furan-5-yl or
2-(4,5-dihydro-1H-pyrrol-2-yl)ethanol; and
[0309] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in
paragraph [022].
[0310] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0311] U is C.dbd.O;
[0312] X--Rd is selected from 2-hydroxy-2-methylpropoxy,
2-hydroxyethoxy, methoxy, benzyloxyethoxy, 2,3-dihydroxypropoxy,
aminocarbonylethoxy, methylaminocarbonylethoxy,
(4-methoxyphenyl)aminocarbonylethoxy, benzylaminocarbonylethoxy,
4-hydroxybutoxy, (5-phenyl-4H-[1,2,4]triazol-3-ylamino)ethoxy,
(3-methyl-[1,2,4]oxadiazol-5-ylamino)ethoxy,
methylcarbonylaminoethoxy, methylcarbonylaminomethyl,
(2,2,2-trifluoroethylamino)ethoxy, ethanesulfonylaminoethoxy,
isobutyrylaminoethoxy, methylaminoethoxy,
isopropylsulfonylaminoethoxy, methylcarbonylaminoethoxy,
dimethylaminoethoxy, N-(2-hydroxyethyl)-N-methylacetamide,
formamide-N-2-ethoxy, methylformamide-N-2-ethoxy,
dimethylsulfonylaminoethoxy, cyanoaminoethoxy,
(5-methylisoxazol-3-ylamino)ethoxy, (pyrimidin-2-ylamino)ethoxy,
(isoxazol-3-ylamino)ethoxy,
(4,6-dimethoxypyrimidin-2-ylamino)ethoxy, 3-hydroxypropyl, and
2-hydroxyethyl; and
[0313] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in
paragraph [022].
[0314] In some embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, wherein:
[0315] U is C.dbd.O;
[0316] X--Rd is selected from hydroxyethoxy,
methylcarbonylaminoethoxy, (4-methoxyphenyl)aminocarbonylethoxy,
and isobutyrylaminoethoxy; and
[0317] P, V, W, X, Ra.sub.1, Ra.sub.2, Ra.sub.3, Ra.sub.4,
Rb.sub.2, Rb.sub.3, Rb.sub.5, and Rb.sub.6 are as defined in
paragraph [022].
[0318] In certain embodiments, the method for reducing IL-6 and/or
VCAM-1 and the method for treating an inflammatory or
cardiovascular disease in a subject, comprises administering a
therapeutically effective amount of at least one compound of
Formula II, selected from: [0319]
3-(4-(2-hydroxy-2-methylpropoxy)-3,5-dimethylphenyl)-6,8-dimethoxyisoquin-
olin-1(2H)-one; [0320]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)--
one; [0321] 5,7-dimethoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one;
[0322]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)--
one; [0323]
5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-on-
e; [0324]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2-
,3-d]pyrimidin-4(3H)-one; [0325]
N-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-
-6-yl)acetamide; [0326]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-morpholinoquinazolin-4(3H)-o-
ne; [0327]
2-(4-(2-(benzyloxy)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyr-
ido[2,3-d]pyrimidin-4(3H)-one; [0328]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylpyrido[2,3-d]pyrim-
idin-4(3H)-one; [0329]
5,7-difluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-o-
ne; [0330]
5,7-dichloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazol-
in-4(3H)-one; [0331]
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3H-quinazol-
in-4-one; [0332]
2-[4-(2-hydroxyethoxy)-3,5-dimethyl-phenyl]-6-morpholin-4-ylmethyl-3H-qui-
nazolin-4-one; [0333]
2-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinaz-
olin-4-one; [0334]
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one; [0335]
2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;
[0336]
2-[4-(2-hydroxy-ethoxy)-naphthalen-1-yl]-5,7-dimethoxy-3H-quinazolin-4-on-
e; [0337]
2-(2-hydroxymethyl-benzofuran-5-yl)-5,7-dimethoxy-3H-quinazolin--
4-one; [0338]
7-(2-benzyloxy-ethoxy)-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-met-
hoxy-3H-quinazolin-4-one; [0339]
7-(2-benzyloxy-ethoxy)-2-(2-hydroxymethyl-benzofuran-5-yl)-5-methoxy-3H-q-
uinazolin-4-one; [0340]
2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-acetamide; [0341]
2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-methylacetamide; [0342]
2-[4-(5,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-(4-methoxy-phenyl)-acetamide; [0343]
N-benzyl-2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimeth-
ylphenoxy]acetamide; [0344]
2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin--
4-one; [0345]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-methoxyquinazolin-4(3H)-one;
[0346]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5-methoxyquinazolin-4(3-
H)-one; [0347]
7-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;
[0348]
8-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H-
)-one; [0349]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-8-methoxyquinazolin-4(3H)-one;
[0350]
5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H-
)-one; [0351]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H)-one;
[0352]
5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)quinazolin-4(3H)-one-
; [0353]
2-(4-(2-hydroxyethoxy)-3-methylphenyl)-5,7-dimethoxyquinazolin-4(-
3H)-one; [0354]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)met-
hyl)quinazolin-4(3H)-one; [0355]
5,7-Dimethoxy-2-{3-methyl-4-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylamino)-eth-
oxyl]-phenyl}-3H-quinazolin-4-one; [0356]
2-{3,5-Dimethyl-4-[2-(3-methyl-[1,2,4]oxadiazol-5-ylamino)-ethoxy]-phenyl-
}-5,7-dimethoxy-3H-quinazolin-4-one; [0357]
N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxy]-ethyl}-acetamide; [0358]
N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylbenzyl)-
acetamide; [0359]
N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-di-
methyl-benzyl]-acetamide; [0360]
2-{3,5-Dimethyl-4-[2-(2,2,2-trifluoro-ethylamino)-ethoxyl]-phenyl}-5,7-di-
methoxy-3H-quinazolin-4-one; [0361]
N-{2-[4-(6,8-Dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxyl]-ethyl}-formamide; [0362]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)methanesulfonamide; [0363]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-4-methoxybenzamide; [0364]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)acetamide; [0365]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)isobutyramide; [0366]
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin--
4(3H)-one; [0367]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)propane-2-sulfonamide; [0368]
2-(4-(2-(isopropylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazol-
in-4(3H)-one; [0369]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)acetamide; [0370]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)isobutyramide; [0371]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)methanesulfonamide; [0372]
2-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazoli-
n-4(3H)-one; [0373]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylacetamide; [0374]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)formamide; [0375]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylformamide; [0376]
N-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)dimethylamino-N-sulfonamide; [0377]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)cyanamide; [0378]
2-(3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)phenyl)-5,7-dimet-
hoxyquinazolin-4(3H)-one; [0379]
2-(3,5-dimethyl-4-(2-(pyrimidin-2-ylamino)ethoxy)phenyl)-5,7-dimethoxyqui-
nazolin-4(3H)-one; [0380]
2-(4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquin-
azolin-4(3H)-one; [0381]
2-(4-(2-(4,6-dimethoxypyrimidin-2-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-
-dimethoxyquinazolin-4(3H)-one; [0382]
2-[4-(3-hydroxy-propyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-3H-quinazolin--
4-one; [0383]
2-[4-(3-hydroxy-propyl)-3-methoxy-phenyl]-5,7-dimethoxy-3H-quinazolin-4-o-
ne; and [0384]
2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one,
or a tautomer, stereoisomer, pharmaceutically acceptable salt, or
hydrate thereof.
[0385] Another aspect of the invention provides compounds of
Formula II selected from: [0386]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-morpholinoquinazolin-4(3H)-o-
ne; [0387]
2-(4-(2-(benzyloxy)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyr-
ido[2,3-d]pyrimidin-4(3H)-one; [0388]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylpyrido[2,3-d]pyrim-
idin-4(3H)-one; [0389]
5,7-difluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-o-
ne; [0390]
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3-
H-quinazolin-4-one; [0391]
2-[4-(2-hydroxyethoxy)-3,5-dimethyl-phenyl]-6-morpholin-4-ylmethyl-3H-qui-
nazolin-4-one; [0392]
2-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinaz-
olin-4-one; [0393]
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one; [0394]
2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;
[0395]
2-[4-(2-hydroxy-ethoxy)-naphthalen-1-yl]-5,7-dimethoxy-3H-quinazolin-4-on-
e; [0396]
2-(2-hydroxymethyl-benzofuran-5-yl)-5,7-dimethoxy-3H-quinazolin--
4-one; [0397]
7-(2-benzyloxy-ethoxy)-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-met-
hoxy-3H-quinazolin-4-one; [0398]
7-(2-benzyloxy-ethoxy)-2-(2-hydroxymethyl-benzofuran-5-yl)-5-methoxy-3H-q-
uinazolin-4-one; [0399]
2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-methylacetamide; [0400]
2-[4-(5,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-(4-methoxy-phenyl)-acetamide; [0401]
N-benzyl-2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimeth-
ylphenoxy]acetamide; [0402]
2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin--
4-one; [0403]
7-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;
[0404]
8-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H-
)-one; [0405]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-8-methoxyquinazolin-4(3H)-one;
[0406]
5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H-
)-one; [0407]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H)-one;
[0408]
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-
-yl)methyl)quinazolin-4(3H)-one; [0409]
5,7-Dimethoxy-2-{3-methyl-4-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylamino)-eth-
oxyl]-phenyl}-3H-quinazolin-4-one; [0410]
2-{3,5-Dimethyl-4-[2-(3-methyl-[1,2,4]oxadiazol-5-ylamino)-ethoxy]-phenyl-
}-5,7-dimethoxy-3H-quinazolin-4-one; [0411]
N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxy]-ethyl}-acetamide; [0412]
N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylbenzyl)-
acetamide; [0413]
N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-di-
methyl-benzyl]-acetamide; [0414]
2-{3,5-Dimethyl-4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-phenyl}-5,7-dim-
ethoxy-3H-quinazolin-4-one; [0415]
N-{2-[4-(6,8-Dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxy]-ethyl}-formamide; [0416]
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin--
4(3H)-one; [0417]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)propane-2-sulfonamide; [0418]
2-(4-(2-(isopropylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazol-
in-4(3H)-one; [0419]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)acetamide; [0420]
2-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazoli-
n-4(3H)-one; [0421]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylacetamide; [0422]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)formamide; [0423]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylformamide; [0424]
N-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)dimethylamino-N-sulfonamide; [0425]
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)cyanamide; [0426]
2-(3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)phenyl)-5,7-dimet-
hoxyquinazolin-4(3H)-one; [0427]
2-(3,5-dimethyl-4-(2-(pyrimidin-2-ylamino)ethoxy)phenyl)-5,7-dimethoxyqui-
nazolin-4(3H)-one; [0428]
2-(4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquin-
azolin-4(3H)-one; [0429]
2-(4-(2-(4,6-dimethoxypyrimidin-2-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-
-dimethoxyquinazolin-4(3H)-one; [0430]
2-[4-(3-hydroxy-propyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-3H-quinazolin--
4-one; [0431]
2-[4-(3-hydroxy-propyl)-3-methoxy-phenyl]-5,7-dimethoxy-3H-quinazolin-4-o-
ne; and [0432]
2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one,
and tautomers, stereoisomers, pharmaceutically acceptable salts,
and hydrates thereof.
Pharmaceutical Compositions
[0433] Pharmaceutical compositions are provided comprising at least
one compound of Formula I or II, or tautomer, stereoisomer,
pharmaceutically acceptable salt or hydrate thereof formulated
together with one or more pharmaceutically acceptable carriers.
These formulations include those suitable for oral, rectal,
topical, buccal and parenteral (e.g., subcutaneous, intramuscular,
intradermal, or intravenous) administration. The most suitable form
of administration in any given case will depend on the degree and
severity of the condition being treated and on the nature of the
particular compound being used.
[0434] Formulations suitable for oral administration may be
presented in discrete units, such as capsules, cachets, lozenges,
or tablets, each containing a predetermined amount of a compound of
the invention as powder or granules; as a solution or a suspension
in an aqueous or non-aqueous liquid; or as an oil-in-water or
water-in-oil emulsion. As indicated, such formulations may be
prepared by any suitable method of pharmacy which includes the step
of bringing into association at least one compound of the invention
as the active compound and a carrier or excipient (which may
constitute one or more accessory ingredients). The carrier must be
acceptable in the sense of being compatible with the other
ingredients of the formulation and must not be deleterious to the
recipient. The carrier may be a solid or a liquid, or both, and may
be formulated with at least one compound described herein as the
active compound in a unit-dose formulation, for example, a tablet,
which may contain from about 0.05% to about 95% by weight of the at
least one active compound. Other pharmacologically active
substances may also be present including other compounds. The
formulations of the invention may be prepared by any of the well
known techniques of pharmacy consisting essentially of admixing the
components.
[0435] For solid compositions, conventional nontoxic solid carriers
include, for example, pharmaceutical grades of mannitol, lactose,
starch, magnesium stearate, sodium saccharin, talc, cellulose,
glucose, sucrose, magnesium carbonate, and the like. Liquid
pharmacologically administrable compositions can, for example, be
prepared by, for example, dissolving or dispersing, at least one
active compound of the invention as described herein and optional
pharmaceutical adjuvants in an excipient, such as, for example,
water, saline, aqueous dextrose, glycerol, ethanol, and the like,
to thereby form a solution or suspension. In general, suitable
formulations may be prepared by uniformly and intimately admixing
the at least one active compound of the invention with a liquid or
finely divided solid carrier, or both, and then, if necessary,
shaping the product. For example, a tablet may be prepared by
compressing or molding a powder or granules of at least one
compound of the invention, which may be optionally combined with
one or more accessory ingredients. Compressed tablets may be
prepared by compressing, in a suitable machine, at least one
compound of the invention in a free-flowing form, such as a powder
or granules, which may be optionally mixed with a binder,
lubricant, inert diluent and/or surface active/dispersing agent(s).
Molded tablets may be made by molding, in a suitable machine, where
the powdered form of at least one compound of the invention is
moistened with an inert liquid diluent.
[0436] Formulations suitable for buccal (sub-lingual)
administration include lozenges comprising at least one compound of
the invention in a flavored base, usually sucrose and acacia or
tragacanth, and pastilles comprising the at least one compound in
an inert base such as gelatin and glycerin or sucrose and
acacia.
[0437] Formulations of the invention suitable for parenteral
administration comprise sterile aqueous preparations of at least
one compound of Formula I or II, or tautomers, stereoisomers,
pharmaceutically acceptable salts, and hydrates thereof, which are
approximately isotonic with the blood of the intended recipient.
These preparations are administered intravenously, although
administration may also be effected by means of subcutaneous,
intramuscular, or intradermal injection. Such preparations may
conveniently be prepared by admixing at least one compound
described herein with water and rendering the resulting solution
sterile and isotonic with the blood. Injectable compositions
according to the invention may contain from about 0.1 to about 5%
w/w of the active compound.
[0438] Formulations suitable for rectal administration are
presented as unit-dose suppositories. These may be prepared by
admixing at least one compound as described herein with one or more
conventional solid carriers, for example, cocoa butter, and then
shaping the resulting mixture.
[0439] Formulations suitable for topical application to the skin
may take the form of an ointment, cream, lotion, paste, gel, spray,
aerosol, or oil. Carriers and excipients which may be used include
Vaseline, lanoline, polyethylene glycols, alcohols, and
combinations of two or more thereof. The active compound (i.e., at
least one compound of Formula I or II, or tautomers, stereoisomers,
pharmaceutically acceptable salts, and hydrates thereof) is
generally present at a concentration of from about 0.1% to about
15% w/w of the composition, for example, from about 0.5 to about
2%.
[0440] The amount of active compound administered may be dependent
on the subject being treated, the subject's weight, the manner of
administration and the judgment of the prescribing physician. For
example, a dosing schedule may involve the daily or semi-daily
administration of the encapsulated compound at a perceived dosage
of about 1 .mu.g to about 1000 mg. In another embodiment,
intermittent administration, such as on a monthly or yearly basis,
of a dose of the encapsulated compound may be employed.
Encapsulation facilitates access to the site of action and allows
the administration of the active ingredients simultaneously, in
theory producing a synergistic effect. In accordance with standard
dosing regimens, physicians will readily determine optimum dosages
and will be able to readily modify administration to achieve such
dosages.
[0441] A therapeutically effective amount of a compound or
composition disclosed herein can be measured by the therapeutic
effectiveness of the compound. The dosages, however, may be varied
depending upon the requirements of the patient, the severity of the
condition being treated, and the compound being used. In one
embodiment, the therapeutically effective amount of a disclosed
compound is sufficient to establish a maximal plasma concentration.
Preliminary doses as, for example, determined according to animal
tests, and the scaling of dosages for human administration is
performed according to art-accepted practices.
[0442] Toxicity and therapeutic efficacy can be determined by
standard pharmaceutical procedures in cell cultures or experimental
animals, e.g., for determining the LD.sub.50 (the dose lethal to
50% of the population) and the ED.sub.50 (the dose therapeutically
effective in 50% of the population). The dose ratio between toxic
and therapeutic effects is the therapeutic index and it can be
expressed as the ratio LD.sub.50/ED.sub.50. Compositions that
exhibit large therapeutic indices are preferable.
[0443] Data obtained from the cell culture assays or animal studies
can be used in formulating a range of dosage for use in humans.
Therapeutically effective dosages achieved in one animal model may
be converted for use in another animal, including humans, using
conversion factors known in the art (see, e.g., Freireich et al.,
Cancer Chemother. Reports 50(4):219-244 (1966) and Table 1 for
Equivalent Surface Area Dosage Factors).
TABLE-US-00001 TABLE 1 Equivalent Surface Area Dosage Factors To:
Mouse Rat Monkey Dog Human From: (20 g) (150 g) (3.5 kg) (8 kg) (60
kg) Mouse 1 1/2 1/4 1/6 1/12 Rat 2 1 1/2 1/4 1/7 Monkey 4 2 1 3/5
1/3 Dog 6 4 3/5 1 1/2 Human 12 7 3 2 1
[0444] The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage may vary within this range
depending upon the dosage form employed and the route of
administration utilized. Generally, a therapeutically effective
amount may vary with the subject's age, condition, and gender, as
well as the severity of the medical condition in the subject. The
dosage may be determined by a physician and adjusted, as necessary,
to suit observed effects of the treatment.
[0445] In one embodiment, a compound of Formula I or II, or a
tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate
thereof, is administered in combination with another therapeutic
agent. The other therapeutic agent can provide additive or
synergistic value relative to the administration of a compound of
the invention alone. The therapeutic agent can be, for example, a
statin; a PPAR agonist, e.g., a thiazolidinedione or fibrate; a
niacin, a RVX, FXR or LXR agonist; a bile-acid reuptake inhibitor;
a cholesterol absorption inhibitor; a cholesterol synthesis
inhibitor; a cholesteryl ester transfer protein (CETP), an
ion-exchange resin; an antioxidant; an inhibitor of AcylCoA
cholesterol acyltransferase (ACAT inhibitor); a tyrophostine; a
sulfonylurea-based drug; a biguanide; an alpha-glucosidase
inhibitor; an apolipoprotein E regulator; a HMG-CoA reductase
inhibitor, a microsomal triglyceride transfer protein; an
LDL-lowing drug; an HDL-raising drug; an HDL enhancer; a regulator
of the apolipoprotein A-IV and/or apolipoprotein genes; or any
cardiovascular drug.
[0446] In another embodiment, a compound of Formula I, II, III, IV,
V or a tautomer, stereoisomer, pharmaceutically acceptable salt or
hydrate thereof, is administered in combination with one or more
anti-inflammatory agents. Anti-inflammatory agents can include
immunosuppressants, TNF inhibitors, corticosteroids, non-steroidal
anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic
drugs (DMARDS), and the like. Exemplary anti-inflammatory agents
include, for example, prednisone; methyiprenisolone (Medrol.RTM.),
triamcinolone, methotrexate (Rheumatrex.RTM., Trexall.RTM.),
hydroxychloroquine (Plaquenil.RTM.), sulfasalzine
(Azulfidine.RTM.), leflunomide (Arava.RTM.), etanercept
(Enbrel.RTM.), infliximab (Remicade.RTM.), adalimumab
(Humira.RTM.), rituximab (Rituxan.RTM.), abatacept (Orencia.RTM.),
interleukin-1, anakinra (Kineret.TM.) ibuprofen, ketoprofen,
fenoprofen, naproxen, aspirin, acetominophen, indomethacin,
sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac,
etodolac, mefenamic acid, meclofenamic acid, flufenamic acid,
tolfenamic acid, diclofenac, oxaprozin, apazone, nimesulide,
nabumetone, tenidap, etanercept, tolmetin, phenylbutazone,
oxyphenbutazone, diflunisal, salsalate, olsalazine or
sulfasalazine.
[0447] Therapeutic Methods
[0448] The invention provides methods of treating or preventing
cardiovascular and inflammatory diseases and related disease
states, characterized by altered levels of markers of inflammation
such as IL-6 and/or VCAM-1. These methods comprise administering to
a subject (e.g., a mammal, such as e.g., a human) a therapeutically
effective amount of at least one compound of the invention, i.e., a
compound of Formula I or II, or a tautomer, stereoisomer,
pharmaceutically acceptable salt or hydrate thereof. In another
embodiment, at least one compound of the invention may be
administered as a pharmaceutically acceptable composition,
comprising one or more compounds of Formula I or II and a
pharmaceutically acceptable carrier.
[0449] In one embodiment, the inflammatory diseases and related
disease states are those where inhibition of IL-6 and/or VCAM-1 is
desirable.
[0450] In some embodiments, the methods of the invention comprise
administering at least one compound of Formula I or Formula II to a
subject, such as a human, as a preventative measure against
cardiovascular and inflammatory diseases and related disease
states, such as, for example, atherosclerosis, asthma, arthritis,
cancer, multiple sclerosis, psoriasis, and inflammatory bowel
diseases, and autoimmune disease(s).
[0451] In one embodiment, at least one compound of Formula I or
Formula II is administered as a preventative measure to a subject,
such as a human, having a genetic predisposition to cardiovascular
and inflammatory diseases and related disease states, such as, for
example, familial hypercholesterolemia, familial combined
hyperlipidemia, atherosclerosis, a dyslipidemia, a
dyslipoproteinemia, arthritis, cancer, multiple sclerosis, or
Alzheimer's disease.
[0452] In another embodiment, at least one compound of Formula I or
Formula II is administered as a preventative measure to a subject,
such as a human, having a non-genetic predisposition to a disease
including a cardiovascular disease or an inflammatory disorder.
Examples of such non-genetic predispositions include cardiac bypass
surgery and PTCA (which can lead to restenosis), an accelerated
form of atherosclerosis, diabetes in women, (which can lead to
polycystic ovarian disease), and cardiovascular disease (which can
lead to impotence). Accordingly, compositions of the invention may
be used for the prevention of one disease or disorder and
concurrently treating another (e.g., prevention of polycystic
ovarian disease while treating diabetes; prevention of impotence
while treating a cardiovascular disease).
[0453] Angioplasty and open heart surgery, such as coronary bypass
surgery, may be required to treat cardiovascular diseases, such as
atherosclerosis. These surgical procedures entail using invasive
surgical devices and/or implants, and are associated with a high
risk of restenosis and thrombosis. Accordingly, the compounds of
Formula I or Formula II may be used as coatings on surgical devices
(e.g., catheters) and implants (e.g., stents) to reduce the risk of
restenosis and thrombosis associated with invasive procedures used
in the treatment of cardiovascular diseases.
[0454] In another embodiment, the compounds of Formula I or Formula
II may be used for the prevention of one disease or disorder while
concurrently treating another (e.g., prevention of polycystic
ovarian disease while treating diabetes; prevention of impotence
while treating a cardiovascular disease).
EXAMPLES
[0455] The invention is further illustrated by the following
non-limiting examples, wherein the following abbreviations have the
following meanings. If an abbreviation is not defined, it has its
generally accepted meaning. [0456] AcOH=acetic acid [0457]
BINAP=2,2'-bis(diphenylphosphino)-1,1'-binaphthyl [0458]
Boc=N-tert-butoxycarbonyl [0459] TBDMS=tert-butyldimethylsilyl
[0460] dba=dibenzylidene acetone [0461] DCM=dichloromethane [0462]
DMAP=dimethylaminopyridine [0463] DMF=dimethylformamide [0464]
DMSO=dimethylsulfoxide [0465]
EDCI=1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide [0466]
EtOH=ethanol [0467] EtOAc=ethyl acetate [0468] IBX=2-Iodoxybenzoic
acid [0469] MeOH=methanol [0470] HOBt=N-hydroxybenzotriazole [0471]
THF=tetrahydrofuran [0472] TEA=triethylamine [0473]
p-TSA=p-toluenesulfonic acid [0474] TBAF=tetrabutylammonium
fluoride [0475] DMA=N,N-dimethylacetamide [0476]
DIBAL-H=diisobutylaluminum hydride [0477] TPAP=tetrapropylammonium
perruthenate [0478] NMO=N-methylmorpholine N-oxide [0479]
DDQ=2,3-dicyano-5,6-dichloro-parabenzoquinone [0480]
DME=1,2-dimethoxyethane [0481] TFA=trifluoroacetic acid [0482]
DPPF=1,1'-bis(diphenylphosphino)ferrocene [0483]
Pd(OAc).sub.2=palladium(II) acetate [0484]
Pd(PPh.sub.3).sub.4=tetrakis(triphenylphosphine)palladium(0)
Example 1. Preparation of
5-(2-dimethylamino-ethoxy)-2(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-q-
uinazolin-4-one
##STR00010##
[0486] To a solution of 3,5-dimethyl-4-hydroxybenzaldehyde (10.0 g,
66.6 mmol) in anhydrous DMF (20 mL) was added NaH (4.00 g, 99.9
mmol) in portions and the mixture was stirred for 1 hour at room
temperature. Benzyl bromide (9.5 mL, 80 mmol) was added dropwise
and stirred for 16 hours at room temperature. Water was added, the
mixture was acidified with acetic acid to pH approximately 4-5, and
the product was isolated by extraction with ethyl acetate. The
solvent was evaporated in vacuo and the residue was purified by
column chromatography (silica gel 230-400 mesh; 2-5% ethyl
acetate/hexane as eluent) to give
4-benzyloxy-3,5-dimethyl-benzaldehyde as white solid. Yield: 15.2 g
(95%).
[0487] A mixture of 2-amino-4,6-difluorobenzamide (2.13 g, 12.4
mmol), 4-benzyloxy-3,5-dimethylbenzaldehyde (2.98 g, 12.4 mmol),
NaHSO.sub.3 (2.50 g, 13.6 mmol) and p-toluene sulfonic acid (0.236
g, 1.24 mmol) in N,N-dimethylacetamide (20 mL) was stirred at
110-120.degree. C. for 16 hours. The solvent was evaporated in
vacuo, water was added and the precipitated solid was filtered off,
washed with water and ether to give
2-(4-benzyloxy-3,5-dimethylphenyl)-5,7-difluoro-3H-quinazolin-4-one
as a light yellow solid. Yield: 1.99 g (41%).
[0488] To a solution of 2-dimethylaminoethanol (180 mg, 2.03 mmol)
in DMF (2 mL) was added NaH (61 mg, 1.5 mmol) at 0.degree. C. The
reaction mixture was stirred at room temperature for 30 minutes.
Then,
2-(4-benzyloxy-3,5-dimethylphenyl)-5,7-difluoro-3H-quinazolin-4-one
(200 mg, 0.510 mmol) was added and the reaction mixture was stirred
at room temperature for 16 hours. The reaction mixture was diluted
with water and extracted with ethyl acetate. The combined organic
layers were washed with water, brine, dried over Na.sub.2SO.sub.4,
and concentrated in vacuo to give product
2-(4-bezyloxy-3,5-dimethyl
phenyl)-5-(2-dimethylamino-ethoxy)-7-fluoro-3H-quinazolin-4-one.
Yield: 220 mg (93%).
[0489] To a solution of
2-(4-bezyloxy-3,5-dimethylphenyl)-5-(2-dimethylaminoethoxy)-7-fluoro-3H-q-
uinazolin-4-one (220 mg, 0.470 mmol) in DMF (3 mL) was added 25%
(w/w) sodium methoxide in methanol (205 mg, 3.81 mmol). The
reaction mixture was heated at 95.degree. C. for 4 hours. The
reaction mixture was cooled to the room temperature, diluted with
water, and extracted with ethyl acetate. The combined organic layer
was washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give crude product,
which was purified by column chromatography (silica gel 230-400
mesh; 5% NH.sub.3 in methanol/CH.sub.2Cl.sub.2 as eluent) to give
pure product
2-(4-bezyloxy-3,5-dimethylphenyl)-5-(2-dimethylamino-ethoxy)-7-me-
thoxy-3H-quinazolin-4-one. Yield: 110 mg (49%).
[0490] To a solution of
2-(4-bezyloxy-3,5-dimethylphenyl)-5-(2-dimethylaminoethoxy)-7-methoxy-3H--
quinazolin-4-one (110 mg, 0.23 mmol) in methanol (5 mL) and THF (5
mL) was added Pd/C (50 mg, 10% on charcoal). The reaction mixture
was hydrogenated for 2 hours at 50 psi at room temperature. The
mixture was filtered through celite and solvent was evaporated in
vacuo to give crude product, which was purified by column
chromatography (silica gel 230-400 mesh; 5% NH.sub.3 in
methanol/CH.sub.2Cl.sub.2 as eluent) to give the title compound as
a light brown solid. Yield: 70 mg (78%). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 7.58 (s, 2H), 6.80 (s, 1H), 6.40 (s, 1H), 4.20
(t, 2H), 3.90 (s, 3H), 2.90 (t, 2H), 2.40 (s, 3H), 2.25 (s, 3H). MS
(ES.sup.+) m/z: 384.09 (M+1).
Example 2. Preparation of
2-(4-hydroxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one
##STR00011##
[0492] To a solution of 2-methoxy-ethanol (2 mL) in anhydrous DMF
(2 mL) was added NaH (0.276 g, 6.90 mmol) in portions at 0.degree.
C. The reaction mixture was allowed to warm to room temperature and
stirred for 30 minutes. The compound
2-(4-benzyloxy-3,5-dimethyl-phenyl)-5,7-difluoro-3H-quinazolin-4-one
(0.25 g, 0.64 mmol) was added and the reaction mixture was stirred
at room temperature for 16 hours. Water was added and the mixture
was acidified with acetic acid to pH approximately 4-5. The
precipitated solid was filtered off and washed with water and dried
over anhydrous Na.sub.2SO.sub.4 to give
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-fluoro-5-(2-methoxy-ethoxy)-3H-quin-
azolin-4-one as a white solid. Yield: 0.28 g (98%).
[0493] To a solution of
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-fluoro-5-(2-methoxy-ethoxy)-3H-quin-
azolin-4-one (0.28 g, 0.62 mmol) in anhydrous DMF (3 mL) was added
a 25% solution of sodium methoxide in methanol (1.5 mL, 7.0 mmol)
and the reaction mixture was heated to 80-90.degree. C. for 6
hours. Water was added and the mixture was acidified with acetic
acid, to pH approximately 4-5. The precipitated solid was filtered
off and purified by column chromatography (silica gel 230-400 mesh;
20-50% ethyl acetate/CH.sub.2Cl.sub.2 as eluent) to give
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-qui-
nazolin-4-one as a white solid. Yield: 0.1 g (35%).
[0494] The compound
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-qui-
nazolin-4-one (0.1 g, 0.22 mmol) was hydrogenated in THF/methanol
(20/20 mL) at room temperature using Pd/C (10 wt %, 0.05 g) for 4
hours. After filtering through celite, the solvent was evaporated
in vacuo and the crude material was purified by column
chromatography (silica gel 230-400 mesh; 20-50% ethyl
acetate/CH.sub.2Cl.sub.2 as eluent) to give the title compound as a
white solid. Yield: 0.05 g (61.7%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.81 (s, 2H), 6.70 (s, 1H), 6.51 (s, 1H),
4.19 (t, 2H), 3.87 (s, 3H), 3.70 (t, 2H), 3.40 (s, 3H), 2.21 (s,
6H). MS (ES.sup.+) m/z: 371.11 (M+1).
Example 3. Preparation of
7-(2-amino-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quinazo-
lin-4-one
##STR00012##
[0496] To a solution of 2-amino-4,6-difluoro-benzamide (0.400 g,
2.32 mmol) and 4-benzyloxy-3,5-dimethylbenzaldehyde (0.560 g, 2.32
mmol) in N,N-dimethylacetamide (5 mL) were added NaHSO.sub.3 (0.450
g, 2.55 mmol) and p-TSA (44 mg, 0.23 mmol) and the reaction mixture
was heated at 115-120.degree. C. for 16 hours. The reaction mixture
was cooled to room temperature. N,N-Dimethylacetamide was removed
under reduced pressure. The residue was diluted with water and the
solid was collected and mixed and stirred for 0.5 hours with
methanol (20 mL). The solid was filtered to give
2-(4-benzyloxy-3,5-dimethyl-phenyl)-5,7-difluoro-3H-quinazolin-4--
one. Yield: 0.41 g (45%).
[0497] A solution of
2-(4-benzyloxy-3,5-dimethyl-phenyl)-5,7-difluoro-3H-quinazolin-4-one
(0.39 g, 1.0 mmol) and 25% sodium methoxide in methanol (0.70 g,
3.2 mmol) in DMF (1.5 mL) was stirred at room temperature for 16
hours. Acetic acid (1.0 mL) was added and the mixture was poured
into water (20 mL) and stirred for 0.5 hours. The solid was
filtered and further rinsed with water (30 mL), and dried to give
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-fluoro-5-methoxy-3H-quinazolin-4-on-
e. Yield: 0.39 g (92%).
[0498] To a solution of
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-fluoro-5-methoxy-3H-quinazolin-4-on-
e (0.390 g, 0.960 mmol) and 2-dimethylamin-ethanol (0.258 g, 2.89
mmol) in DMF (1.5 mL) was added sodium hydride (0.135 g, 2.97
mmol). The reaction mixture was kept at 80.degree. C. for 16 hours
and then poured into water (20 mL). The aqueous layer was adjusted
to pH 9.0, and extracted with dichloromethane. The crude product
was purified by column chromatography on silica gel (230-400 mesh)
using 10% methanol in dichloromethane with 1% triethylamine as
eluent to give
7-(2-amino-ethoxy)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quina-
zolin-4-one. Yield: 0.25 g (58%).
[0499] To a solution of
7-(2-amino-ethoxy)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quina-
zolin-4-one (0.25 g, 0.56 mmol) in methanol (15 mL) was added 10%
palladium charcoal wet (0.17 g) and the reaction mixture was
subjected to hydrogenation under hydrogen balloon at room
temperature for 16 hours. The catalyst was filtered through celite
and methanol was removed. The resulting material was further washed
with an ethyl acetate and ether mixture (20 mL/20 mL) to give the
title compound. Yield: 0.13 g (75%). .sup.1H NMR (400 Hz,
DMSO-d.sub.6): .delta. 11.70 (s, 1H), 8.98 (s, 1H), 7.83 (s, 2H),
6.78 (s, 1H), 6.48 (s, 1H), 4.25 (t, 2H), 3.82 (s, 3H), 2.81 (t,
2H), 2.35 (s, 6H), 2.24 (s, 6H). MS (ES.sup.+) m/z: 384.14
(M+1).
Example 4. Preparation of
2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3H-quina-
zolin-4-one
##STR00013##
[0501] Sodium hydride (0.340 g, 8.62 mmol) was taken in anhydrous
DMF (5 mL). Anhydrous 2-methoxy-ethanol (1.64 g, 21.6 mmol) was
added dropwise at 0.degree. C. under nitrogen over a period of 15
minutes. Stirring was continued at 0.degree. C. for 5 minutes. The
ice-bath was removed and stirring continued at room temperature for
10 minutes. Then,
2-(4-benzyloxy-3,5-dimethyl-phenyl)-7-fluoro-5-methoxy-3H-quinazolin-4-on-
e (0.436 g, 1.08 mmol) was added. The color changed to green and
stirring continued at 100.degree. C. for 4 hours (progress of the
reaction was monitored by TLC). The reaction mixture was cooled to
room temperature, then quenched with glacial acetic acid (2 mL).
Water (75 mL) was added. A white precipitate formed, which was
filtered, washed with water, and dried under vacuum. Crude compound
was purified by column chromatography (silica gel 230-400 mesh;
0-3% methanol in CH.sub.2Cl.sub.2 as eluent) to give
2-(4-benzyloxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3-
H-quinazolin-4-one as a white solid. Yield: 0.09 g (18%).
[0502] To a solution of
2-(4-benzyloxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3H-qui-
nazolin-4-one (0.083 g, 0.18 mmol) in methanol (15 mL) and THF (5
mL) was added palladium on charcoal (75 mg). The reaction mixture
was hydrogenated at 50 psi for 16 hours at room temperature then
filtered through celite. The filtrate was concentrated under
reduced pressure and the crude compound was purified by preparative
HPLC to give the title compound as a white solid. Yield: 0.043 g
(45%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.80 (s, 2H),
7.00 (s, 1H), 6.52 (s, 1H), 4.20 (m, 2H), 3.80 (m, 5H), 3.48 (s,
3H), 2.22 (s, 6H).
Example 5. Preparation of
7-(2-benzyloxy-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-qui-
nazolin-4-one
##STR00014##
[0504] To a suspension of sodium hydride (2.00 g, 50.0 mmol) in
anhydrous DMF (30 mL) at 0.degree. C. was added a solution of
4-hydroxy-3,5-dimethyl-benzaldehyde (5.00 g, 33.3 mmol) in
anhydrous DMF (20 mL), dropwise over a period of 30 minutes, under
nitrogen. Stirring continued at room temperature for 30 minutes and
the mixture was cooled to 0.degree. C. Chloromethoxymethane (5.06
mL, 66.6 mmol) was added and the reaction mixture was stirred at
room temperature for 16 hours under nitrogen. The reaction mixture
was poured into water (200 mL), extracted with ethyl acetate
(2.times.50 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated. The crude compound was purified by column
chromatography (SiO.sub.2, ethyl acetate/hexanes=1:3) to afford
4-methoxymethoxy-3,5-dimethyl-benzaldehyde as colorless oil. Yield:
5.97 g (92%).
[0505] To a solution of 4-methoxymethoxy-3,5-dimethyl-benzaldehyde
(4.00 g, 20.6 mmol) and 2-amino-4,6-difluoro-benzamide (3.55 g,
20.6 mmol) in N,N-dimethylacetamide (20 mL) were added sodium
hydrogen sulfite (58.5 wt %) (5.45 g, 30.9 mmol) and
p-toluenesulfonic acid (0.20 g, 1.0 mmol). The reaction mixture was
stirred at 120.degree. C. for 16 hours under nitrogen and cooled to
room temperature. The solvent was evaporated under reduced
pressure. Methanol (50 mL) and water (200 mL) were added, the
separated solid was filtered, washed with water (30 mL), methanol
(30 mL), hexanes (100 mL), and dried under vacuum, to afford
5,7-difluoro-2-(4-methoxymethoxy-3,5-dimethyl-phenyl)-3H-quinazolin-4-one
as a white solid. Yield: 1.40 g (20%).
[0506] To a solution of
5,7-difluoro-2-(4-methoxymethoxy-3,5-dimethyl-phenyl)-3H-quinazolin-4-one
(1.40 g, 4.04 mmol) in anhydrous DMF (20 mL) was added a solution
of sodium methoxide in methanol (25 wt %, 5.0 mL, 24 mmol). The
reaction mixture was stirred at room temperature for 16 hours under
nitrogen, diluted with water (100 mL), extracted with ethyl
acetate, dried over sodium sulfate, and concentrated on a rotary
evaporator to afford
7-fluoro-5-methoxy-2-(4-methoxymethoxy-3,5-dimethyl-phenyl)-3H-quinazolin-
-4-one as a white solid. Yield: 1.1 g (76%).
[0507] To a suspension of sodium hydride (0.176 g, 4.40 mmol) in
anhydrous DMF (20 mL) was added benzyloxyethanol (1.02 g, 6.70
mmol) at room temperature under nitrogen. The reaction mixture was
stirred 60.degree. C. for 30 minutes to get a clear solution. Then,
7-fluoro-5-methoxy-2-(4-methoxymethoxy-3,5-dimethyl-phenyl)-3H-quinazolin-
-4-one (0.200 g, 0.559 mmol) was added and the reaction mixture was
stirred at 105.degree. C. for 16 hours under nitrogen. The reaction
was diluted with water (100 mL), extracted with ethyl acetate (100
mL), and concentrated on a rotary evaporator. The oily residue was
subjected to column chromatography (SiO.sub.2, hexanes/ethyl
acetate/methanol=6:2:1) to afford a mixture of two components of
very similar polarity. The mixture was dissolved in 50% aqueous
acetic acid (60 mL) and mixed with concentrated HCl (3 mL). The
resulting mixture was stirred at 70.degree. C. for 1 hour and
concentrated to dryness on a rotary evaporator. The residue was
diluted with saturated sodium bicarbonate aqueous solution (50 mL),
extracted with ethyl acetate (150 mL), and concentrated. The
residue was purified by column chromatography (SiO.sub.2,
hexanes/ethyl acetate/methanol=7:2:1) to afford the title compound
as a light yellow solid. Yield: 45 mg (18%). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 9.68 (br s, 1H), 7.69 (s, 2H), 7.40-7.30 (m,
5H), 6.79 (d, 1H), 6.50 (d, 1H), 4.66 (s, 2H), 4.27 (t, 2H), 3.96
(s, 3H), 3.88 (t, 2H), 2.33 (s, 6H). MS (ES.sup.+) m/z: 447.59
(M+1).
Example 6. Preparation of
2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)etho-
xy]-3H-quinazolin-4-one
##STR00015##
[0509] To a stirred solution of
5,7-difluoro-2-(4-methoxymethoxy-3,5-dimethylphenyl)-3H-quinazolin-4-one
(1.04 g, 3.00 mmol) in anhydrous DMF (10 mL) was added a solution
of sodium methoxide (25 wt %) in methanol (3.9 mL, 18.0 mmol) at
room temperature. The reaction mixture was stirred at room
temperature for 16 hours under nitrogen. Water (100 mL) was added,
the white precipitated solid was filtered off, washed with water
and dried under vacuum. The solid was further washed with 10%
methanol in ether (20 mL), then ether (20 mL), and dried under
vacuum. Yield 0.95 g (88%).
[0510] Sodium hydride (60% in mineral oil; 1.00 g, 25.0 mmol) was
added slowly to ethylene glycol (1.48 g, 239 mmol), cooled to
0.degree. C. under nitrogen. The cooling bath was removed, and the
mixture was stirred for a further 15 minutes at room temperature,
before 3-(bromomethyl)pyridine hydrobromide (2.53 g, 10.0 mmol) was
added. Then, the mixture was stirred at room temperature for 2.5
days. Water was added, the mixture was extracted with EtOAc
(5.times.100 mL), the extracts were washed with brine, dried over
anhydrous Na.sub.2SO.sub.4, and concentrated under vacuum.
Purification by column chromatography on silica gel, with
CH.sub.2Cl.sub.2/MeOH (95:5) as the eluent, gave
2-(pyridin-3-ylmethoxy)-ethanol as a colorless liquid. Yield 0.90
g, 59%.
[0511] To a solution of
7-fluoro-5-methoxy-2-(4-methoxymethoxy-3,5-dimethyl-phenyl)-3H-quinazolin-
-4-one (0.30 g, 0.86 mmol) and 2-(pyridin-3-ylmethoxy)ethanol (0.20
g, 1.3 mmol) in DMF (2.0 mL), was added sodium hydride (60% in
mineral oil) (0.30 g, 6.9 mmol). The mixture was stirred at room
temperature under nitrogen for 3 h, then in an oil bath at
95.degree. C. for 2.5 days. The mixture was concentrated under
vacuum, water (approximately 50 mL) was added, and the mixture
extracted with dichloromethane (3.times.50 mL). The dichloromethane
solution was dried over anhydrous Na.sub.2SO.sub.4, concentrated
under vacuum, and purified by column chromatography on silica gel,
with CH.sub.2Cl.sub.2/MeOH (95:5) as eluent, to give
5-methoxy-2-(4-methoxymethoxy-3,5-dimethylphenyl)-7-[2-(pyridin-3-ylmetho-
xy)-ethoxy]-3H-quinazolin-4-one. Yield 150 mg (35%).
[0512] To a solution of
5-methoxy-2-(4-methoxymethoxy-3,5-dimethylphenyl)-7-[2-(pyridin-3-ylmetho-
xy)ethoxy]-3H-quinazolin-4-one (0.10 g, 0.20 mmol) in acetic acid
(10 mL) and water (10 mL), sulphuric acid (0.5 mL) was added. The
solution was stirred in a 75.degree. C. oil bath for 5 hours. The
mixture was then concentrated under reduced pressure. The residue
was dissolved in methanol, and 2 M Na.sub.2CO.sub.3 was added until
the pH reached 8. The mixture was concentrated under reduced
pressure. The resulting precipitate was filtered, washed with
water, and dried in air. The precipitate was washed further with
methanol to give the title compound. Yield: 67 mg (74%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 11.69 (s, 1H), 8.95 (s, 1H),
8.59 (s, 1H), 8.51 (d, J=3.2 Hz, 1H), 7.84 (s, 2H), 7.79 (dt, J=7.6
and 2.0 Hz, 1H), 7.41-7.38 (m, 1H), 6.72 (d, J=2.0 Hz, 1H), 6.49
(d, J=2.4 Hz, 1H), 4.63 (s, 2H), 4.30 (m, 2H), 3.86 (m, 2H), 3.83
(s, 3H), 2.23 (s, 6H). MS (ES.sup.-) m/z: 446.52 (M-1).
Example 7. Preparation of
7-(2-dimethylamino-ethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-
-4-one
##STR00016##
[0514] To a solution of 2-amino-4-fluoro-benzamide (0.77 g, 5.00
mmol) and 4-benzyloxy-3,5-dimethyl-benzaldehyde (1.20 g, 5.00 mmol)
in N,N-dimethyl acetamide (20 mL) were added sodium hydrogen
sulfite (58.5 wt %, 1.10 g, 6.00 mmol) and p-toluenesulfonic acid
monohydrate (0.19 g, 1.00 mmol). The reaction mixture was stirred
at 120.degree. C. for 16 hours under nitrogen, and then cooled to
room temperature. Solvent was evaporated under reduced pressure,
and water (100 mL) was added. The separated solid was filtered,
washed with water (50 mL), and dried under vacuum to give a white
solid. Yield: 0.74 g (39%).
[0515] Sodium hydride (60% suspension in mineral oil; 0.36 g, 9.00
mmol) was taken in anhydrous DMF (20 mL). Then,
2-dimethylamino-ethanol (1.07 g, 12.0 mmol) was added drop-wise at
room temperature under nitrogen. After the addition, the reaction
mixture was stirred at room temperature for 20 minutes. Then,
2-(4-benzyloxy-3,5-dimethylphenyl)-7-fluoro-3H-quinazolin-4-one
(0.56 g, 1.50 mmol) was added and the reaction mixture was stirred
at 80.degree. C. for 16 hours. The reaction mixture was cooled to
room temperature. Water (100 mL) was added and the mixture was
neutralized to pH approximately 8 with aqueous 2 N HCl. The
separated solid was filtered, washed with water, and dried under
vacuum. The crude compound was purified by the Simpliflash system
(0-5% methanol in CH.sub.2Cl.sub.2 and 7 N ammonia in methanol 5%
in CH.sub.2Cl.sub.2 as eluent) to give
2-(4-benzyloxy-3,5-dimethylphenyl)-7-(2-dimethylamino-ethoxy)-3H-quinazol-
in-4-one as a white solid. Yield: 0.32 g (48%).
[0516]
2-(4-Benzyloxy-3,5-dimethylphenyl)-7-(2-dimethylamino-ethoxy)-3H-qu-
inazolin-4-one (0.30 g, 11.2 mmol) was dissolved in a mixture of
methanol and THF (1:1, 60 mL). Palladium on carbon (10 wt %, 0.20
g) was added and the reaction mixture was hydrogenated at 45 psi
for 6 hours. The reaction mixture was filtered, and the filtrate
was concentrated. The residue was washed with 10% methanol in
ether, then ether, and dried under vacuum to give the title
compound as a white solid. Yield: 0.18 g (75%). .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 11.98 (br s, 1H), 8.94 (br s, 1H), 7.99
(d, J=8.59 Hz, 1H), 7.86 (s, 2H), 7.13 (s, 1H), 7.01 (d, J=8.98 Hz,
1H), 4.21 (t, J=5.46 Hz, 2H), 2.68 (t, J=5.27 Hz, 2H), 2.24 (s,
12H). MS (ES+) m/z 354.16 (100%).
Example 8. Preparation of
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-o-
ne
##STR00017##
[0518] To a solution of
6-amino-2-(4-hydroxy-3,5-dimethyl-phenyl)-3H-quinazolin-4-one (300
mg, 1.07 mmol) in pyridine (3 mL), were added 4-bromopridinium
hydrochloride (207 mg, 1.07 mmol), Pd.sub.2(dba).sub.3 (19 mg, 0.02
mmol), dppf (18 mg, 0.03 mmol) and NaO-t-Bu (328 mg, 3.41 mmol).
The reaction mixture was heated at 140.degree. C. for 1 hour in a
microwave oven. Solvent was removed under reduced pressure. The
crude compound was purified by the Simpliflash system (5% 7 N
ammonia in methanol and dichloromethane as eluent) to give the
title compound as a yellow solid. Yield: 58 mg (15%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.13 (s, 1H), 9.16 (s, 1H), 8.92
(s, 1H), 8.25 (br s, 2H), 7.84 (d, J=2.0 Hz, 1H), 7.81 (s, 2H),
7.65 (m, 2H), 6.99 (d, J=5.2 Hz, 2H), 2.22 (s, 6H). MS (ES) m/z:
359.26 (M+1) (100%).
Example 9. Preparation of
2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-2-ylamino)-3H-quinazolin-4-o-
ne
##STR00018##
[0520] To a solution of
6-amino-2-(4-hydroxy-3,5-dimethyl-phenyl)-3H-quinazolin-4-one (300
mg, 1.07 mmol) in pyridine (3.5 mL), were added 2-bromopyridine
(202 mg, 1.28 mmol), Pd.sub.2(dba).sub.3 (20 mg, 0.02 mmol), dppf
(18 mg, 0.03 mmol) and NaO-t-Bu (329 mg, 3.42 mmol). The reaction
mixture was heated at 125.degree. C. for 1 hour in a microwave oven
(100 W). Solvent was removed under reduced pressure. The crude
compound was purified by column chromatography (silica gel 230-400
mesh; 3% methanol, 37% ethyl acetate and 60% CH.sub.2Cl.sub.2 as
eluent). The compound was further purified by preparative HPLC to
give the title compound as a beige-colored solid. Yield: 35 mg
(9%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.01 (br s,
1H), 9.40 (s, 1H), 8.87 (br s, 1H), 8.60 (d, J=2.34 Hz, 1H), 8.23
(d, J=3.91 Hz, 1H), 7.97 (dd, J=8.99 and 2.74 Hz, 1H), 7.82 (s,
2H), 7.72-7.44 (m, 2H), 6.87 (d, J=8.60 Hz, 1H), 6.83-6.78 (m, 1H),
2.23 (s, 6H). MS (ES) m/z: 359.01 (M+1) (100%).
Example 10. Preparation of
2-(4-hydroxy-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)methyl)quinaz-
olin-4(3H)-one
##STR00019##
[0522] A solution of 2-amino-5-bromobenzamide (12.0 g, 55.8 mmol)
and 4-hydroxy-3,5-dimethylbenzaldehyde (8.4 g, 55.8 mmol) in DMA
(200 mL) was treated with NaHSO.sub.3 (7.7 g, 72.5 mmol) and p-TsOH
(1.1 g, 5.6 mmol). The reaction was heated at 135.degree. C. for
2.5 hours, at which time, H.sub.2O (10 mL) and CH.sub.2Cl.sub.2
(100 mL) were added and the solids were collected by filtration.
The solids were washed with CH.sub.2Cl.sub.2 and dried in vacuo to
afford 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one
(13.1 g, 68%).
[0523] A solution of
6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one (2.0
g, 5.8 mmol) in DMF (20 mL) was treated with vinyltributyltin (2.6
mL, 8.70 mmol), Pd(PPh.sub.3).sub.4 (0.670 g, 0.58 mmol), and LiCl
(0.730 g, 17.4 mmol). The reaction was stirred at reflux for 30
minutes, then concentrated in vacuo. The residue was purified by
flash chromatography on silica gel, eluting with 30% to 100% of
92:7:1 CHCl.sub.3/MeOH/concentrated NH.sub.4OH in CH.sub.2Cl.sub.2,
to afford
2-(4-hydroxy-3,5-dimethylphenyl)-6-vinylquinazolin-4(3H)-one (0.780
g, 46%).
[0524] To a suspension of
2-(4-hydroxy-3,5-dimethylphenyl)-6-vinylquinazolin-4(3H)-one (0.500
g, 1.70 mmol) in THF (30 mL) and H.sub.2O (10 mL) was added
NaIO.sub.4 (1.09 g, 5.10 mmol), followed by OsO.sub.4 (0.2 mL,
0.017 mmol). The reaction was stirred overnight, then concentrated
in vacua. The residue was purified by flash chromatography on
silica gel, eluting with 92:7:1 to 6:3:1
CHCl.sub.3/MeOH/concentrated NH.sub.4OH to afford
2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazoline-6-carbaldeh-
yde (0.475 g, 95%).
[0525] To a solution of
2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazoline-6-carbaldeh-
yde (0.115 g, 0.40 mmol) in DCE/CH.sub.2Cl.sub.2 (1:1, 15 mL) was
added 1-methylpiperazine (0.13 mL, 1.20 mmol) and NaBH(OAc).sub.3
(0.250 g, 1.20 mmol). The reaction stirred at room temperature
overnight. After this time, the mixture was concentrated in vacuo
and purified by flash chromatography on silica gel eluting with
92:7:1 CHCl.sub.3/MeOH/concentrated NH.sub.4OH to afford the title
compound (0.036 g, 25%) as a white solid: .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 11.63 (br s, 1H), 8.77 (br s, 1H), 8.00 (s,
1H), 7.85 (s, 2H), 7.65-7.69 (m, 2H), 3.57 (s, 2H), 2.15-2.39 (m,
17H); APCI MS m/z 377 [M-H].sup.-.
Example 11. Preparation of
N-((2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)met-
hyl)methanesulfonamide
##STR00020##
[0527] To a solution of methyl-5-methyl-2-nitrobenzoate (2.3 g,
11.8 mmol) in CHCl.sub.3 (150 mL) was added NBS (5.3 g, 30.0 mmol)
and benzoyl peroxide (0.285 g, 1.2 mmol). The reaction was heated
at reflux temperature overnight. Then, the resulting mixture was
washed sequentially with H.sub.2O, Na.sub.2CO.sub.3, and brine. The
organic layer was then dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. Purification by flash chromatography on
silica gel, eluting with 5% to 20% ethyl acetate/heptane, afforded
methyl 5-(bromomethyl)-2-nitrobenzoate (1.3 g, 40%).
[0528] To a solution of methyl 5-(bromomethyl)-2-nitrobenzoate (1.3
g, 4.7 mmol) in DMF (15 mL) was added potassium phthalimide (1.0 g,
5.2 mmol) and the reaction was stirred at room temperature for 1
hour and concentrated in vacuo. Purification by flash
chromatography, eluting with 15% to 70% ethyl acetate/heptane,
afforded methyl
5-((1,3-dioxoisoindolin-2-yl)methyl)-2-nitrobenzoate (1.4 g,
88%).
[0529] A solution of methyl
5-((1,3-dioxoisoindolin-2-yl)methyl)-2-nitrobenzoate (0.50 g, 1.4
mmol) in EtOH (10 mL) was treated with hydrazine (0.14 mL, 4.4 mol)
and the reaction was stirred at room temperature overnight. After
this time, the mixture was concentrated in vacuo and purified by
flash chromatography on silica gel, eluting with 30% to 100% of
92:7:1 CHCl.sub.3/MeOH/concentrate NH.sub.4OH in CH.sub.2Cl.sub.2,
to afford methyl 5-(aminomethyl)-2-nitrobenzoate (0.23 g, 78%).
[0530] To a solution of methyl 5-(aminomethyl)-2-nitrobenzoate
(0.23 g, 1.1 mmol) in CH.sub.2Cl.sub.2 (5 mL) was added Et.sub.3N
(0.31 mL, 2.2 mmol) and methanesulfonyl chloride (0.08 mL, 1.1
mmol). The reaction was stirred for 15 minutes at room temperature,
concentrated in vacuo, and purified by flash chromatography on
silica gel, eluting with 2% to 20% MeOH/CH.sub.2Cl.sub.2, to afford
methyl 5-(methylsulfonamidomethyl)-2-nitrobenzoate (0.18 g,
57%).
[0531] A mixture of methyl
5-(methylsulfonamidomethyl)-2-nitrobenzoate (0.18 g, 0.62 mmol) in
EtOH (10 mL) was flushed with N.sub.2. Pd/C (0.018 g) was added and
the reaction was flushed with H.sub.2 for 2 hours. Then, the
resulting mixture was filtered through celite and the filtrate was
concentrated. Purification by flash chromatography, eluting with
15% to 60% of 92:7:1 CHCl.sub.3/MeOH/concentrate NH.sub.4OH in
CH.sub.2Cl.sub.2, afforded methyl
2-amino-5-(methylsulfonamidomethyl)-benzoate (0.085 g, 53%).
[0532] To a solution of methyl
2-amino-5-(methylsulfonamidomethyl)benzoate (0.085 g, 0.33 mmol) in
THF (7 mL) and H.sub.2O (3 mL) was added LiOH.H.sub.2O (0.028 g,
0.65 mol). The reaction was stirred at room temperature for 2 hours
and then neutralized with 1 N HCl. The resulting aqueous solution
was extracted with EtOAc. The organics were washed with brine,
dried (Na.sub.2SO.sub.4), filtered, and concentrated, to afford
2-amino-5-(methylsulfonamidomethyl)benzoic acid (0.066 g, 82%).
[0533] A solution of 2-amino-5-(methylsulfonamidomethyl)benzoic
acid (0.066 g, 0.27 mol) in THF (5 mL) was treated with EDCI (0.062
g, 0.32 mmol), HOBT (0.044 g, 0.32 mol) and NMM (0.035 mL, 0.32
mmol.) The reaction was stirred at room temperature for 1.5 hours.
Then, NH.sub.4OH (0.03 mL, 0.35 mmol) in H.sub.2O (0.03 mL) was
added. The mixture was stirred at room temperature for 5 hours and
then concentrated. Purification by flash chromatography, eluting
with 92:7:1 to 7:2.5:0.5 CHCl.sub.3/MeOH/concentrated NH.sub.4OH,
afforded 2-amino-5-(methylsulfonamidomethyl)benzamide (0.035 g,
53%).
[0534] A mixture of 2-amino-5-(methylsulfonamidomethyl)benzamide
(0.035 g, 0.14 mmol), 4-hydroxy-3,5-dimethyl benzaldehyde (0.022 g,
0.14 mmol) and CuCl.sub.2 (0.039 g, 0.28 mmol) in EtOH (5 mL) was
refluxed for 3 h, then concentrated in vacuo. Purification by flash
chromatography on silica gel, eluting with 92/7/1
CHCl.sub.3:MeOH:concentrated NH.sub.4OH, followed by reverse-phase
chromatography, eluting with 10% to 50% CH.sub.3CN in H.sub.2O with
0.1% TFA, and finally flash chromatography on silica gel, eluting
with 7:2.5:0.5 CHCl.sub.3/MeOH/concentrated NH.sub.4OH, afforded
the title compound (0.030 g, 57%) as a white solid. .sup.1H NMR
(300 MHz, DMSO-d.sub.6): .delta. 8.09 (s, 1H), 7.83-7.90 (m, 2H),
7.65-7.78 (m, 3H), 6.81-7.54 (m, 2H), 4.30 (d, J=6.2 Hz, 2H), 2.91
(s, 3H), 2.24 (s, 6H). ESI MS m/z 374 [M+H].sup.+.
Example 12. Preparation of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-morpholinoquinazolin-4(3H)-o-
ne
##STR00021##
[0536] A mixture of 3,5-dimethoxy-4-hydroxybenzaldehyde (10 g,
66.67 mmol), (2-bromoethoxy)-dimethyl-tert-butylsilane (15 mL, 70
mmol), potassium iodide (1.1 g, 6.67 mmol), and sodium hydride (4
g, 100 mmol) in DMF (150 mL) was heated and stirred at 70.degree.
C. for 14 hours. The reaction was then cooled and quenched by
adding water (100 mL). The mixture was extracted with EtOAc
(3.times.100 mL) and concentrated on a rotary evaporator. The
resulting residue was purified by column (SiO.sub.2, hexanes/EtOAc,
6:1) to yield
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(15.4 g, 75%).
[0537] A solution of 5-morpholin-4-yl-2-nitro-benzamide (2 g, 7.96
mmol) in MeOH (50 mL) and DMF (150 mL) in a Parr bottle was mixed
with Pd/C (0.5 g) and was subjected to hydrogenation (35 psi) at
room temperature for 14 hours. The suspension was then passed
through a celite pad and the filtrated was concentrated on a rotary
evaporator, to provide 2-amino-5-morpholin-4-yl-benzamide (1.69 g,
96%).
[0538] A mixture of 2-amino-5-morpholin-4-yl-benzamide (0.2 g,
0.905 mmol),
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzald-
ehyde (0.28 g, 0.905 mol), sodium hydrogensulfite (0.162 g, 0.905
mmol) and p-toluenesulfonic acid (0.224 g, 1.177 mol) in
N,N-dimethyl acetamide (10 mL) was stirred at 150.degree. C. for 4
hours. The reaction mixture was cooled to room temperature, diluted
with water (50 L), basified with sodium bicarbonate to pH
approximately 8-9, extracted with EtOAc (3.times.100 mL), and
concentrated on a rotary evaporator, affording a solid residue.
Further purification on a column (SiO.sub.2, DCM/MeOH/EtOAc=6:1:2)
yielded
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-6-m-
orpholin-4-yl-3H-quinazolin-4-one (66 mg, 14%).
[0539] The above compound (66 mg, 0.129 mmol) in THF (10 mL) was
mixed with TBAF in THF (2 mL, 2 mmol) and stirred at room
temperature for 5 hours. The mixture was then concentrated on a
rotary evaporator and subjected to column chromatography
(SiO.sub.2, DCM/MeOH/EtOAc=6:1:2) to yield the title compound as a
light yellow solid (35 mg, 68%). MP 279.5-281.degree. C.
Example 13. Preparation of
2-(4-(2-(benzyloxy)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]-
pyrimidin-4(3H)-one
##STR00022##
[0541] A mixture of dimethyl acetone-1,3-dicarboxylate (200 g 1.148
mol), cyanamide (48.3 g, 1.148 mol), and Ni(acac).sub.2 (14.75 g,
0.0574 mol) in dioxane (200 mL) was heated to reflux in a 1-L flask
with a reflux condenser. The reaction mixture was heated at reflux
for 16 hours and then cooled to room temperature. The precipitate
was filtered off, and the solid was mixed with methanol (200 mL),
stirred for 30 minutes, and filtered again to give methyl
2-amino-4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate (93 g,
44%).
[0542] In a 1-L flask with a reflux condenser was added methyl
2-amino-4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate (93.0 g,
0.505 mol) and POCl.sub.3 (425 mL) and the reaction mixture was
heated to reflux for 35 minutes. About 300 mL POCl.sub.3 was
evaporated under vacuum. The residue was poured into ice and water
(400 mL), which was further neutralized with KOH to pH
approximately 6-7. The precipitate was filtered off and extracted
with ethyl acetate (2.times.300 mL). The organic solution was
concentrated and passed through a column, eluting with hexane:ethyl
acetate 4:1, to give methyl
2-amino-4,6-dichloropyridine-3-carboxylate (22.5 g, 20.1%).
[0543] In a 500-mL flask with a reflux condenser was added methyl
2-amino-4.6-dichloropyridine-3-carboxylate (22.5 g, 0.101 mol) and
25 wt % sodium methoxide in methanol (88 mL, 0.407 mol), together
with methanol (20 mL). The mixture was heated to reflux for 5
hours, then cooled to room temperature. Acetic acid (15 mL) was
added to the mixture and pH was adjusted to approximately 7.
Methanol was removed and the residue was poured into water (100
mL). The precipitated solid was filtered and further rinsed with
water (3.times.200 mL) to give methyl
2-amino-4,6-dimethoxypyridine-3-carboxylate (18.5 g, 86.4%).
[0544] In a 500-mL flask with a reflux condenser was added methyl
2-amino-4,6-dimethoxypyridine-3-carboxylate (18.5 g, 0.0872 mol),
potassium hydroxide (19.5 g, 0.349 mol) in water (80 mL) and
ethanol (100 mL). The mixture was heated to 80.degree. C. for 16
hours. The solvent was removed and aqueous HCl was used to adjust
the pH to 6. The water was removed by freeze drying. The obtained
solid was extracted with methanol to yield
2-amino-4,6-dimethoxy-nicotinic acid (17.2 g, 100%).
[0545] 2-Amino-4,6-dimethoxy-nicotinic acid (17.2 g, 0.0872 mol)
was added to THF (110 mL).
1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (21/3
g, 0.113 mol), 1-hydroxybenzotriazole hydrate (12.96 g, 0.0959 mol)
and 4-methyl morpholine (9.7 g, 0.0959 mol) were then added to the
suspension. After stirring for 10 minutes at room temperature, 50%
v/v ammonium hydroxide (18.3 g, 0.262 mol) was added. The reaction
mixture was kept at room temperature for 16 hours. THF was removed
and the residue was poured into cold water (100 mL). The
precipitate was filtered off and washed with cold water to yield
2-amino-4,6-dimethoxy-nicotinamide (10.8 g, 62.3%).
[0546] To a solution of 4-hydroxy-3,5-dimethylbenzaldehyde (6.84 g,
0.0455 mol) in anhydrous DMF (15 mL) was added NaH in mineral oil
(60%, 2.23 g, 0.0558 mol). (2-Bromo-ethyoxymethyl)-benzene (10.0 g,
0.0465 mol) was added and the reaction was kept at 65.degree. C.
overnight. The reaction mixture was poured into water and extracted
with dichloromethane to yield
(4-(2-benzyloxy-ethoxy)-3,5-dimethylbenzaldehyde (10.5 g, 81%),
which was used for next step reaction without further
purification.
[0547] To a solution of 2-amino-4,6-dimethoxy-nicotinamide (2.55 g,
12.9 mmol) and 4-(2-benzyloxy-ethoxy)-3,5-dimethylbenzaldehyde
(3.68 g, 12.9 mmol) in N,N-dimethyl acetamide (20 mL), were added
NaHSO.sub.3 (2.52 g, 14.2 mmol) and p-TSA (1.98 g, 10.4 mmol). The
reaction mixture was heated at 150.degree. C. for 14 hours. The
reaction mixture was cooled to room temperature. The solvent was
removed under reduced pressure. The residue was diluted with water
and the solid was collected and further washed with methanol. The
crude product was purified by column chromatography (silica gel
230-400 mesh; 2% methanol in CH.sub.2Cl.sub.2 as eluent) to give
the title compound as an off-white solid (0.88 g, 14.7%). MP
204.5-205.9.degree. C.
Example 14. Preparation of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylpyrido[2,3-d]pyrim-
idin-4(3H)-one
##STR00023##
[0549] A mixture of 3,5-dimethoxy-4-hydroxybenzaldehyde (10 g, 67
mmol), (2-bromoethoxy)-dimethyl-tert-butylsilane (15 mL, 70 mmol),
potassium iodide (1.1 g, 6.7 mmol), and sodium hydride (4 g, 100
mmol) in DMF (150 mL) was heated and stirred at 70.degree. C. for
14 hours. The reaction was then cooled and quenched by adding water
(100 mL). The mixture was extracted with EtOAc (3.times.100 mL) and
concentrated on a rotary evaporator. The resulting residue was
purified by column (SiO.sub.2, hexanes/EtOAc=6:1) to yield
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(15.4 g, 75%).
[0550] A mixture of 2-amino-4,6-dimethyl-nicotinamide (0.25 g, 1.5
mmol),
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(0.468 g, 1.5 mmol), sodium hydrogensulfite (0.271 g, 1.51 mmol)
and p-toluenesulfonic acid (0.358 g, 1.82 mmol) in N,N-dimethyl
acetamide (10 mL) was stirred at 150.degree. C. for 4 hours. The
reaction mixture was cooled to room temperature, diluted with water
(50 mL), basified with sodium bicarbonate, to pH approximately 8-9,
extracted with EtOAc (3.times.100 mL), and concentrated on a rotary
evaporator, to afford a solid residue, which was purified by column
chromatography (SiO.sub.2, DCM/MeOH/EtOAc=6:1:2) to yield
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-5,7-
-dimethyl-3H-pyrido[2,3-d]pyrimidin-4-one (56 mg, 8%).
[0551] To a solution of
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-5,7-
-dimethyl-3H-pyrido[2,3-d]pyrimidin-4-one (107 mg, 0.234 mmol) in
THF (10 mL) was added TBAF in THF (3 mL, 3 mmol) and the mixture
was stirred at room temperature for 15 hours. The mixture was then
concentrated on a rotary evaporator and subjected to column
chromatography (SiO.sub.2, DCM/MeOH/EtOAc=6:1:2) to yield
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethyl-3H-pyrido[2,3-d-
]pyrimidin-4-one (36 mg, 45%).
[0552] A solution of
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethyl-3H-pyrido-[2,3--
d]pyrimidin-4-one (36 mg, 0.105 mmol) in MeOH (5 mL) and DCM (5 mL)
was mixed with HCl in ether (2 mL, 2 mmol) and stirred at room
temperature for 30 minutes. The reaction mixture was then
concentrated on a rotary evaporator. The resulting solid residue
was re-dissolved in minimal volume of MeOH-DCM (1:1) and triturated
with hexanes. The solid was collected by filtration and washed with
MeOH-DCM (1:20) to yield the title compound as a yellow solid (16.6
mg, 41%).
Example 15. Preparation of
5,7-difluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-o-
ne
##STR00024##
[0554] A mixture of 3,5-dimethoxy-4-hydroxybenzaldehyde (10 g,
66.67 mmol), (2-bromoethoxy)-dimethyl-tert-butylsilane (15 mL, 70
mmol), potassium iodide (1.1 g, 6.67 mmol), and sodium hydride
(4.00 g, 100 mmol) in DMF (150 mL) was heated and stirred at
70.degree. C. for 14 hours. The reaction was then cooled and
quenched by addition of water (100 mL). The mixture was extracted
with EtOAc (3.times.100 mL) and concentrated on a rotary
evaporator. The resulting residue was purified by column
(SiO.sub.2, hexanes/EtOAc=6:1) to yield
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(15.4 g, 75%).
[0555] A solution of 2-amino-4,6-difluorobenzoic acid (0.5 g, 2.9
mmol), EDCI.HCl (0.887 g, 4.62 mmol), HOBt (0.975 g, 7.22 mmol),
and triethylamine (1.6 mL, 11.552 mmol) in THF (50 mL) was stirred
at room temperature for 1 hour. Ammonium hydroxide (50% aqueous, 10
mL) was then added to the reaction mixture. The resulting mixture
was stirred at room temperature for 6 hours. The reaction was
quenched by adding water (50 mL), extracted with DCM (3.times.100
mL), and concentrated on a rotary evaporator to afford
2-amino-4,6-difluorobenzamide (0.25 g, 50%).
[0556] A mixture of 2-amino-4,6-difluoro benzamide (0.25 g, 1.45
mmol),
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(0.448 g, 1.45 mmol), sodium hydrogensulfite (0.26 g, 1.45 mmol)
and p-toluenesulfonic acid (0.276 g, 1.45 mmol) in N,N-dimethyl
acetamide (10 mL) was stirred at 155.degree. C. for 14 hours. The
reaction mixture was cooled to room temperature, diluted with water
(50 mL), extracted with EtOAc (3.times.100 mL), and concentrated on
a rotary evaporator, to afford impure product. The residue was
re-dissolved in THF (20 mL) and mixed with TBAF in THF (10 mL, 10
mmol). The reaction mixture was stirred at room temperature for 3
hours and concentrated on a rotary evaporator to afford an oily
residue. Further purification by column (SiO.sub.2, EtOAc/DCM=3:1)
yielded a light yellow solid. This solid was diluted with MeOH (10
mL) to make a slurry. The solid was collected by filtration and
washed with MeOH to afford the title compound as a light yellow
solid (49 mg, 5% overall yield).
Example 16. Preparation of
2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3H-quinazol-
in-4-one
##STR00025##
[0558] To a solution of 3,5-dihydroxybenzoic acid (10.0 g, 64.9
mmol) in anhydrous ethanol (100 mL) at room temperature was slowly
added concentrated sulfuric acid (10 mL). The resulting mixture was
stirred at reflux for 36 hours. The reaction was cooled to room
temperature, diluted with water (200 mL), extracted with
CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated on a rotary
evaporator, to afford 3,5-dihydroxybenzoic acid ethyl ester as a
colorless oil. Yield: 8.2 g (69%).
[0559] A solution of 3,5-dihydroxybenzoic acid ethyl ester (6.0 g,
33 mmol) and 2-iodo-propane (9.9 mL, 99 mmol) in DMF (200 mL) was
mixed with potassium carbonate (13.7 g, 98.9 mmol) and the mixture
was stirred at room temperature for 14 hours. The reaction mixture
was then diluted with water (300 mL), and extracted with ethyl
acetate (3.times.100 mL). The residue obtained upon concentration
was subjected to column chromatography (SiO.sub.2, hexanes/ethyl
acetate=3:1) to afford 3,5-diisopropoxybenzoic acid ethyl ester.
Yield: 8.80 g (100%).
[0560] A solution of 3,5-diisopropoxybenzoic acid ethyl ester (8.80
g, 33.1 mmol) and lithium hydroxide (3.18 g, 132 mmol) in water
(100 mL), methanol (50 mL), and THF (50 mL) was stirred at reflux
for 3 hours. It was then cooled to room temperature, diluted with
water (200 mL), acidified with 2 N hydrochloric acid, to pH
approximately 2, extracted with CH.sub.2Cl.sub.2 (3.times.100 mL),
and concentrated on a rotary evaporator, to afford
3,5-diisopropoxybenzoic acid as a white solid. Yield: 7.60 g
(97%).
[0561] A solution of 3,5-diisopropoxybenzoic acid (7.60 g, 31.9
mmol), triethylamine (5.3 mL, 38 mmol), and diphenylphosphoroyl
azide (8.3 mL, 38 mmol) in 1,4-dioxane (120 mL) and tert-butanol
(30 mL) was stirred at reflux for 16 hours. The reaction mixture
was then cooled to room temperature, diluted with 0.2 N sodium
bicarbonate aqueous (200 mL), extracted with CH.sub.2Cl.sub.2
(3.times.100 mL), and concentrated on a rotary evaporator. The
residue obtained was subjected to column chromatography (SiO.sub.2,
hexanes/ethyl acetate=3:1) to afford
3,5-diisopropoxyphenyl)-carbamic acid tert-butyl ester as a white
solid. Yield: 5.60 g (57%).
[0562] A solution of 3,5-diisopropoxyphenyl)-carbamic acid
tert-butyl ester (5.60 g, 18.2 mmol) in trifluoroacetic acid (30
mL) was stirred at reflux for 30 minutes and concentrated on a
rotary evaporator to dryness to afford 3,5-diisopropoxyphenylamine
trifluoroacetic acid salt as an oil. Yield: 5.27 g (90%).
[0563] To a round-bottomed flask contained
3,5-diisopropoxyphenylamine trifluoroacetic acid salt (5.27 g, 16.4
mmol) was slowly added oxalyl chloride (20 mL) and the mixture was
stirred at reflux for 1 hour. Extra oxalyl chloride was removed by
distillation and methanol (100 mL) was added to the residue. It was
then stirred at room temperature for 30 minutes and concentrated to
dryness on a rotary evaporator to afford
4,6-diisopropoxy-1H-indole-2,3-dione as a semi-solid. Yield: 4.33 g
(100%).
[0564] A solution of potassium hydroxide (15.3 g, 273 mmol) in
water (60 mL) was mixed with 4,6-diisopropoxy-1H-indole-2,3-dione
(4.33 g, 16.4 mmol). To this mixture was slowly added hydrogen
peroxide. The resulting mixture was stirred at 70.degree. C. for 30
minutes and cooled to 0.degree. C. The mixture was acidified at
0.degree. C. with 2 N hydrochloric acid to pH approximately 4,
extracted with CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated
on a rotary evaporator to afford 2-amino-4,6-diisopropoxy-benzoic
acid as a semi-solid. Yield: 2.91 g (70%).
[0565] A solution of 2-amino-4,6-diisopropoxybenzoic acid (2.91 g,
11.5 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (3.20 g, 16.7 mmol), HOBt (3.10 g, 23.0 mmol), and
triethylamine (4.2 mL, 30 mmol) in THF (200 mL) was stirred at room
temperature for 20 minutes. 50% (v/v) ammonia aqueous (20 mL) was
then added. The resulting solution was stirred at room temperature
for 14 hours, diluted with water (200 mL), extracted with
CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated on a rotary
evaporator. The residue obtained was subjected to column
chromatography (SiO.sub.2, ethyl
acetate/dichloromethane/methanol=6:2:1) to afford
2-amino-4,6-diisopropoxybenzamide. Yield: 1.2 g (41%).
[0566] A solution of 2-amino-4,6-diisopropoxybenzamide (0.30 g, 1.2
mmol), 4-(2-hydroxy-ethoxy)-3,5-dimethylbenzaldehyde (0.28 g, 1.4
mmol), sodium bisulfite (0.25 g, 1.4 mmol), and p-toluenesulfonic
acid (20 mg, 0.11 mmol) in dimethyl acetamide (10 mL) was stirred
at 150.degree. C. for 12 hours. Extra solvent was evaporated on a
rotary evaporator and the residue was diluted with saturated sodium
bicarbonate aqueous solution (100 mL) and extracted with
CH.sub.2Cl.sub.2 (3.times.100 mL). The residue obtained upon
concentration was subjected to column chromatography (SiO.sub.2,
ethyl acetate/dichloromethane/hexanes/methanol=4:4:4:1) to afford
the title compound as a light yellow solid. Yield: 35 mg (6.9%).
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.78 (br s, 1H), 7.66
(s, 2H), 6.78 (d, 1H), 6.42 (d, 1H), 4.72 (m, 1H), 4.63 (m, 1H),
3.97 (t, 3H), 3.92 (t, 2H), 2.33 (s, 6H), 1.45 (d, 3H), 1.41 (d,
3H). MS (ES.sup.+) m/z: 427.13 (M+1).
Example 17. Preparation of
2-[4-(2-hydroxyethoxy)-3,5-dimethyl-phenyl]-6-morpholin-4-ylmethyl-3H-qui-
nazolin-4-one
##STR00026##
[0568] To a solution of 5-methyl-2-nitrobenzoic acid (25.0 g, 138
mmol) in ethanol (200 mL) was slowly added concentrated sulfuric
acid (30 mL). The resulting solution was stirred at reflux for 48
hours. The reaction mixture was then poured into icy water (300
mL), extracted with CH.sub.2Cl.sub.2 (3.times.100 mL), and
concentrated on a rotary evaporator, to afford
5-methyl-2-nitrobenzoic acid ethyl ester. Yield: 28.9 g (100%).
[0569] A solution of 5-methyl-2-nitrobenzoic acid ethyl ester (28.9
g, 138 mmol), N-bromosuccinimide (24.6 g, 138 mmol), and benzoyl
peroxide (7.41 g, 30.6 mmol) in carbon tetrachloride (400 mL) was
stirred at 80.degree. C. under irradiation from a medium pressure
mercury lamp for 3 hours. The lamp was then removed and the
reaction was cooled to 40.degree. C. To this solution was slowly
added morpholine (14.6 mL, 168 mmol) and triethylamine (43.0 mL,
306 mmol). The resulting mixture was stirred at 40.degree. C. for
14 hours, diluted with saturated sodium bicarbonate aqueous (300
mL), extracted with CH.sub.2Cl.sub.2 (3.times.100 mL), and
concentrated on a rotary evaporator. The residue was subjected to
column chromatography (SiO.sub.2, hexanes/ethyl ether=1:2) to
afford 5-morpholin-4-ylmethyl-2-nitrobenzoic acid ethyl ester as an
oil. Yield: 20 g (49%).
[0570] To a solution of 5-morpholin-4-ylmethyl-2-nitrobenzoic acid
ethyl ester (20 g, 68 mmol) in acetic acid (100 mL) was added iron
powder (13.0 g, 231 mmol). The resulting suspension was stirred at
60.degree. C. for 3 hours, cooled to room temperature, and diluted
with water (200 mL) and CH.sub.2Cl.sub.2 (200 mL). The solid was
filtered off, and the filtrate was extracted with CH.sub.2Cl.sub.2
(3.times.100 mL) and concentrated on a rotary evaporator to remove
all solvent. The residue was re-dissolved in CH.sub.2Cl.sub.2 (400
mL), and backwashed with 2 N potassium hydroxide aqueous
(2.times.200 mL). The organic layer was dried over anhydrous sodium
sulfate and concentrated, to afford
2-amino-5-morpholin-4-ylmethylbenzoic acid ethyl ester as an oil.
Yield: 17.7 g (100%).
[0571] A solution of 2-amino-5-morpholin-4-ylmethylbenzoic acid
ethyl ester (3.82 g, 15.3 mmol) and lithium hydroxide (0.733 g,
30.6 mmol) in THF (25 mL), methanol (15 mL), and water (10 mL) was
stirred at reflux for 2.5 hours. The reaction mixture was then
concentrated to dryness on a rotary evaporator and further dried
under high vacuum for 24 hours to afford lithium
2-amino-5-morpholin-4-ylmethylbenzoate. Complete conversion was
assumed and the solid obtained was used in the next step without
further purification.
[0572] A solution of lithium 2-amino-5-morpholin-4-ylmethylbenzoate
(3.70 g, 15.3 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (5.87 g, 30.6 mmol), HOBt (4.54 g, 33.6 mmol), and
4-methylmorpholine (5.0 mL, 46 mmol) in THF (200 mL) was stirred at
room temperature for 40 minutes. 50% (v/v) aqueous ammonia (20 mL)
was then added. The resulting solution was stirred at room
temperature for 14 hours, diluted with water (200 mL), extracted
with CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated on a
rotary evaporator, to afford
2-amino-5-morpholin-4-ylmethylbenzamide as a light yellow solid.
Yield: 1.2 g (33%).
[0573] A solution of 2-amino-5-morpholin-4-ylmethylbenzamide (0.60
g, 2.6 mmol), 4-(2-hydroxyethoxy)-3,5-dimethylbenzaldehyde (0.58 g,
3.9 mmol), sodium bisulfite (1.14 g, 6.44 mmol), and
p-toluenesulfonic acid (0.88 g, 4.6 mmol) in dimethyl acetamide (10
mL) was stirred at 150.degree. C. for 12 hours. Extra solvent was
evaporated on a rotary evaporator and the residue was diluted with
saturated sodium bicarbonate aqueous solution (100 mL) and
extracted with CH.sub.2Cl.sub.2 (3.times.100 mL). The residue
obtained on concentration was subjected to column chromatography
(SiO.sub.2, hexanes/ethyl acetate/dichloromethane/methanol=4:4:8:1)
to afford
2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-morpholin-4-ylmethyl--
3H-quinazolin-4-one as a light yellow solid. Yield: 0.15 g
(14%).
[0574] A solution of
2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-morpholin-4-ylmethyl-3H-quin-
azolin-4-one (0.15 g, 0.37 mmol) in CH.sub.2Cl.sub.2 (10 mL) was
mixed with 1 N HCl in ethyl ether (3 mL, 3 mmol) and was stirred at
room temperature for 10 minutes to form a suspension. The solid was
filtered, and washed with CH.sub.2Cl.sub.2 to afford the title
compound as a light yellow solid. Yield: 52 mg (29%). .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.49 (s, 1H), 8.13 (d, 1H), 7.93 (d,
1H), 7.77 (s, 2H), 4.58 (s, 2H), 4.05 (m, 2H), 3.98 (t, 2H), 3.91
(t, 2H), 3.80 (m, 2H), 3.41 (m, 2H), 3.30 (m, 2H), 2.44 (s, 6H). MS
(ES.sup.+) m/z: 410.05 (M+1).
Example 18. Preparation of
2-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinaz-
olin-4-one
##STR00027##
[0576] To a solution of 4-hydroxy-3,5-dimethylbenzaldehyde (1.50 g,
10.0 mmol) in anhydrous DMF (20 mL) were added cesium carbonate
(6.52 g, 20.0 mmol) and 4-chloromethyl-2,2-dimethyl-[1,3]dioxolane
(1.50 g, 10.0 mmol). The reaction mixture was stirred at 80.degree.
C. for 4 days under nitrogen, then cooled to room temperature.
Water (100 mL) was added, and the mixture extracted with ethyl
acetate (200 mL). The organic phase was separated, washed with 1 N
aqueous NaOH solution (100 mL), water (2.times.100 mL), brine (100
mL), and dried over anhydrous Na.sub.2SO.sub.4. Solvent was removed
under reduced pressure, and the crude compound was purified using
the Simpliflash system (20% ethyl acetate in hexanes as eluent) to
give
4-(2,2-dimethyl-[1,3]dioxolane-4-ylmethoxy)-3,5-dimethyl-benzaldehyde
as a yellow oil. Yield: 0.95 g (36%).
[0577] To a solution of 2-amino-4,6-dimethoxybenzamide (0.35 g, 1.8
mmol) in N,N-dimethyl acetamide (10 mL) were added
4-(2,2-dimethyl-[1,3]dioxolane-4-ylmethoxy)-3,5-dimethyl-benzaldehyde
(0.520 g, 1.98 mmol), sodium hydrogensulfite (58.5 wt %) (0.350 g,
1.98 mmol) and p-toluenesulfonic acid (0.17 g, 0.90 mmol). The
reaction mixture was stirred at 120.degree. C. for 16 hours under
nitrogen, then cooled to room temperature. Solvent was evaporated
under reduced pressure, water (50 mL) was added, the separated
solid was filtered, washed with water, then dichloromethane (10
mL), and dried under vacuum to give the title compound as a yellow
solid. Yield: 0.34 g (47%). .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 11.8 (s, 1H), 7.83 (s, 2H), 6.64 (s, 1H), 6.44 (s, 1H),
4.95 (d, 1H), 4.40 (t, 1H), 3.88 (s, 3H), 3.84-3.66 (m, 6H), 3.46
(t, 2H), 2.28 (s, 6H). MS (ES) m/z: 401.04 (M+1) (100%).
Example 19. Preparation of
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one hydrochloride
##STR00028##
[0579] Bromine (33.7 mL, 657 mmol) and 1,4-dioxane (56.0 mL, 657
mmol) was mixed at room temperature to provide fresh dioxane
dibromide, which was then diluted with ethyl ether (900 mL). To a
solution of 2,6-dimethoxytoluene (50.0 g, 328 mmol) in ether (450
mL) was added the freshly prepared dioxane dibromide in ether (900
mL) over 30 minutes while stirring at room temperature. After the
addition, the mixture was stirred at room temperature for an
additional 1.5 hours, and was poured into a beaker containing water
(500 mL) and partitioned. The aqueous was discarded and the
ethereal layer was washed sequentially with water (2.times.500 mL),
saturated sodium bicarbonate aqueous (2.times.500 mL), dried over
anhydrous sodium sulfate, and concentrated on a rotary evaporator,
to afford 3-bromo-2,6-dimethoxytoluene as a colorless oil. Yield:
76 g, (100%).
[0580] A cooling well was used to collect 300 mL of ammonia at
-78.degree. C., which was then mixed with 0.5 g potassium and 0.5 g
ferric nitrate. After the initial blue color discharged, potassium
(14.2 g, 364 mmol) was added at -78.degree. C., portion-wise so
that the blue color discharged before to each addition. After
complete addition of potassium, the solution was stirred at
-78.degree. C. for 15 minutes. To this solution was slowly added
3-bromo-2,6-dimethoxytoluene (42.0 g, 182 mmol) in THF (100 mL).
The resulting mixture was stirred at -78.degree. C. for 3 hours and
then 0.degree. C. for 1 hour. The reaction was quenched by adding
water (150 mL) and was extracted with CH.sub.2Cl.sub.2 (3.times.200
mL) to afford a brown oil as the crude product. The product was
further purified by column chromatography (SiO.sub.2, hexanes/ethyl
acetate=1:1) to yield 3,5-dimethoxy-4-methylaniline. Yield: 22.1 g
(73%).
[0581] A solution of 3,5-dimethoxy-4-methylaniline (22.1 g, 132
mmol) in 1,4-dioxane (380 mL) and water (380 mL) was mixed with
potassium carbonate (45.6 g, 331 mmol) and (Boc).sub.2O (34.6 g 159
mmol) and stirred at room temperature for 14 hours. The reaction
mixture was then extracted with CH.sub.2Cl.sub.2 (3.times.100 mL)
and concentrated on a rotary evaporator. The resulting solid
residue was purified by column chromatography (SiO.sub.2,
hexanes/ethyl acetate=2:1) to yield a solid. A mixed solvent of
CH.sub.2Cl.sub.2-hexanes (20 mL/300 mL) was used to make a slurry
and the solid was collected by filtration and washed with hexanes
to provide (3,5-dimethoxy-4-methylphenyl)-carbamic acid tert-butyl
ester as a light yellow needle-like solid. Yield: 28.6 g (81%).
[0582] A solution of (3,5-dimethoxy-4-methylphenyl)-carbamic acid
tert-butyl ester (28.6 g, 107 mmol) in carbon tetrachloride (450
mL) was mixed with NBS (19.05 g, 107.1 mmol) and AIBN (1.55 g, 9.37
mmol) and was stirred at 80.degree. C. under irradiation from a
medium-pressure mercury lamp for 2 hours. The reaction was then
quenched by adding water (150 mL) and extracted with
CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated on a rotary
evaporator to afford a solid residue. Further purification on
column (SiO.sub.2, hexanes/ethyl acetate=2:1) yielded
(2-bromo-3,5-dimethoxy-4-methylphenyl)-carbamic acid tert-butyl
ester. Yield: 34.9 g (94%).
[0583] solution of (2-bromo-3,5-dimethoxy-4-methylphenyl)-carbamic
acid tert-butyl ester (34.9 g, 101 mmol) in carbon tetrachloride
(450 mL) was mixed with N-bromosuccinimide (21.5 g, 121 mmol) and
AIBN (1.55 g, 9.37 mmol) and was stirred at 80.degree. C. under
irradiation from a medium-pressure mercury lamp for 4 hours. The
reaction was then quenched by adding water (150 mL) and extracted
with CH.sub.2Cl.sub.2 (3.times.100 mL), and concentrated on a
rotary evaporator to afford a solid residue. Further purification
on a column (SiO.sub.2, hexanes/ethyl acetate=2:1) yielded
(2-bromo-4-bromomethyl-3,5-dimethoxyphenyl)-carbamic acid
tert-butyl ester. Yield: 39.0 g (91%).
[0584] A solution of
(2-bromo-4-bromomethyl-3,5-dimethoxyphenyl)-carbamic acid
tert-butyl ester (39.0 g, 91.8 mmol) in THF (600 mL) was mixed with
morpholine (45.0 mL, 515 mmol) and stirred at room temperature for
7 hours. The reaction was diluted with water (300 mL), extracted
with CH.sub.2Cl.sub.2 (3.times.200 mL), and concentrated on a
rotary evaporator. The residue was further purified by column
(SiO.sub.2, dichloromethane/methanol=20:1) to provide
(2-bromo-3,5-dimethoxy-4-morpholin-4-ylmethylphenyl)-carbamic acid
tert-butyl ester. Yield: 35 g (88%).
[0585] A solution of
(2-bromo-3,5-dimethoxy-4-morpholin-4-ylmethylphenyl)-carbamic acid
tert-butyl ester (3.0 g, 6.9 mmol) in THF (150 mL) was mixed with
sodium hydride (0.333 g, 8.33 mmol) and stirred at room temperature
for 1.5 hours. The resulting mixture was then cooled to -78.degree.
C. and mixed with nBuLi (3.33 mL, 8.33 mmol). The reaction was
stirred for 1.5 hours at -78.degree. C. before addition of tBuLi
(8.16 mL, 13.9 mmol). After addition of tBuLi, the reaction was
stirred at -78.degree. C. for 1 hour and carbon dioxide gas was
then bubbled through for 8 hours, allowing the temperature to rise
gradually to room temperature. The reaction was quenched by adding
water (0.50 mL, 28 mmol) and concentrated on a rotary evaporator.
The solid residue was made into a slurry in a minimal amount of
methanol and the solid was filtered off. The filtrate was then
concentrated on a rotary evaporator and the solid was made into a
slurry again in methanol and filtered. After repeating three times,
the filtrate was concentrated to yield impure
6-tert-butoxycarbonylamino-2,4-dimethoxy-3-morpholin-4-ylmethyl-benzoic
acid. Crude yield: 1.80 g (40%).
[0586] A solution of crude
6-tert-butoxycarbonylamino-2,4-dimethoxy-3-morpholin-4-ylmethyl-benzoic
acid (1.80 g, 4.54 mmol),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.31
g, 6.82 mmol), HOBt (1.23 g, 9.09 mmol), and triethylamine (3.3 mL,
24 mmol) in THF (50 mL) was stirred at room temperature for 1 hour.
50% (v/v) aqueous ammonia (20 mL) was then added. The resulting
solution was stirred at room temperature for 14 hours, diluted with
water (100 mL), extracted with CH.sub.2Cl.sub.2 (3.times.100 mL),
and concentrated on a rotary evaporator. The residue was further
purified by column chromatography (SiO.sub.2,
dichiorometane/methanol/ethyl acetate=2:1:4) to provide
(2-carbamoyl-3,5-dimethoxy-4-morpholin-4-ylmethyl-phenyl)-carbamic
acid tert-butyl ester. Yield: 0.90 g (50%).
[0587] A solution of
(2-carbamoyl-3,5-dimethoxy-4-morpholin-4-ylmethylphenyl)-carbamic
acid tert-butyl ester (0.90 g, 2.7 mmol) in acetic acid (20 mL) and
12 N HCl aqueous (20 mL) was stirred at 50.degree. C. for 1 hour,
and then concentrated to dryness on a rotary evaporator. The
residue was mixed with saturated sodium bicarbonate aqueous (40
mL), extracted with CH.sub.2Cl.sub.2 (3.times.100 mL), and
concentrated on a rotary evaporator. The residue was further
purified on a column (SiO.sub.2, dichloromethane/methanol/ethyl
acetate=3:2:3), to provide
6-amino-2,4-dimethoxy-3-morpholin-4-ylmethylbenzamide. Yield: 0.6 g
(89%).
[0588] A solution of
6-amino-2,4-dimethoxy-3-morpholin-4-ylmethylbenzamide (0.50 g, 1.7
mmol), 4-(2-hydroxyethoxy)-3,5-dimethylbenzaldehyde (0.50 g, 2.5
mmol), sodium bisulfite (0.90 g, 5.1 mmol), and p-toluenesulfonic
acid (0.80 g, 4.2 mmol) in dimethyl acetamide (15 mL) was stirred
at 150.degree. C. for 14 hours. Extra solvent was evaporated on a
rotary evaporator and the residue was diluted with saturated sodium
bicarbonate aqueous solution (100 mL) and extracted with
CH.sub.2Cl.sub.2 (3.times.100 mL). The residue obtained upon
concentration was subjected to column chromatography (SiO.sub.2,
hexanes/ethyl acetate/dichloromethane/methanol=1:2:5:1) to afford
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one as a light yellow solid. Yield: 0.12 g
(15%).
[0589] A solution of
2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-morpholin-4-y-
lmethyl-3H-quinazolin-4-one (0.12 g, 0.26 mmol) in CH.sub.2Cl.sub.2
(10 mL) was mixed with 1 N HCl in ethyl ether (3 mL, 3 mmol) and
was stirred at room temperature for 10 minutes to form a
suspension. The solid was filtered, and washed with
CH.sub.2Cl.sub.2 to afford the title compound as a light yellow
solid. Yield: 32 mg (23%). .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 7.62 (s, 2H), 7.08 (s, 1H), 4.00 (m, 4H), 3.96 (s, 3H),
3.87 (s, 3H), 3.80 (br s, 2H), 3.70 (br s, 4H), 2.67 (br s, 4H),
2.40 (s, 6H). MS (ES.sup.+) m/z: 470.17 (M+1).
Example 20. Preparation of
2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one
##STR00029##
[0591] To a flask (250 mL) with a magnetic stirrer were added
4-hydroxybenzalde (10.0 g, 81.8 mmol), 2-chloroethanol (26.3 g, 327
mmol), potassium carbonate (22.6 g, 163 mmol), and ethanol (80 mL).
The reaction mixture was stirred at 70.degree. C. for 16 hours.
Potassium carbonate was filtered and ethanol was removed. The
residue was diluted with ethyl acetate (200 mL) and washed with 5%
sodium hydroxide (100 mL), water (100 mL), and brine (100 mL). The
crude product was purified by column chromatography (silica gel,
230-400 mesh), using hexane/ethyl acetate (1:1) as eluent, to
afford 4-(2-hydroxy-ethoxy)-benzaldehyde. Yield: 10.0 g (73%).
[0592] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.400 g,
2.00 mmol) and 4-(2-hydroxy-ethoxy)-benzaldehyde (0.340 g, 2.00
mmol) in N,N-dimethylacetamide (8 mL) were added NaHSO.sub.3 (0.390
g, 2.20 mmol) and p-TSA (38 mg, 0.20 mmol). The reaction mixture
was stirred at 115-120.degree. C. for 5 hours and cooled to room
temperature. The solvent was removed under reduced pressure. The
residue was diluted with water (40 mL) and the solid was collected,
mixed with methanol (50 mL), and stirred for 30 min. The solid was
filtered and rinsed with ether (30 mL) to give the title compound
as white solid. Yield: 0.42 g (61%). .sup.1H NMR (400 Hz,
DMSO-d.sub.6): .delta. 11.98 (s, 1H), 8.18 (d, 2H), 7.08 (d, 2H),
6.78 (s, 1H), 6.52 (s, 1H), 4.98 (s, 1H), 4.10 (t, 2H), 3.90 (s,
3H), 3.84 (s, 3H), 3.74 (t, 2H). MS (ES.sup.+) m/z: 343.13
(M+1).
Example 21. Preparation of
2-[4-(2-hydroxy-ethoxy)-naphthalen-1-yl]-5,7-dimethoxy-3H-quinazolin-4-on-
e
##STR00030##
[0594] To a mixture of 4-hydroxy-naphthalene-1-carbaldehyde (1.0 g,
5.8 mmol) and potassium carbonate (2.40 g, 17.4 mmol) in
N,N-dimethylformamide (3 mL) under nitrogen was added
2-chloroethanol (0.80 mL, 12 mmol). The reaction mixture was heated
at reflux for 20 hours and the solvent was then removed under
reduced pressure. The residue was diluted with ethyl acetate,
washed with water, 0.2 N aqueous sodium hydroxide, brine, and dried
over anhydrous sodium sulfate. The crude oil (1.03 g) was purified
by column chromatography (silica gel 230-400 mesh; methylene
chloride/EtOAc=3/7), to give
4-(2-hydroxy-ethoxy)-naphthalene-1-carbaldehyde as a colorless oil.
Yield: 0.6 g (48%).
[0595] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.45 g,
2.3 mmol) in N,N-dimethylacetamide (25 mL) under nitrogen was added
4-(2-hydroxy-ethoxy)-naphthalene-1-carbaldehyde (0.50 g, 2.3 mmol)
followed by sodium hydrogensulfite (0.26 g, 2.5 mmol) and
p-toluenesulfonic acid (0.22 g, 1.1 mmol). The resulting mixture
was heated at 130.degree. C. for 15 hours and the solvent was
removed under reduced pressure. The residue was diluted with ethyl
acetate, washed with water, and dried over sodium sulfate. The
crude orange solid (0.37 g) was purified by column chromatography
(silica gel, 230-400 mesh; 3/7 methylene chloride/EtOAc then 9/1
methylene chloride/MeOH as eluent) and by triturating with
methylene chloride and ether to afford the title compound as a
light orange solid. Yield: 0.16 g (36%). .sup.1H NMR (400 MHz,
CDCl.sub.3+CD.sub.3OD): .delta. 8.34 (d, 1H), 8.19 (d, 1H), 7.62
(d, 1H), 7.44-7.53 (m, 2H), 6.84 (d, 1H), 6.75 (s, 1H), 6.43 (s,
1H), 4.22-4.24 (m, 2H), 4.01-4.03 (m, 2H), 9.90 (s, 3H), 3.85 (s,
3H). MS (ES.sup.+) M/z: 393.27 (M+1).
Example 22. Preparation of
2-(2-hydroxymethyl-benzofuran-5-yl)-5,7-dimethoxy-3H-quinazolin-4-one
##STR00031##
[0597] To a solution of 4-hydroxy-benzaldehyde (3.66 g, 30.0 mmol)
in 50% (v/v) aqueous ammonium hydroxide (250 mL) was quickly added
a solution of potassium iodide (24.9 g, 150 mmol) and iodine (7.62
g, 30.0 mmol) in water (60 mL). The dark colored solution was
stirred at room temperature for 1 hour and the color changed to
yellow. Stirring was continued at room temperature for 16 hours.
The color changed to gray. Then, the reaction mixture was filtered
through a celite pad. The filtrate was acidified with concentrated
HCl to pH approximately 1 and extracted with ethyl acetate
(1.times.300 mL). The organic phase was washed with water (150 mL)
and brine (150 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated to give 4-hydroxy-3-iodo-benzaldehyde as an off-white
solid (1:1 mixture of starting material and product). Yield: 5.34 g
(crude).
[0598] To a degassed solution of 4-hydroxy-3-iodo-benzaldehyde
(5.34 g, 15.0 mmol) in anhydrous DMF (100 mL) were added
bis(triphenylphosphine)palladium(II) dichloride (0.53 g, 0.75
mmol), copper (I) iodide (0.14 g, 0.75 mmol), 1,1,3,3-tetramethyl
guanidine (8.64 g, 75.0 mmol), and propargyl alcohol (1.18 g, 21.0
mmol). The reaction mixture was stirred at room temperature for 24
hours under nitrogen and then concentrated to dryness under reduced
pressure. The residue was diluted with 2 N aqueous HCl (150 mL) and
extracted with ethyl acetate (1.times.200 mL). Organic phase was
washed with water (2.times.100 mL), brine (100 mL), and dried over
anhydrous Na.sub.2SO.sub.4. Solvent was evaporated and crude
compound was purified using the Simpliflash system (30% ethyl
acetate in hexanes as eluent) to give
2-hydroxymethyl-benzofuran-5-carbaldehyde as a pale yellow solid.
Yield: 1.36 g (26% for two steps).
[0599] To a solution of 2-hydroxymethyl-benzofuran-5-carbaldehyde
(0.450 g, 2.55 mmol) and 2-amino-4,6-dimethoxy-benzamide (0.500 g,
2.55 mmol) in N,N-dimethylacetamide (5 mL) were added sodium
hydrogen sulfite (58.5 wt %; 0.510 g, 2.80 mmol) and
p-toluenesulfonic acid (50 mg, 0.25 mmol). The reaction mixture was
stirred at 120.degree. C. for 6 hours under nitrogen and cooled to
room temperature. The separated solid was filtered, washed with
ether (30 mL), water (30 mL), and ethyl acetate (20 mL), and then
dried under vacuum to give the title compound as a yellow solid.
Yield: 0.572 g (64%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
12.07 (br s, 1H), 8.44 (d, J=2.0 Hz, 1H), 8.10 (dd, J=8.8 and 1.6
Hz, 1H), 7.67 (d, J=8.8 Hz, 1H), 6.89 (s, 1H), 6.76 (d, J=2.4 Hz,
1H), 6.54 (d, J=2.4 Hz, 1H), 4.61 (s, 2H), 3.90 (s, 3H), 3.86 (s,
3H). MS (ES') m/z: 353.20 (M+1).
Example 23. Preparation of
7-(2-benzyloxy-ethoxy)-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-met-
hoxy-3H-quinazolin-4-one
##STR00032##
[0601] To a solution of 4-hydroxy-3,5-dimethyl-benzaldehyde (1.00
g, 6.70 mmol) in DMF (20 mL) was added cesium carbonate (8.70 g,
26.6 mmol) followed by (2-bromo-ethoxy)-tert-butyl-dimethyl-silane
(2.9 mL, 13 mmol). The reaction mixture was stirred at room
temperature for 16 hours. Water was added and the product was
extracted with ethyl acetate. The solvent was evaporated in vacuo
to obtain
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
as a colorless oil. It was contaminated with
(2-bromo-ethoxy)-tert-butyl-dimethyl-silane, but was used in the
next step without further purification. Yield: 2.5 g (71%).
[0602] To a stirred solution of 2-amino-4,6-difluoro-benzamide
(0.50 g, 2.9 mmol) and
4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-benzaldehyde
(1.3 g, 2.9 mmol) in N,N-dimethylacetamide (10 mL) were added
sodium hydrogen sulfite (0.60 g, 3.5 mmol) and p-toluenesulfonic
acid (0.1 g, 0.6 mmol) and the reaction mixture was stirred at
120.degree. C. for 16 hours. The solvent was evaporated in vacuo,
water was added, and the precipitated solid was filtered off to
obtain
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-5,7-
-difluoro-3H-quinazolin-4-one as a yellow solid, which was used in
the next step without further purification. Yield: 0.490 g
(36%).
[0603] To a suspension of
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-5,7-
-difluoro-3H-quinazolin-4-one (0.490 g, 1.06 mmol) in DMF (3 mL)
was added sodium methoxide in methanol (2.3 mL, 11 mmol) and the
reaction mixture was stirred at room temperature for 16 hours.
Water was added, the mixture was acidified with acetic acid, to pH
approximately 4-5, and the precipitated solid was filtered off to
obtain
7-fluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3H-quinaz-
olin-4-one as a white solid. Yield: 0.21 g (55%).
[0604] To a solution of
7-fluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3H-quinaz-
olin-4-one (0.21 g, 0.59 mmol) in THF (12 mL) was added imidazole
(80 mg, 1.2 mmol), followed by tert-butyldiphenylsilyl chloride
(0.20 mL, 0.65 mmol). The reaction mixture was stirred at room
temperature for 16 hours. Saturated NH.sub.4Cl aqueous solution was
added and the product was extracted with ethyl acetate. The solvent
was evaporated in vacuo and the residue was purified by column
chromatography (silica gel; 230-400 mesh; eluting with 5-10% ethyl
acetate/CH.sub.2Cl.sub.2) to afford
2-{4-[2-(tert-butyl-diphenyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-7-f-
luoro-5-methoxy-3H-quinazolin-4-one. Yield: 0.36 g
(quantitative).
[0605] To a solution of 2-benzyloxy-ethanol (3 mL) in dimethyl
sulfoxide (3 mL) was added sodium hydride (0.24 g, 6.0 mmol) in
portions and the reaction mixture was stirred at room temperature
for 45 minutes. To this mixture was added
2-{4-[2-(tert-butyl-diphenyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-7-f-
luoro-5-methoxy-3H-quinazolin-4-one (0.36 g, 0.60 mmol) and the
reaction mixture was heated at 70.degree. C. for 16 hours. Water
was added, and the mixture was acidified with acetic acid, to pH
approximately 4-5, and the precipitated solid was filtered off to
obtain a crude product, which was purified by preparative HPLC to
obtain the title compound as a white solid. Yield: 0.12 g (42%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.83 (s, 1H), 7.89
(s, 2H), 7.37 (m, 5H), 6.75 (s, 1H), 6.53 (s, 1H), 4.91 (s, 1H),
4.58 (s, 2H), 4.30 (s, 2H), 3.84-3.73 (m, 9H), 2.31 (s, 6H). MS
(ES.sup.+) m/z: 491.55 (M+1).
Example 24. Preparation of
7-(2-benzyloxy-ethoxy)-2-(2-hydroxymethyl-benzofuran-5-yl)-5-methoxy-3H-q-
uinazolin-4-one
##STR00033##
[0607] To a stirred solution of
2-hydroxymethyl-benzofuran-5-carbaldehyde (2.00 g, 11.4 mmol) in
anhydrous CH.sub.2Cl.sub.2 (25 mL) were added N,N-diisopropylethyl
amine (5.17 g, 40.0 mmol) and chloromethyl methyl ether (2.76 g,
34.3 mmol) at room temperature. The reaction mixture was stirred at
room temperature for 16 hours under nitrogen. Phosphate buffer (pH
7, 100 mL) was added and the mixture was extracted with
dichloromethane (100 mL). The organic phase was separated, washed
with brine, and dried over anhydrous Na.sub.2SO.sub.4. Removal of
solvent gave 2-methoxymethoxymethyl-benzofuran-5-carbaldehyde as an
orange oil. Yield 2.41 g (96%).
[0608] To a solution of
2-methoxymethoxymethyl-benzofuran-5-carbaldehyde (2.31 g, 10.5
mmol) and 2-amino-4,6-difluoro-benzamide (1.20 g, 7.00 mmol) in
N,N-dimethyl acetamide (15 mL) were added sodium hydrogen sulfite
(58.5 wt %; 1.54 g, 8.40 mmol) and p-toluenesulfonic acid
monohydrate (0.26 g, 1.40 mmol). The reaction mixture was stirred
at 120.degree. C. for 4 hours under nitrogen, then cooled to room
temperature. Solvent was evaporated under reduced pressure and
water (100 mL) was added. The separated solid was filtered, washed
with water (50 mL), and dried under vacuum, to give
5,7-difluoro-2-(2-methoxymethoxymethyl-benzofuran-5-yl)-3H-quinazolin-4-o-
ne as a white solid. Yield 0.96 g (37%).
[0609] To a suspension of
5,7-difluoro-2-(2-methoxymethoxymethyl-benzofuran-5-yl)-3H-quinazolin-4-o-
ne (0.95 g, 2.56 mmol) in anhydrous DMF (5 mL) was added a solution
of sodium methoxide (25 wt %) in methanol at 0.degree. C. under
nitrogen. Then, the reaction mixture was stirred at 0.degree. C.
for 6 hours. Water (20 mL) was added, the mixture was acidified to
pH approximately 6 with glacial acetic acid. The separated solid
was filtered, washed with water (20 mL), and dried under vacuum to
give
7-fluoro-5-methoxy-2-(2-methoxymethoxymethyl-benzofuran-5-yl)-3H-quinazol-
in-4-one as a white solid. Yield 0.94 g (95%).
[0610] Sodium hydride (60% suspension in mineral oil; 0.48 g, 12.0
mmol) was taken in anhydrous DMF (5 mL). 2-Benzyloxyethanol (3.65
g, 24.0 mmol) was added dropwise at room temperature under
nitrogen. After the addition, the reaction mixture was stirred at
room temperature for 30 minutes. Then,
7-fluoro-5-methoxy-2-(2-methoxymethoxymethyl-benzofuran-5-yl)-3H-quinazol-
in-4-one (0.46 g, 1.2 mmol) was added and the reaction mixture was
stirred at 80.degree. C. for 16 hours. The reaction mixture was
then cooled to room temperature. Water (50 mL) was added, the
mixture was acidified to pH approximately 6 with glacial acetic
acid and extracted with CH.sub.2Cl.sub.2 (2.times.100 mL). The
organic phase was washed with brine (100 mL) and then dried over
anhydrous Na.sub.2SO.sub.4. Removal of solvent, followed by
purification, by the Simpliflash system (0-2% methanol in
CH.sub.2Cl.sub.2 as eluent) gave
7-(2-benzyloxy-ethoxy)-5-methoxy-2-(2-methoxymethoxymethyl-benzofuran-5-y-
l)-3H-quinazolin-4-one as a white solid. Yield 0.28 g (45%).
[0611] To a solution of
7-(2-benzyloxy-ethoxy)-5-methoxy-2-(2-methoxymethoxymethyl-benzo-furan-5--
yl)-3H-quinazolin-4-one (0.27 g, 0.53 mmol) in 50% aqueous acetic
acid (15 mL), conc. H.sub.2SO.sub.4 (0.3 mL) was added. The
reaction mixture was stirred at 75.degree. C. for 2 hours, then
cooled to room temperature. Water (50 mL) was added, and the
mixture was neutralized to pH approximately 7 with 4 N aqueous NaOH
solution. The separated solid was filtered, washed with water (20
mL), and dried under vacuum. Crude compound was purified by column
chromatography (silica gel 230-400 mesh; 2:20:78 methanol/ethyl
acetate/CH.sub.2Cl.sub.2 as eluent) to give the title compound as a
white solid. Yield 0.13 g (52%).
[0612] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.03 (bs, 1H),
8.43 (s, 1H), 8.09 (dd, J=8.58 and 1.95 Hz, 1H), 7.65 (d, J=8.58
Hz, 1H), 7.37-7.29 (m, 5H), 6.88 (s, 1H), 6.77 (d, J=1.95 Hz, 1H),
6.55 (d, J=1.56 Hz, 1H), 5.51 (s, 1H), 4.60 (t, J=4.68 Hz, 4H),
4.31 (s, 2H), 3.90-3.83 (m, 5H). MS (ES+) m/z 473.48 (100%).
Example 25. Preparation of
2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-methylacetamide
##STR00034##
[0614] To a solution of
[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy-
]-acetic acid (0.20 g, 0.52 mmol) in anhydrous DMF (8 mL) were
added EDCI (0.12 g, 0.62 mmol) and HOBt (0.084 g, 0.62 mmol). Then,
a solution of N-methyl amine (2.0 M solution in THF, 1.3 mL, 2.60
mmol) was added and the reaction mixture was stirred at room
temperature for 16 hours under nitrogen. Solvent was evaporated
under reduced pressure, water (20 mL) was added, and the separated
solid was filtered, washed with water (30 mL), ether (20 mL) and
dried under vacuum to give the title compound as a white solid.
Yield: 0.13 g (63%). .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.11.86 (br s, 1H), 8.19 (br s, 1H), 7.91 (s, 2H), 6.74 (d,
J=1.95 Hz, 1H), 6.52 (d, J=1.95 Hz, 1H), 4.26 (s, 2H), 3.89 (s,
3H), 3.85 (s, 3H), 2.72 (d, J=4.30 Hz, 3H), 2.30 (s, 6H). MS (ES)
m/z: 398.53 (M+1) (100%).
Example 26. Preparation of
2-[4-(5,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-pheno-
xy]-N-(4-methoxy-phenyl)-acetamide
##STR00035##
[0616] To a solution of 4-hydroxy-3,5-dimethyl-benzaldehyde (9.00
g, 60.0 mmol) in ethanol (300 mL) were added potassium carbonate
(24.9 g, 180 mmol) and methyl bromoacetate (11.4 mL, 120 mmol). The
reaction mixture was stirred at 95.degree. C. under nitrogen for 16
hours. The mixture was concentrated to dryness under reduced
pressure. Water (150 mL) and 1 N NaOH solution (90 mL) were added
to the residue. The mixture was stirred at room temperature for 30
minutes, then washed with ether. Concentrated HCl was added slowly
to the aqueous solution until a large amount of white precipitate
formed. The solid was filtered, washed with water, and air-dried,
to give (4-formyl-2,6-dimethyl-phenoxy)-acetic acid as a white
solid. Yield: 11.1 g (89%).
[0617] To a solution of (4-formyl-2,6-dimethyl-phenoxy)-acetic acid
(3.12 g, 15.0 mmol) and 2-amino-4,6-dimethoxy-benzamide (2.94 g,
15.0 mmol) in N,N-dimethylacetamide (50 mL) were added sodium
hydrogen sulfite (58.5 wt %, 3.02 g, 16.5 mmol) and
p-toluenesulfonic acid monohydrate (0.285 g, 1.50 mmol). The
reaction mixture was stirred at 120.degree. C. for 17 hours under
nitrogen and cooled to room temperature. The precipitate was
filtered, washed with water, then methanol, and air-dried to give
1.29 g
[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy-
]-acetic acid. The filtrate was concentrated to dryness and water
was added. The suspension was stirred for 30 minutes and filtered.
The solid was washed with water, then methanol. After air drying,
3.78 g more
[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy-
]-acetic acid was obtained. Yield: 5.07 g (88%).
[0618] To a mixture of
[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy-
]-acetic acid (0.400 g, 1.04 mmol),
1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI;
0.240 g, 1.24 mmol), 1-hydroxybenzotriazole hydrate (HOBt; 0.17 g,
1.24 mmol) in DMF (10 mL) was added 4-methylmorpholine (0.20 mL,
1.8 mmol). After 10 minutes, p-anisidine (0.26 g, 2.08 mmol) was
added. The mixture was stirred at room temperature under nitrogen
for 2.5 days. The solvent was removed under reduced pressure. Water
was added, stirred for 30 minutes. The solid was filtered, washed
with water, and dried in air. The crude product was purified by
column chromatography (silica gel, 230-400 mesh; 5% MeOH in
CH.sub.2Cl.sub.2 as eluent). The product fractions were combined,
concentrated to dryness. The solid was dissolved in small amount of
dichloromethane, precipitate out by adding ether. The precipitate
was filtered, washed with ether, dried under vacuum to afford the
title compound as a white solid. Yield: 0.26 g (51%). .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 10.30 (br s, 1H), 8.52 (s, 1H), 7.83
(s, 2H), 7.58 (dd, J=6.8 and 2.0 Hz, 2H), 6.93 (dd, J=6.8 and 2.0
Hz, 2H), 6.84 (d, J=2.4 Hz, 1H), 6.48 (d, J=2.0 Hz, 1H), 4.44 (s,
2H), 3.97 (s, 3H), 3.94 (s, 3H), 3.83 (s, 3H), 2.42 (s, 3H). MS
(ES.sup.+) m/z: 490.55 (M+1).
Example 27. Preparation of
N-benzyl-2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimeth-
ylphenoxy]acetamide
##STR00036##
[0620] To a mixture of
[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy]a-
cetic acid (0.25 g, 0.65 mmol), 1-ethyl-3-(3'-dimethylaminopropyl)
carbodiimide hydrochloride (EDCI; 0.137 g, 0.715 mmol),
1-hydroxybenzotriazole hydrate (HOBT; 0.110 g, 0.715 mmol) in DMF
(3 mL) was added 4-methylmorpholine (0.08 mL, 0.715 mmol) at room
temperature. After 10 minutes, benzylamine (0.142 mL, 1.30 mmol)
was added. The mixture was stirred at room temperature under
nitrogen for 15 hours. The solvent was removed under reduced
pressure. The crude compound was purified by column chromatography
(silica gel 230-400 mesh; 3% methanol in dichloromethane as
eluent), followed by triturating with an ether-hexane mixture to
afford the title compound as a white solid. Yield: 60 mg (39%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.86 (s, 1H), 8.79
(t, J=6.2 Hz, 1H), 7.89 (s, 2H), 7.34-7.21 (m, 5H), 6.72 (d, J=2.0
Hz, 1H), 6.50 (d, J=2.0 Hz, 1H), 4.38 (d, J=6.0 Hz, 2H), 4.33 (s,
2H), 3.87 (s, 3H), 3.82 (s, 3H), 2.30 (s, 6H). MS (ES.sup.+) m/z:
474.49 (M+1).
Example 28. Preparation of
2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin--
4-one
##STR00037##
[0622] To a solution of 4-hydroxy-3,5-dimethyl benzaldehyde (5.00
g, 33.3 mmol) in DMF (30 mL) were added 4-bromo butan-1-ol (6.11 g,
39.9 mmol) and Cs.sub.2CO.sub.3 (16.24 g, 50.0 mmol). The reaction
mixture was stirred at room temperature for 48 hours. Water was
added and the products were extracted with ethyl acetate
(2.times.200 mL). The combined organic phase was washed with water
(100 mL), brine (100 mL), and dried over anhydrous
Na.sub.2SO.sub.4. Solvent was removed and the crude compound was
purified using the Simpliflash system (40% ethyl acetate in hexane
as eluent) to give 4-(4-hydroxybutoxy)-3,5-dimethyl benzaldehyde as
a colorless liquid. Yield: 0.66 g (7%).
[0623] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.50 g,
2.53 mmol) and 4-(4-hydroxybutoxy)-3,5-dimethyl benzaldehyde (0.66
g, 2.53 mmol) in N,N-dimethyl acetamide (10 mL), NaHSO.sub.3 (0.50
g, 2.79 mmol) and p-TSA (96 mg, 0.50 mmol) were added and the
reaction mixture was heated at 115.degree. C. for 16 hours, then
cooled to room temperature. Solvent was removed under reduced
pressure. Water (100 mL) was added and the mixture was stirred for
1 hour. The solid separated was filtered and dried. The solid was
again washed with diethyl ether to give the title compound as a
white solid. Yield: 1.69 g (82%). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 9.10 (s, 1H), 7.66 (s, 2H), 6.83 (d, J=2.4 Hz,
1H), 6.46 (d, J=2.0 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.85 (t,
J=6.0 Hz, 2H), 3.78 (m, 2H), 2.36 (s, 6H), 1.94 (m, 2H), 1.85 (m,
2H). MS (ES) m/z: 399.12 (M+1) (100%).
Example 29. Preparation of
7-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one
##STR00038##
[0625] Following the method described in Example 33, the title
compound was made starting from 2-amino-4-chlorobenzoic acid and
isolated as a white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.46 (s, 1H), 8.12 (d, J=8.49 Hz, 1H), 7.90 (s, 2H), 7.77
(d, J=2.00 Hz, 1H), 7.52 (dd, J=8.49, 2.00 Hz, 1H), 4.90 (t, J=5.51
Hz, 1H), 3.86 (t, J=4.88 Hz, 2H), 3.76-3.69 (m, 2H), 2.32 (s, 6H).
MS (APCI) m/z 345 [C.sub.18H.sub.17ClN.sub.2O.sub.3+H].sup.+.
Example 30. Preparation of
8-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one
##STR00039##
[0627] Following the procedure described in Example 33, the title
compound was made starting from 2-amino-3-chlorobenzoic acid and
isolated as a white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6:
.delta. 12.55 (s, 1H), 8.09 (dd, J=7.88, 1.37 Hz, 1H), 8.00-7.93
(m, 3H), 7.46 (t, J=7.88 Hz, 1H), 4.91 (t, J=5.54 Hz, 1H), 3.86 (t,
J=4.90 Hz, 2H), 3.77-3.69 (m, 2H), 2.33 (s, 6H). MS (APCI) m/z 345
[C.sub.18H.sub.17ClN.sub.2O.sub.3+H].sup.+.
Example 31. Preparation of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-8-methoxyquinazolin-4(3H)-one
##STR00040##
[0629] Following the procedure described in Example 33, the title
compound was made starting from 2-amino-3-methoxybenzoic acid and
isolated as a white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.34 (s, 1H), 7.87 (s, 2H), 7.69 (dd, J=7.63, 1.59 Hz,
1H), 7.45-7.34 (m, 2H), 4.90 (t, J=5.53 Hz, 1H), 3.94 (s, 3H), 3.85
(t, J=4.92 Hz, 2H), 3.77-3.69 (m, 2H), 2.33 (s, 6H). MS (APCI) m/z
341 [C.sub.19H.sub.20N.sub.2O.sub.4+H].sup.+.
Example 32. Preparation of
5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one
##STR00041##
[0631] A mixture of 2-amino-6-chlorobenzoic acid (5.00 g, 29.1
mmol) in acetonitrile (50.0 mL) was stirred at room temperature
under nitrogen. Pyridine (4.72 mL, 58.3 mmol) was added, followed
by drop-wise addition of triphosgene (2.85 g, 9.60 mmol) in
CH.sub.2Cl.sub.2 (20.0 mL). After the addition, the mixture was
heated at 55.degree. C. for 2 hours, then cooled to 25.degree. C.
and stirred overnight. Water (100 mL) was added to quench, the
mixture was filtered, and washed with cold CH.sub.2Cl.sub.2, to
provide 5-chloro-1H-benzo[d][1,3]oxazine-2,4-dione (3.54 g, 62%) as
a white solid.
[0632] A mixture of 5-chloro-1H-benzo[d][1,3]oxazine-2,4-dione
(3.50 g, 17.7 mmol) and 2 M NH.sub.3 in EtOH (11.5 mL, 23.0 mmol)
and EtOH (10.0 mL) was stirred at room temperature for 2 hours. The
volatiles were removed under reduced pressure, the residue was
triturated with water (50 mL), and the solid was filtered, to
provide 2-amino-6-chlorobenzamide (1.60 g, 49%) as a tan solid.
[0633] A mixture of 2-amino-6-chlorobenzamide (0.490 g, 3.00 mmol),
4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylbenzaldehyde
(0.925 g, 3.00 mmol), NaHSO.sub.3 (94%, 0.468 g, 4.50 mmol), and
p-TsOH.H.sub.2O (0.171 g, 0.900 mmol) in DMA (10.0 mL) was heated
at 140.degree. C. for 16 hours. The mixture was cooled to room
temperature and the solvent was removed under reduced pressure. The
residue was diluted with EtOAc (50 mL), washed with water (50 mL),
then brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4,
filtered, and the solvent was removed under reduced pressure, to
provide
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-5-chloroq-
uinazolin-4(3H)-one as an off-white solid. The crude material was
used directly in the next step without characterization.
[0634] Following the method described for desilylation using TBAF
in Example 33 below, the title compound was made from
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-5-chloroq-
uinazolin-4(3H)-one in 21% yield and was isolated as a white solid.
.sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 12.32 (s, 1H), 7.90
(s, 2H), 7.82-7.55 (m, 2H), 7.48 (dd, J=7.54, 1.35 Hz, 1H), 4.90
(t, J=5.51 Hz, 1H), 3.86 (t, J=4.90 Hz, 2H), 3.77-3.68 (m, 2H),
2.32 (s, 6H). MS (APCI) m/z 345
[C.sub.18H.sub.17ClN.sub.2O.sub.3+H].sup.+.
Example 33. Preparation of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H)-one
##STR00042##
[0636] A mixture of 2-nitro-4-methoxybenzoic acid (1.00 g, 5.10
mmol) in methanol (10.0 mL) was stirred at room temperature under
nitrogen. Palladium on carbon (10% wt, 50% wet, 0.559 g, 0.255
mmol) was added. The round-bottomed flask was capped with a new
septa and degassed under vacuum. The flask was charged with
hydrogen and degassed again. This was repeated twice and a
hydrogen-filled balloon was attached to the flask. The mixture was
stirred at room temperature for 4 hours. Nitrogen was then bubbled
through the mixture to displace any excess hydrogen. The mixture
was filtered through celite 521 and the filtrate was concentrated
under reduced pressure to provide 2-amino-4-methoxybenzoic acid
(0.890 g, >99%) as an off-white solid. The crude material was
used directly in the next step without characterization.
[0637] A mixture of 2-amino-4-methoxybenzoic acid (0.490 g, 3.00
mmol), EDCI (1.12 g, 5.83 mmol), HOBt (0.788 g, 5.83 mmol),
N-methylmorpholine (0.590 g, 5.83 mmol) and 14.8 N NH.sub.4OH
(0.781 mL, 10.6 mmol) in THF was stirred at room temperature for 16
hours. The solvent was removed under reduced pressure, then the
residue was diluted with EtOAc (100 mL), washed with water
(2.times.100 mL), then brine (100 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered, and the solvent was removed under
reduced pressure to provide 2-amino-4-methoxybenzamide as a tan
solid.
[0638] A mixture of 2-amino-4-methoxybenzamide (0.490 g, 3.00
mmol),
4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylbenzaldehyde
(0.925 g, 3.00 mmol), NaHSO.sub.3 (94%, 0.468 g, 4.50 mmol), and
p-TsOH.H.sub.2O (0.171 g, 0.900 mmol) in benzene (10.0 mL) was
heated at 80.degree. C. for 36 hours. The mixture was cooled to
room temperature and the solvent was removed under reduced
pressure. The residue was diluted with EtOAc (50 mL), washed with
water (50 mL) then brine (50 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered, and the solvent was removed under
reduced pressure to provide
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-7-methoxy-
quinazolin-4(3H)-one as a pink solid. The crude material was used
directly in the next step without characterization.
[0639] A mixture of
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-7-methoxy-
quinazolin-4(3H)-one (1.09 g, 2.30 mmol) in 1 M TBAF (11.6 mL, 11.6
mmol) was stirred at room temperature for 3 hours. The mixture was
diluted with water (100 mL) and extracted with EtOAc (2.times.100
mL). The organic layers were combined, washed with saturated
aqueous NH.sub.4Cl (2.times.75 mL), then brine (100 mL), dried over
anhydrous Na.sub.2SO.sub.4, filtered, and the solvent was removed
under reduced pressure. The residue was purified over silica gel
(12 g, EtOAc/hexanes), triturated in ether, and the product was
freeze-dried from MeCN/H.sub.2O to yield the title compound (0.0960
g, 12%) as a white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.18 (s, 1H), 8.02 (d, J=8.79 Hz, 1H), 7.91 (s, 2H), 7.16
(d, J=2.46 Hz, 1H), 7.07 (dd, J=8.79, 2.46 Hz, 1H), 4.90 (t, J=5.53
Hz, 1H), 3.91 (s, 3H), 3.89-3.82 (m, 2H), 3.77-3.67 (m, 2H), 2.32
(s, 6H), 2.22 (d, J=6.92 Hz, 1H). MS (APCI) m/z 341
[C.sub.19H.sub.20N.sub.2O.sub.4+H].sup.+.
Example 34. Preparation of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)met-
hyl)quinazolin-4(3H)-one
##STR00043##
[0641] To a solution of
4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylbenzaldehyde
(7.5 g, 24.4 mmol) in DMA (50 mL) was added
2-amino-5-bromobenzamide (5.2 g, 24.4 mmol), NaHSO3 (3.9 g, 36.5
mmol) and p-TsOH (0.46 g, 2.4 mmol), and the reaction was heated at
160.degree. C. After 1 hour, the resulting mixture was cooled to
room temperature, diluted with water, and filtered to afford
6-bromo-2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylph-
enyl) quinazolin-4(3H)-one (6.7 g, 55%) as a white solid (6.7 g,
55%).
[0642] A mixture of
6-bromo-2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)
quinazolin-4(3H)-one (5.0 g, 9.9 mmol), vinyltributyltin (4.3 mL,
14.9 mmol) and PdCl.sub.2(PPh.sub.3).sub.2 (0.70 g, 1.0 mmol) in
CH.sub.3CN (150 mL) was stirred at reflux overnight. Then,
additional PdCl.sub.2(PPh.sub.3).sub.2 (0.10 g, 0.14 mmol) and
vinyltributyltin (2.0 mL, 6.8 mmol) were added and the reaction
continued to reflux overnight. The resulting mixture was cooled to
room temperature, filtered through celite, and the filtrate
concentrated. The residue was purified by flash chromatography
(silica, eluting with 98:2 CH.sub.2Cl.sub.2/MeOH) to afford
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-6--
vinylquinazolin-4(3H)-one (2.0 g, 45%).
[0643] To a solution of
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-6-vinylqu-
inazolin-4(3H)-one (0.63 g, 1.4 mmol) in THF (50 mL) and H.sub.2O
(5 mL) was added NaIO.sub.4 (0.90 g, 4.2 mmol) and OsO.sub.4 (0.11
mL, 0.014 mmol), and the reaction was stirred overnight at room
temperature. Then, the mixture was concentrated in vacuo and the
residue was purified by flash chromatography (silica gel, eluting
with 98:2 to 95:5 CH.sub.2Cl.sub.2/MeOH) to afford
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-4-oxo-3,4-
-dihydroquinazoline-6-carbaldehyde (0.52 g, 82%).
[0644] A solution of
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-4-oxo-3,4-
-dihydroquinazoline-6-carbaldehyde (0.11 g, 0.24 mmol) in
DCE/CH.sub.2Cl.sub.2 (1:1, 15 mL) was treated with
1-methylpiperazine (0.05 mL, 0.48 mmol) and NaBH(OAc).sub.3 (0.103
g, 0.48 mmol) and the reaction mixture was stirred at room
temperature overnight. Then, the mixture was concentrated in vacuo
and the residue was purified by flash chromatography (silica gel,
eluting with 60% of 92:7:1 CHCl.sub.3/MeOH/concentrated NH.sub.4OH
in CH.sub.2Cl.sub.2) to afford
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-6-((4-met-
hylpiperazin-1-yl)methyl)quinazolin-4(3H)-one (0.14 g, 98%).
[0645] A solution of
2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)-6-((4-met-
hylpiperazin-1-yl)methyl)quinazolin-4(3H)-one (0.087 g, 0.16 mmol)
in a 1 M TBAF/THF solution (1.3 mL, 1.3 mmol) was stirred for 2
hours at room temperature. Then, the resulting mixture was
concentrated in vacuo and purified by flash chromatography (silica
gel, eluting with 70% of 92:7:1 CHCl.sub.3/MeOH/concentrated
NH.sub.4OH in CH.sub.2Cl.sub.2) to afford the title compound (0.070
g, 100%): .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 12.31 (s,
1H), 8.02 (s, 1H), 7.89 (s, 2H), 7.56-7.79 (m, 2H), 4.92 (t, J=5.3
Hz, 1H), 3.77-3.93 (m, 2H), 3.64-3.75 (m, 2H), 3.58 (s, 2H),
2.21-2.45 (m, 14H), 2.15 (s, 3H). APCI MS m/z 423 [M+H].sup.+.
Example 35. Preparation of
5,7-Dimethoxy-2-{3-methyl-4-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylamino)-eth-
oxy]-phenyl}-3H-quinazolin-4-one
##STR00044##
[0647] To a solution of
2-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4--
one (0.37 g, 1.00 mmol) in anhydrous dichloroethane (20 mL) was
added benzoyl isothiocyanate (0.18 g 1.10 mmol). The reaction
mixture was stirred at room temperature for 3 hours. The solvent
was removed and ether (30 mL) was added. The mixture was stirred
for 30 minutes and the solid was filtered and dried to give
1-benzoyl-3-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2-met-
hyl-phenoxy]-ethyl}-thiourea as a white solid. Yield: 0.53 g
(99%).
[0648] To a solution of
1-benzoyl-3-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2-met-
hyl-phenoxy]-ethyl}-thiourea (0.42 g, 0.785 mmol) in chloroform (20
mL) was added hydrazine hydrate (1.30 mL, 26.5 mmol). The reaction
mixture was stirred at reflux for 16 hours. After the solvent was
removed, the residue was purified by preparative HPLC to afford the
title compound as a white solid. Yield: 35 mg (29%). .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 12.26 (s, 1H), 11.82 (s, 1H), 7.91
(m, 2H), 7.89 (s, 2H), 7.40 (m, 3H), 6.84 (s, 1H), 6.73 (d, J=2.0
Hz, 1H), 6.51 (d, J=2.0 Hz, 1H), 3.98 (t, J=5.6 Hz, 2H), 3.88 (s,
3H), 3.84 (s, 3H), 3.62 (m, 2H), 2.29 (s, 6H). MS (ES.sup.+) m/z
513.53 (M+1).
Example 36. Preparation of
2-{3,5-Dimethyl-4-[2-(3-methyl-[1,2,4]oxadiazol-5-ylamino)-ethoxy]-phenyl-
}-5,7-dimethoxy-3H-quinazolin-4-one
##STR00045##
[0650] Acetamide oxime (5.00 g, 67.5 mmol) and trichloroacetic
anhydride (49.3 mL, 270 mmol) were stirred at 120-130.degree. C.
for 3 hours. The mixture was then distilled under vacuum. The
fraction at approximately 50-70.degree. C./approximately 5 mmHg was
collected. The collected fraction was added to cold saturated
aqueous NaHCO.sub.3 and extracted with ethyl acetate. The organic
phase was washed with saturated aqueous NaHCO.sub.3 solution and
dried over Na.sub.2SO.sub.4. The solvent was evaporated to give
3-methyl-5-trichloromethyl-[1,2,4]oxadiazole as a colorless liquid.
Yield: 7.69 g (52%)
[0651] A mixture of 3-methyl-5-trichloromethyl-[1,2,4]oxadiazole
(56 mg, 0.28 mmol),
2-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4--
one (92 mg, 0.25 mmol), and cesium carbonate (179 mg, 0.55 mmol) in
DMF (3 mL) was stirred at room temperature under nitrogen for 3.5
days. Water was added, and the mixture was extracted with
MeOH/CH.sub.2Cl.sub.2. The organic phase was washed with brine,
dried over anhydrous Na.sub.2SO.sub.4, purified by column
chromatography (silica gel; 5% MeOH in CH.sub.2Cl.sub.2 as eluent)
to give the title compound as a beige solid. Yield: 75 mg (60%).
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.68 (s, 1H), 7.71 (s,
2H), 6.82 (d, J=2.4 Hz, 1H), 6.46 (d, J=2.4 Hz, 1H), 5.80 (t, J=5.6
Hz, 1H), 4.00-3.97 (m, 5H), 3.93 (s, 3H), 3.83 (m, 2H), 2.34 (s,
6H), 2.24 (s, 3H). MS (ES.sup.+) m/z: 452.57 (M+1).
Example 37. Preparation of
N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxy]-ethyl}-acetamide
##STR00046##
[0653] To a solution of 4-hydroxy-3,5-dimethyl-benzaldehyde (15.0
g, 0.10 mol) in anhydrous DMF (30 mL) was added 60% sodium hydride
(4.80 g, 0.12 mol) and the reaction mixture was kept stirring for
20 minutes. 2-(2-Bromo-ethyl)-isoindole-1,3-dione (25.4 g, 0.10
mol) in anhydrous DMF (30 mL) was added drop-wise. The reaction
mixture was heated to 65.degree. C. for 5 hours. Acetic acid (3 mL)
was added, DMF was removed, and the residue was poured into water
(150 mL), and extracted with dichloromethane (200 mL). The crude
compound was purified by column chromatography (silica gel 230-400
mesh; eluting with ethyl acetate and hexane 1:1) to give
4-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethoxy]-3,5-dimethyl-benzaldeh-
yde. Yield: 11.0 g (34%).
[0654] To a solution of 2-amino-4,6-dimethoxy-nicotinamide (0.40 g,
2.02 mmol, and
4-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethoxy]-3,5-dimethyl-
-benzaldehyde (0.65 g, 2.02 mmol) in N,N-dimethylacetamide (30 mL)
was added NaHSO.sub.3 (58.5 wt %, 0.40 g, 2.20 mol) and p-TSA (0.12
g, 6.00 mmol). The reaction mixture was heated to 145.degree. C.
for 16 hours, and then cooled to room temperature. Solvent was
removed under reduced pressure. Aqueous sodium bicarbonate solution
(50 mL) was added and the solid separated was filtered and washed
with ether (50 mL). Crude compound was purified by column
chromatography (silica gel, 230-400 mesh; methanol, ethyl acetate
and dichloromethane 5:20:75) to give
2-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxyl]-ethyl}-isoindole-1,3-dione as a light yellow
solid. Yield: 0.43 g (43%).
[0655] Hydrazine hydrate (0.2 mL, 4.1 mmol) was added to a solution
of
2-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-
-dimethyl-phenoxyl]-ethyl}-isoindole-1,3-dione (0.43 g, 0.86 mmol)
in ethanol (10 mL). The reaction mixture was heated to 70.degree.
C. for 4 hours, solvent was removed, and the residue was purified
by column chromatography (silica gel, 230-400 mesh; eluting with 5%
7 N ammonia in methanol and dichloromethane) to give
2-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-pyrido[2,3-d]-
pyrimidin-4-one as a white solid. Yield: 0.22 g (69%).
[0656] To a solution of
2-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-pyrido[2,3-d]-
pyrimidin-4-one (0.21 g, 0.56 mmol) in pyridine (4 mL) and
dichloromethane (10 mL) was added acetyl chloride (51 mg, 0.65
mmol), and the reaction mixture was stirred at room temperature for
3 hours. The solvent was removed under reduced pressure, the
residue was poured into water (50 mL) and stirred for 30 minutes.
The solid separated was filtered and washed with cold water and
ether, and then dried under vacuum to give the title compound as a
white solid. Yield: 0.19 g (81%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.15 (s, 1H), 7.90 (s, 2H), 6.36 (s, 1H),
3.93 (s, 3H), 3.88 (s, 3H), 3.79 (t, J=5.6 Hz, 3H), 3.42 (q, J=5.6
Hz, 2H), 2.28 (s, 6H), 1.84 (s, 3H). MS (ES) m/z: 411.15 (M-1).
Example 38. Preparation of
N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylbenzyl)-
acetamide
##STR00047##
[0658] 4-Bromo-2,6-dimethylaniline (4.49 g, 22.4 mmol), water (25
mL) and concentrated HCl (8.0 mL) were sonicated and cooled to
0.degree. C. Sodium nitrite (1.67 g, 24.2 mmol) in water (5 mL) was
added over 20 minutes. The mixture was stirred at 0.degree. C. for
30 minutes, and solid Na.sub.2CO.sub.3 was added to adjust the pH
to approximately 7. The liquid portion was added, in portions, to
copper (I) cyanide (2.42 g, 27.0 mmol) and potassium cyanide (3.65
g, 56.1 mmol) in water (25 mL) at 70.degree. C. over a period of 25
minutes and the mixture was heated at 70.degree. C. for 45 minutes.
The mixture was cooled and extracted with toluene (2.times.150 mL).
The organic phase was washed with water (100 mL), then brine (100
mL), dried (Na.sub.2SO.sub.4), filtered, and evaporated to afford a
brown oil. Purification by column chromatography (silica gel
230-400 mesh; 25% dichloromethane in hexanes as the eluent) gave
4-bromo-2,6-dimethylbenzonitrile as an orange solid. Yield: 2.3 g
(49%).
[0659] To 4-bromo-2,6-dimethylbenzonitrile (1.84 g, 8.75 mmol) in
anhydrous THF (95 mL), at -78.degree. C. under nitrogen, was added
n-butyllithium (2.5 M in hexanes; 3.85 mL, 9.63 mmol) dropwise over
10 minutes. The solution was stirred at -78.degree. C. for 1 hour,
and anhydrous DMF (1.00 mL, 12.91 mmol) was added dropwise. The
mixture was stirred at -78.degree. C. for 1 hour and at 0.degree.
C. for 25 minutes. The reaction was quenched with 1 M HCl, to pH
approximately 3. The solution was poured into water (370 mL) and
extracted with CHCl.sub.3 (7.times.100 mL). The organic phase was
dried over anhydrous Na.sub.2SO.sub.4, filtered, and evaporated, to
give 4-formyl-2,6-dimethylbenzonitrile as a yellow-orange solid
(1.20 g, 86%).
[0660] 4-Formyl-2,6-dimethylbenzonitrile (1.20 g, 7.53 mmol),
anhydrous MeOH (80 mL), trimethylorthoformate (18.0 mL, 164.5
mmol), and camphorsulfonic acid (0.050 g, 0.215 mmol) were stirred
at room temperature under nitrogen for 23 hours. Triethylamine (7.5
mL) was added and the solution was evaporated to an oil. The oil
was diluted with NaHCO.sub.3 (100 mL) and extracted with CHCl.sub.3
(5.times.75 mL). The organic phase was dried over anhydrous
Na.sub.2SO.sub.4, filtered, and evaporated to afford
4-(dimethoxymethyl)-2,6-dimethylbenzonitrile as a golden-red oil.
Yield: 1.40 g (90%).
[0661] To 4-(dimethoxymethyl)-2,6-dimethylbenzonitrile (0.86 g,
4.18 mmol) in anhydrous THF (40 mL), at 0.degree. C. under
nitrogen, was added solid lithium aluminum hydride (0.34 g, 8.94
mmol) in portions over 15 minutes. The mixture was stirred at
0.degree. C. for 30 minutes and at room temperature for 20 hours.
The mixture was cooled to 0.degree. C. and quenched with solid
Na.sub.2SO.sub.4.10H.sub.2O, stirred for 10 minutes, and then
stirred at room temperature for 15 minutes. Solids were removed by
filtration and washed with THF (100 mL). The filtrate was
evaporated to give
(4-(dimethoxymethyl)-2,6-dimethylphenyl)methanamine as a
golden-brown semi-solid. Yield: 0.87 g (100%)
[0662] To (4-(dimethoxymethyl)-2,6-dimethylphenyl)methanamine (0.87
g, 4.18 mmol), anhydrous CH.sub.2Cl.sub.2 (20 mL), Et.sub.3N (5.84
mL, 41.89 mmol), at 0.degree. C. under nitrogen, was added acetic
anhydride (0.44 mL, 4.65 mmol), followed by DMAP (0.018 g, 0.147
mmol). The mixture was stirred at 0.degree. C. for 15 minutes and
then at room temperature for 23 hours. The mixture was evaporated
to a solid. The solid was stirred with NaHCO.sub.3 (100 mL) and
CHCl.sub.3 (50 mL) for 15 minutes. The organic phase was separated
and the aqueous phase extracted with CHCl.sub.3 (4.times.50 mL).
The combined organic phase was washed with brine (75 mL), dried
over anhydrous Na.sub.2SO.sub.4, filtered, and evaporated to afford
N-(4-(dimethoxymethyl)-2,6-dimethylbenzyl)acetamide as a light
orange solid (1.00 g, 95%).
[0663] To N-(4-(dimethoxymethyl)-2,6-dimethylbenzyl)acetamide (0.83
g, 3.30 mmol) in CHCl.sub.3 (65 mL), at 0.degree. C. was added
trifluoroacetic acid/water (1:1, 10 mL) added dropwise. The
solution was stirred at 0.degree. C. for 1.75 hours. The solution
was diluted with water (200 mL) and the organic phase separated.
The aqueous phase was extracted with CHCl.sub.3 (4.times.75 mL).
The combined organic phase was washed with NaHCO.sub.3 (200 mL).
The aqueous phase was back-extracted with CHCl.sub.3 (3.times.30
mL). The combined organic phase was dried (Na.sub.2SO.sub.4),
filtered, and evaporated to give a
N-(4-formyl-2,6-dimethylbenzyl)acetamide as a brown solid. Yield:
0.56 g (82%)
[0664] 2-Amino-4,6-dimethoxybenzamide (0.334 g, 1.70 mmol),
N-(4-formyl-2,6-dimethylbenzyl)acetamide (0.35 g, 1.70 mmol),
anhydrous N,N-dimethylacetamide (10 mL), sodium bisulfite (58.5 wt
%, 0.343 g, 1.87 mmol) and p-TsOH.H.sub.2O (0.065 g, 0.341 mmol)
were heated at 120.degree. C. for 19.5 hours. The solution was
evaporated in vacuo and the residue was triturated with water (50
mL). The yellow solid was filtered off and washed with water (50
mL). The product was purified by column chromatography (silica gel,
230-400 mesh; 6% methanol in dichloromethane as the eluent) and
triturated with Et.sub.2O (6 mL) to afford the title compound as a
white solid. Yield: 0.202 g (31%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.89 (s, 1H), 7.93 (t, J=4.49 Hz, 1H), 7.85
(s, 2H), 6.74 (d, J=1.95 Hz, 1H), 6.51 (d, J=1.95 Hz, 1H), 4.28 (d,
J=4.69 Hz, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 2.37 (s, 6H), 1.80 (s,
3H). MS (ES+) m/z: 382.18 (100%), 383.19.
Example 39. Preparation of
N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-di-
methyl-benzyl]-acetamide
##STR00048##
[0666] To a solution of 2-amino-4,6-dimethoxy-nicotinamide (300 mg,
1.52 mmol), N-(4-formyl-2,6-dimethyl-benzyl)-acetamide (342 mg,
1.67 mmol) in N,N-dimethylacetamide (5 mL) were added sodium
hydrogen sulfite (58.5 wt %, 300 mg, 1.68 mmol) and
p-toluenesulfonic acid monohydrate (60 mg, 0.32 mmol). The reaction
mixture was stirred at 150.degree. C. for 17 hours under nitrogen
and then cooled to room temperature. The solvent was evaporated
under reduced pressure to dryness. Water (50 mL) was added, and
extracted with dichloromethane. The organic phase was dried over
anhydrous sodium sulfate. Solvent was evaporated and the crude
compound was purified by column chromatography (silica gel 230-400
mesh; eluting with 5% methanol in dichloromethane) to give the
title compound as a white solid. Yield: 78 mg (13%). .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 7.79 (s, 2H), 6.40 (s, 1H), 4.46 (s,
2H), 4.05 (s, 3H), 3.98 (s, 3H), 2.46 (s, 6H), 1.95 (s, 3H). MS
(ES.sup./) m/z: 383.13 (M+1).
Example 40. Preparation of
2-{3,5-dimethyl-4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-phenyl}-5,7-dim-
ethoxy-3H-quinazolin-4-one
##STR00049##
[0668] A solution of
2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4--
one (500 mg, 1.15 mmol) and 2,2,2-trifluoroethyl amine (1.14 g,
11.53 mmol) and TEA (5 mL) in DMF:THF (10:5 ml) was heated at
40.degree. C. for 24 hours. Then, water (100 mL) was added and
product was extracted with ethyl acetate (2.times.250 mL). The
combined organic layer was washed with water, then brine, dried
over Na.sub.2SO.sub.4, and evaporated, to give crude product. The
crude product was purified by the Simpliflash system, using 2%
methanol in dichloromethane as eluent, to give the title compound
as a white solid. Yield: 81 mg (15%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.44 (s, 1H), 7.69 (s, 2H), 6.83 (d, J=2.4 Hz,
1H), 6.46 (d, J=2.4 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.91 (s,
br, 2H), 3.33 (d, J=4.4 Hz, 2H), 3.14 (d, J=1.2 Hz, 2H), 2.37 (s,
6H). MS (ES) m/z: 450.07 (M-1) (100%).
Example 41. Preparation of
N-{2-[4-(6,8-dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxy]-ethyl}-formamide
##STR00050##
[0670] To a suspension of
3-[4-(2-Hydroxy-ethoxy)-3,5-dimethyl-phenyl]-6,8-dimethoxy-2H-isoquinolin-
-1-one (0.80 g, 2.16 mmol), isoindole-1,3-dione (0.35 g, 2.38
mmol), and triphenyl phosphine (0.85 g, 3.25 mmol) in THF (30 mL),
was added diethyl azodicarboxylate (0.56 g, 3.25 mmol), and the
reaction mixture was stirred at room temperature for 16 hours. The
solvent was evaporated in vacuo and the residue was washed with
ether to give
2-{2-[4-(6,8-dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxy]-ethyl}-isoindole-1,3-dione as an off-white solid. Yield:
1.11 g (crude).
[0671] Hydrazine hydrate (0.29 mL, 6.07 mmol) was added to the
solution of
2-{2-[4-(6,8-dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-p-
henoxy]-ethyl}-isoindole-1,3-dione (1.01 g, 2.03 mmol) in ethanol
(20 mL). The reaction mixture was heated to 70.degree. C. for 5
hours. The solvent was removed and the residue was purified by the
Simpliflash system, using 5% 7 N ammonia in methanol with
dichloromethane as eluent, to give
3-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-6,8-dimethoxy-2H-isoquinolin-1-
-one as a white solid. Yield: 0.59 g (80.2%).
[0672] To a solution of
3-[4-(2-amino-ethoxy)-3,5-dimethyl-phenyl]-6,8-dimethoxy-2H-isoquinolin-1-
-one (0.30 g, 0.8 mmol) in formic acid (20 mL), was heated at
reflux for 72 hours. The reaction mixture was cooled to room
temperature and solvent was removed under reduced pressure. Water
(100 mL) was added to the residue and neutralized with solid
NaHCO.sub.3. The product was extracted with dichloromethane
(2.times.200 mL). The combined organic layer was washed with water,
then brine, dried over Na.sub.2SO.sub.4, and evaporated to give
crude product. The crude product was purified by the Simpliflash
system, using 5% 7 N ammonia in methanol with dichloromethane as
eluent, to give the title compound as a white solid. Yield: 97 mg
(30%). .sup.1H NMR (400 MHz, DMSO): .delta. 10.70 (s, 1H), 8.31 (br
s, 1H), 8.09 (s, 1H), 7.45 (s, 2H), 6.67 (d, J=2.0 Hz, 1H), 6.64
(s, 1H), 6.45 (d, J=2.0 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.77
(m, 2H), 3.48 (m, 3H), 2.25 (s, 6H). MS (ES) m/z: 397.11 (M+1)
(100%).
Example 42. Preparation of
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin--
4(3H)-one
##STR00051##
[0674] To a mixture of
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)--
one (2.00 g, 5.40 mmol) and Et.sub.3N (0.977 mL, 7.02 mmol) in
CH.sub.2Cl.sub.2 (27.0 mL) was added slowly MsCl (0.543 mL, 7.02
mmol) at room temperature. After 1 day, additional Et.sub.3N (0.977
mL, 7.02 mmol) and MsCl (0.543 mL, 7.02 mmol) was added and the
mixture was stirred for 2 hours, then diluted with EtOAc (300 mL)
and washed with 10% aqueous citric acid (3.times.75 mL), saturated
aqueous NaHCO.sub.3 (75 mL), and brine (75 mL). An insoluble white
solid was collected by filtration to provide
2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethy-
l-phenoxy)ethyl methanesulfonate (0.890 g, 37%).
[0675] A mixture of compound
2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethyl-phenox-
y)ethyl methanesulfonate (0.200 g, 0.446 mmol) and 33%
CH.sub.3NH.sub.2 in EtOH (5.00 mL) was heated at reflux overnight.
The solvent was removed under vacuum and the residue was purified
on silica gel (12 g, CH.sub.2Cl.sub.2/CH.sub.3OH) and the product
freeze-dried from MeCN/H.sub.2O to provide the title compound
(0.0968 g, 57%) as a light yellow solid. .sup.1H NMR (300 MHz,
DMSO-d.sub.6: .delta. 7.90 (s, 2H), 6.73 (d, J=2.29 Hz, 1H), 6.52
(d, J=2.29 Hz, 1H), 3.94-3.80 (m, 8H), 2.98 (t, J=5.46 Hz, 2H),
2.45 (s, 3H), 2.33-2.28 (m, 8H). MS (APCI) m/z 384
[C.sub.21H.sub.25N.sub.3O.sub.4+H].sup.+.
Example 43. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)propane-2-sulfonamide
##STR00052##
[0677] A mixture of 3,5-dimethyl-4-hydroxybenzaldehyde (0.600 g,
4.00 mmol), N-(2-bromoethyl)-phthalimide (1.22 g, 4.80 mmol),
K.sub.2CO.sub.3 (0.829 g, 6.00 mmol), NaI (3.00 g, 20.0 mmol) in
DMF (40.0 mL) was heated at 80.degree. C. for 2.5 hours. The
reaction was cooled to room temperature, diluted with EtOAc (200
mL), washed with 1 M NaOH (2.times.100 mL), 1 M HCl (2.times.100
mL), brine (75 mL), dried over sodium sulfate, filtered, and
concentrated under vacuum. The residue was chromatographed on
silica gel (40 g, hexanes/EtOAc) to provide the expected ether
(0.300 g, 23%) as a yellow solid. A mixture of this ether (0.293 g,
0.907 mmol), 2-amino-4,6-dimethoxybenzamide (0.178 g, 0.907 mmol),
NaHSO.sub.3 (94%, 0.100 g, 0.907 mmol), and p-TsOH.H.sub.2O (0.0173
g, 0.0907 mmol) in DMA (11.3 mL) was stirred at reflux for 1.5
hours, then cooled to room temperature. The mixture was diluted
with EtOAc (250 mL), washed with saturated aqueous ammonium
chloride (3.times.75 mL), them brine (75 mL), dried over sodium
sulfate, filtered, and concentrated under vacuum. The residue was
chromatographed on silica gel (40 g, CH.sub.2Cl.sub.2/CH.sub.3OH)
to provide the expected product (0.075 g, 17%) as a light yellow
solid. A mixture of the above compound (0.213 g, 0.426 mmol) and 2
M methylamine in THF (25.0 mL) was stirred at room temperature for
17 hours. The volatiles were removed under vacuum and
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H-
)-one was isolated (0.036 g, 23%) as a white solid.
[0678] A mixture of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.125 g, 0.338 mmol), 2-propylsulfonyl chloride (0.040 mL, 0.36
mmol), and DBU (0.100 mL, 0.67 mmol) in THF (2.5 mL) was stirred at
60.degree. C. for 18 hours. Then, the mixture was cooled to room
temperature and purified by silica gel chromatography, eluting with
92:7:1 CHCl.sub.3/MeOH/concentrated NH.sub.4OH. The mixture was
further purified by reverse-phase HPLC, eluting with 10% to 90%
CH.sub.3CN in H.sub.2O with 0.1% TFA, to afford the desired
product. The product was freeze-dried from CH.sub.3CN/H.sub.2O to
afford the title compound (0.080 g, 50%) as a white solid. .sup.1H
NMR (300 MHz, DMSO-d.sub.6: .delta. 11.85 (s, 1H), 8.09 (s, 2H),
7.33 (t, J=6.0 Hz, 1H), 6.74 (d, J=2.3 Hz, 1H), 6.52 (d, J=2.3 Hz,
1H), 3.89 (s, 3H), 3.82-3.86 (m, 5H), 3.21-3.39 (m, 3H), 2.31 (s,
6H), 1.26 (d, J=6.8 Hz, 6H). APCI MS m/z 476 [M+H].sup.+.
Example 44. Preparation of
2-(4-(2-(isopropylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazol-
in-4(3H)-one
##STR00053##
[0680] A solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.200 g, 0.54 mmol) in EtOH (10 mL) and acetone (0.198 mL, 2.71
mmol) was treated with PtO.sub.2 (0.050 g). The reaction mixture
was stirred under 1 atmosphere of hydrogen for 48 hours. Then, the
mixture was filtered through celite with ethanol washings,
concentrated, and purified by silica gel chromatography, to afford
the title compound (0.155 g, 70%). The product was further purified
by reverse-phase HPLC, eluting with 10% to 90% CH.sub.3CN in
H.sub.2O with 0.1% TFA, to afford the title compound as a white
solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6: .delta. 7.90 (s, 2H),
6.74 (d, J=2.3 Hz, 1H), 6.52 (s, J=2.3 Hz, 1H), 3.83-3.89 (m, 8H),
2.89 (t, J=5.6 Hz, 2H), 2.75-2.84 (m, 1H), 2.30 (s, 6H), 1.01 (d,
J=6.2 Hz, 6H); APCI MS m/z 412 [M+H].sup.+.
Example 45. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)-
ethyl)acetamide
##STR00054##
[0682]
2-(4-(2-Aminoethoxy)-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)--
one was synthesized as described for
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e from 3-methyl-4-hydroxybenzaldehyde (See Example 43).
[0683] A suspension of
2-(4-(2-aminoethoxy)-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one
(0.12 g, 0.33 mmol) in CH.sub.2Cl.sub.2 (5 mL) was treated with
Et.sub.3N (0.05 mL, 0.41 mmol) and acetyl chloride (0.026 mL, 0.37
mmol) and the mixture stirred at room temperature for 3 hours.
Then, the mixture was concentrated in vacuo and the residue
purified by flash chromatography on silica gel, eluting with 97:3
to 90:10 CH.sub.2Cl.sub.2/MeOH to 92:7:1
CHCl.sub.3/MeOH/concentrated NH.sub.4OH, to afford crude product.
Further purification on a reverse-phase C.sub.18 column, eluting
with 10% to 90% CH.sub.3CN in H.sub.2O with 0.05% TFA, afforded the
title compound (0.080 g, 61%) as a white solid. .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 11.65 (s, 1H), 7.93-8.18 (m, 3H), 7.05
(d, J=8.4 Hz, 1H), 6.71 (d, J=2.3 Hz, 1H), 6.50 (d, J=2.3 Hz, 1H),
4.07 (t, J=5.6 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.35-3.52 (m,
2H), 2.23 (s, 3H), 1.83 (s, 3H). APCI MS m/z 398 [M+H].sup.+.
Example 46. Preparation of
2-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazoli-
n-4(3H)-one
##STR00055##
[0685] To a solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.150 g, 0.41 mmol) in MeOH (16 mL) and CH.sub.2Cl.sub.2 (5 mL)
was added 37% aqueous formaldehyde (0.300 mL, 4.0 mmol) and the
mixture stirred for 1 hour. Then, NaBH.sub.4 (0.078 g, 2.05 mmol)
was added and the reaction was stirred for 16 hours at room
temperature. Additional 37% aqueous formaldehyde (1.0 mL) was added
and stirred for 1 hour, at which time, additional NaBH.sub.4 (0.100
g, 2.63 mmol) was added and stirred for 1 hour. The reaction
mixture was concentrated, redissolved in CH.sub.2Cl.sub.2, washed
with brine (100 mL), dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The residue was purified by silica gel
chromatography, eluting with 9:1 CH.sub.2Cl.sub.2/MeOH to 92:7:1
CHCl.sub.3/MeOH/concentrated aqueous NH.sub.4OH. The residue was
further purified by reverse-phase HPLC, eluting with 10% to 90%
CH.sub.3CN in H.sub.2O with 0.1% TFA, to afford the title compound
as a white solid (0.070 g, 43%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 11.70 (br s, 1H), 7.90 (s, 2H), 6.74 (d,
J=2.3 Hz, 1H), 6.52 (d, J=2.3 Hz, 1H), 3.84-3.89 (m, 8H), 2.64 (t,
J=5.8 Hz, 2H), 2.30 (s, 6H), 2.24 (s, 6H). APCI MS m/z 398
[M+H].sup.+.
Example 47. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylacetamide
##STR00056##
[0687] To a solution of
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin--
4(3H)-one (0.110 g, 0.287 mmol) in CH.sub.2Cl.sub.2 (10 mL) was
added Et.sub.3N (0.080 mL, 0.574 mmol), followed by acetyl chloride
(0.022 mL, 0.315 mmol). The mixture was stirred at room temperature
under nitrogen for 10 minutes, concentrated, and purified by silica
gel chromatography, eluting with 9:1 CH.sub.2Cl.sub.2/MeOH,
followed by reverse-phase HPLC, eluting with 10% to 90% CH.sub.3CN
in H.sub.2O with 0.1% TFA, to afford the title compound as a white
solid (0.078 g, 64%). .sup.1H NMR (mixture of amide rotomers, 300
MHz, DMSO-d.sub.6: .delta. 11.85 (s, 1H), 7.90 (d, J=2.7 Hz, 2H),
6.74 (d, J=2.2 Hz, 1H), 6.52 (d, J=2.2 Hz, 1H), 3.84-3.95 (m, 8H),
3.65-3.74 (m, 2H), 3.12 (s, 1.5H), 2.92 (s, 1.5H), 2.27 (d, J=1.1
Hz, 6H), 2.11 (s, 1.5H), 2.03 (s, 1.5H). APCI MS m/z 424
[M-H].sup.-.
Example 48. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)formamide
##STR00057##
[0689] A solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.086 g, 0.23 mmol) in ethanol (10 mL) and methyl formate (0.028
mL, 0.46 mmol) was stirred at room temperature for 5 hours. At this
time, an additional portion of methyl formate (5 mL, 80.6 mmol) was
added and the mixture heated at reflux for 4 days. The mixture was
concentrated and purified by silica gel chromatography, eluting
with 92:7:1 CHCl.sub.3/MeOH/concentrated NH.sub.4OH. The product
was freeze-dried from CH.sub.3CN/H.sub.2O to yield the title
compound (0.065 g, 71%) as a white solid. .sup.1H NMR (300 MHz,
DMSO-d.sub.6: .delta. 11.84 (s, 1H), 8.29-8.37 (m, 1H), 8.11 (d,
J=1.3 Hz, 1H), 7.90 (s, 2H), 6.74 (d, J=2.3 Hz, 1H), 6.52 (d, J=2.3
Hz, 1H), 3.89 (s, 3H), 3.79-3.84 (m, 5H), 3.47-3.53 (m, 2H), 2.29
(s, 6H). APCI MS m/z 396 [M-H].sup.-.
Example 49. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)-N-methylformamide
##STR00058##
[0691] To a solution of
2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin--
4(3H)-one (0.080 g, 0.21 mmol) in EtOH (15 mL) was added methyl
formate (5 mL). The mixture was heated at reflux for 24 hours,
concentrated, and purified by silica gel chromatography, eluting
with 9:1 CH.sub.2Cl.sub.2/MeOH, to afford the title compound as a
white solid (0.080 g, 93%): .sup.1H NMR (mixture of amide rotomers,
300 MHz, DMSO-d.sub.6: .delta. 11.85 (s, 1H), 8.12 (d, J=1.9 Hz,
1H), 7.90 (s, 2H), 6.74 (d, J=2.2 Hz, 1H), 6.52 (d, J=2.2 Hz, 1H),
3.88-3.93 (m, 5H), 3.84 (s, 3H), 3.62-3.68 (m, 2H), 3.08 (s, 0.5H),
2.88 (s, 0.5H), 2.25-2.35 (m, 6H); APCI MS m/z 410 [M-H].sup.-.
Example 50. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)dimethylamino-N-sulfonamide
##STR00059##
[0693] A solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.150 g, 0.41 mmol) in CH.sub.2Cl.sub.2 (10 mL) was treated with
Et.sub.3N (0.083 g, 0.82 mmol), then dimethylsulfamoylchloride
(0.065 g, 0.45 mmol), and the reaction mixture stirred under
nitrogen at room temperature for 1 hour. Then, DBU (0.100 mL) was
added and stirring continued for 1 hour at room temperature. Then,
the reaction mixture was heated at reflux for 18 hours, additional
dimethylsulfamoylchloride (0.150 mL) was added, and heating
continued at reflux for a further 2 hours. The reaction mixture was
cooled and purified by flash chromatography on silica gel, eluting
with 100% CH.sub.2Cl.sub.2 to 100% (92:7:1
CHCl.sub.3/MeOH/concentrated NH.sub.4OH). The resulting solid was
further purified by reverse-phase HPLC, eluting with 10% to 90%
CH.sub.3CN in H.sub.2O with 0.1% TFA. The solids were then
triturated with CH.sub.3CN to afford the title compound as a white
solid. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 9.20 (s, 1H), 7.69
(s, 2H), 6.82 (d, J=2.3 Hz, 1H), 6.5 (d, J=2.3 Hz, 1H), 4.72-4.80
(m, 1H), 3.93-3.98 (m, 8H), 3.46-3.56 (m, 2H), 2.87 (s, 6H), 2.38
(s, 6H); ESI MS m/z 477 [M+H].sup.+.
Example 51. Preparation of
N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphen-
oxy)ethyl)cyanamide
##STR00060##
[0695] To a solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.150 g, 0.41 mmol) in MeOH (15 mL) was added BrCN (0.043 g,
0.41 mmol) and NaHCO.sub.3 (0.044 g, 0.52 mmol). The reaction was
stirred at room temperature for 1 hour and then concentrated in
vacuo. Purification by flash chromatography on silica gel, eluting
with 2% to 10% MeOH/CH.sub.2Cl.sub.2, afforded the title compound
(0.120 g, 74%) as a white solid. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 11.85 (s, 1H), 7.82-7.92 (m, 2H), 7.03-7.14
(m, 1H), 6.72 (d, J=1.4 Hz, 1H), 6.59 (d, J=1.4 Hz, 1H), 3.81-3.93
(m, 8H), 3.15-3.29 (m, 2H), 2.28 (s, 6H). APCI MS m/z 395
[M+H].sup.+.
Example 52. Preparation of
2-(3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)phenyl)-5,7-dimet-
hoxyquinazolin-4(3H)-one
##STR00061##
[0697] To a solution of 5-methylisoxazol-3-amine (1.0 g, 10.2 mmol)
in CH.sub.2Cl.sub.2 was added Et.sub.3N (1.03 g, 10.2 mmol) and
bromoacetyl chloride (1.60 g, 10.2 mmol). The mixture was stirred
at room temperature for 1 hour, washed with water (100 mL), then
brine (100 mL), dried (Na.sub.2SO.sub.4), filtered, and
concentrated, to afford 2-bromo-N-(5-methylisoxazol-3-yl)acetamide
as a white solid (1.2 g, 55%).
[0698] To a solution of 2-bromo-N-(5-methylisoxazol-3-yl)acetamide
(0.223 g, 1.0 mmol) in THF (10 mL) under nitrogen was added 1.0 M
BH.sub.3.THF (3.0 mL, 3.0 mmol). The reaction mixture was stirred
at room temperature for 18 hours, quenched with 1 M NaOH, extracted
with ethyl acetate (2.times.100 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
purified by flash chromatography on silica gel, eluting with 1:1
ethyl acetate/hexane to 100% ethyl acetate, to afford
N-(2-bromoethyl)-5-methylisoxazol-3-amine as a white solid (0.061
g, 30%).
[0699] To a solution of 4-hydroxy-3,5-dimethylbenzaldehyde (0.036
g, 0.24 mmol) in DMF (1.5 mL) was added K.sub.2CO.sub.3 (0.050 g,
0.36 mmol) and the mixture stirred at room temperature under
nitrogen for 30 minutes. After this time, a solution of
N-(2-bromoethyl)-5-methylisoxazol-3-amine (0.060 g, 0.29 mmol) in
DMF (1.5 mL) was added and the reaction heated at reflux for 2
hours. The mixture was concentrated and purified by flash
chromatography on silica gel, eluting with 1:1 ethyl
acetate/heptane to 100% ethyl acetate, to afford
3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)benzaldehyde
(0.028 g, 26%).
[0700] A mixture of
3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)benzaldehyde
(0.121 g, 0.44 mmol), 2-amino-4,6-dimethoxybenzamide (0.087 g, 0.44
mmol), NaHSO.sub.3 (0.050 g, 0.48 mmol), and p-TsOH (0.008 g, 0.044
mmol) in DMA (3 mL) was heated at 155.degree. C. under nitrogen for
9 hours. Then, the reaction mixture was cooled, diluted with ethyl
acetate (200 mL), and washed with water (100 mL), brine (100 mL),
dried over anhydrous Na.sub.2SO.sub.4, filtered, and concentrated.
The residue was purified by flash chromatography on silica gel,
eluting with 100% CH.sub.2Cl.sub.2 to 100% 92:7:1
CHCl.sub.3/MeOH/concentrated NH.sub.4OH, to afford the title
compound (0.129 g, 65%). .sup.1H NMR (300 MHz, DMSO-d.sub.6:
.delta. 11.99 (s, 1H), 7.99 (s, 2H), 6.77 (d, J=2.3 Hz, 1H), 6.55
(d, J=2.3 Hz, 1H), 5.29 (s, 1H), 4.70-4.72 (m, 1H), 3.90 (s, 3H),
3.85 (s, 3H), 3.55-3.61 (m, 4H), 2.22 (s, 6H), 2.21 (s, 3H). APCI
MS m/z 451 [M+H].sup.+.
Example 53. Preparation of
2-(3,5-dimethyl-4-(2-(pyrimidin-2-ylamino)ethoxy)phenyl)-5,7-dimethoxyqui-
nazolin-4(3H)-one
##STR00062##
[0702] To a solution of
2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-on-
e (0.145 g, 0.40 mmol) in t-butanol (10 mL) was added Et.sub.3N
(0.06 mL, 0.47 mmol) and 2-chloropyrimidine (0.045 g, 0.40 mmol).
The reaction was stirred and heated at reflux temperature
overnight, then concentrated in vacuo. Purification by flash
chromatography on silica gel, eluting with 95:5
CH.sub.2Cl.sub.2/MeOH, afforded the title compound (0.038 g, 21%)
as a white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.29
(d, J=4.7 Hz, 2H), 7.87 (s, 2H), 7.31 (t, J=6.1 Hz, 1H), 6.72 (d,
J=2.3 Hz, 1H), 6.58 (t, J=4.7 Hz, 1H), 6.51 (s, 1H), 3.95 (t, J=5.9
Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.65-311 (m, 2H), 2.25 (s,
6H). ESI MS m/z 448 [M+H].sup.+.
Example 54. Preparation of
2-(4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquin-
azolin-4(3H)-one
##STR00063##
[0704] To a solution of isoxazol-3-amine (2.28 g, 27.1 mmol) in
CH.sub.2Cl.sub.2 at 0.degree. C. under nitrogen was added Et.sub.3N
(2.74 g, 27.1 mmol), followed by bromoacetyl chloride (4.26 g, 27.1
mmol). The mixture was warmed to room temperature, stirred for 2
hours, washed sequentially with water (200 mL) and brine (200 mL),
dried (Na.sub.2SO.sub.4), filtered, and concentrated, to afford
2-bromo-N-(isoxazol-3-yl)acetamide as a tan solid (4.5 g, 81%).
[0705] To a solution of 2-bromo-N-(isoxazol-3-yl)acetamide (1.0 g,
4.9 mmol) in THF (50 mL) under nitrogen was added 1.0 M
BH.sub.3.THF (14.6 mL, 14.6 mmol). The mixture was stirred at room
temperature for 3.5 hours and then an additional portion of
BH.sub.3.THF (5.0 mL, 5.0 mmol) was added. After an additional 15
hours at room temperature, the reaction was quenched with 1 M NaOH,
extracted with ethyl acetate (2.times.150 mL), dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The residue was
purified by flash chromatography on silica gel, eluting with 1:1
ethyl acetate/heptane to 100% ethyl acetate, to afford
N-(2-bromoethyl)isoxazol-3-amine (0.133 g, 14%).
[0706] To a solution of 4-hydroxy-3,5-dimethylbenzaldehyde (0.471
g, 3.14 mmol) in DMF (20 mL) was added K.sub.2CO.sub.3 (0.650 g,
4.71 mmol). The reaction mixture was stirred at room temperature
under nitrogen for 30 minutes. Then, a solution of
N-(2-bromoethyl)isoxazol-3-amine (0.600 g, 3.14 mmol) in DMF (10
mL) was added. The mixture was heated at reflux for 3 hours,
concentrated, and purified by flash chromatography on silica gel,
eluting with 30% ethyl acetate/heptane to 100% ethyl acetate, to
afford 4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylbenzaldehyde as
a white solid (0.260 g, 32%).
[0707] A mixture of
4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylbenzaldehyde (0.253 g,
0.97 mmol), 2-amino-4,6-dimethoxybenzamide (0.190 g, 0.97 mmol),
NaHSO.sub.3 (0.111 g, 1.07 mmol), and p-TsOH (0.018 g, 0.097 mmol)
in DMA (10 mL) was heated at 150.degree. C. under nitrogen for 44
hours. Then, the reaction mixture was concentrated, diluted with
ethyl acetate (200 mL), and washed with water (150 mL), then brine
(150 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered, and
concentrated. The residue was purified by flash chromatography on
silica gel, eluting with 100% CH.sub.2Cl.sub.2 to 100% 92:7:1
CHCl.sub.3/MeOH/concentrated NH.sub.4OH, to afford the title
compound (0.150 g, 35%). .sup.1H NMR (300 MHz, DMSO-d.sub.6:
.delta. 11.82 (s, 1H), 8.39 (d, J=1.7 Hz, 1H), 7.89 (s, 2H), 6.73
(d, J=2.2 Hz, 1H), 6.51 (d, J=2.2 Hz, 1H), 6.44 (t, J=6.1 Hz, 1H),
6.02 (d, J=1.7 Hz, 1H), 3.94 (t, J=5.5 Hz, 2H), 3.89 (s, 3H), 3.84
(s, 3H), 3.46-3.51 (m, 2H), 2.27 (s, 6H). APCI MS m/z 437
[M+H].sup.+.
Example 55. Preparation of
2-(4-(2-(4,6-dimethoxypyrimidin-2-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-
-dimethoxyquinazolin-4(3H)-one
##STR00064##
[0709] Following the method described for Example 51 above, the
title compound was made from 2-chloro-4,6-dimethoxypyrimidine
(0.071 g, 0.40 mmol) in 35% yield. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 11.82 (s, 1H), 7.88 (s, 2H), 7.22 (t, J=6.1
Hz, 1H), 6.72 (d, J=2.3 Hz, 1H), 6.51 (s, 1H), 5.38 (s, 1H),
3.90-4.02 (m, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.77 (s, 6H),
3.59-3.72 (m, 2H), 2.27 (s, 6H). APCI MS m/z 506 [M-H].sup.-.
Example 56. Preparation of
2-[4-(3-hydroxy-propyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-3H-quinazolin--
4-one
##STR00065##
[0711] To a stirred solution of
4-hydroxy-3,5-dimethoxylbenzaldehyde (5.87 g, 32.2 mmol) in
CH.sub.2Cl.sub.2 (50 mL) and pyridine (8.6 mL) was added
trifluoromethanesulfonic anhydride (10.0 g, 35.4 mmol) at 0.degree.
C. After the addition was complete, stirring was continued for 16
hours at room temperature. The reaction mixture was diluted with
ethyl acetate (150 mL) and washed with water (3.times.100 mL). The
separated organic phase was dried over anhydrous sodium sulfate,
filtered, and concentrated. The crude product,
trifluoromethanesulfonic acid 4-formyl-2,6-dimethoxyphenyl ester,
was used in the next step without further purification. Yield: 10.0
g (98.9%).
[0712] To a stirred solution of trifluoromethanesulfonic acid
4-formyl-2,6-dimethoxyphenyl ester (8.00 g, 25.4 mmol) in anhydrous
DMF (80 mL) under nitrogen at room temperature were sequentially
added triethylamine (5.14 g, 50.8 mmol), methyl acrylate (21.9 g,
254.0 mmol), 1,3-bis-(diphenylphosphino)-propane (0.84 g, 2.03
mmol), and palladium acetate (0.40 g, 1.77 mmol). The reaction
mixture was stirred at 115.degree. C. for 16 hours. DMF was removed
under reduced pressure and the residue was taken in ethyl acetate
(200 mL) and washed with 1 N HCl solution (2.times.50 mL), and
saturated sodium bicarbonate solution (100 mL). The organic phase
was dried over anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by column chromatography
(silica gel 230-400 mesh; eluting with hexane/ethyl acetate=3:1) to
give 3-(4-formyl-2,6-dimethoxyphenyl)-acrylic acid methyl ester.
Yield: 4.0 g (62%).
[0713] To a solution of 3-(4-formyl-2,6-dimethoxyphenyl)-acrylic
acid methyl ester (5.00 g, 20.0 mmol) in methanol (80 mL), 1.5 N
sodium hydroxide (45 mL) was added. The suspension was stirred at
room temperature for 16 hours. Methanol was evaporated and acetic
acid (4.0 mL) was added. The aqueous layer was extracted with
dichloromethane (200 mL) then acidified, to pH 3, with 2 N HCl. The
solid was filtered and further washed with cold water (100 mL) to
obtain 3-(4-formyl-2,6-dimethoxyphenyl)-acrylic acid as a yellow
solid. Yield: 4.20 g (89%).
[0714] To a solution of 3-(4-formyl-2,6-dimethoxyphenyl)-acrylic
acid (4.20 g, 17.7 mmol) and N,N-diisopropylethylamine (3.5 mL) in
ethanol (80 mL) were added Pd/C (400 mg, 10 wt %). The suspension
was vigorously stirred under 1 bar of hydrogen pressure for 16
hours. The mixture was filtered through a celite pad and the
filtrate was evaporated. The residue was poured into chilled 1 N
HCl (200 mL), the solid was filtered, and further washed with cold
water (100 mL) to give a mixture of
3-(4-formyl-2,6-dimethoxyphenyl)-propionic acid and
3-(4-hydroxymethyl-2,6-dimethoxyphenyl)-propionic acid as a white
solid. Yield: 3.30 g.
[0715] To a suspension of LiAlH.sub.4 (1.00 g, 26.3 mmol) in
anhydrous THF (40 mL) was added dropwise a solution of a mixture of
3-(4-formyl-2,6-dimethoxyphenyl)-propionic acid and
3-(4-hydroxymethyl-2,6-dimethoxyphenyl)-propionic acid (3.30 g,
13.8 mmol). After the addition was complete, the reaction mixture
was stirred at reflux for 2 hours. The suspension was diluted with
THF (20 mL) and another portion of LiAlH.sub.4 (0.60 g, 15.8 mmol)
was added. The mixture was refluxed for an additional 1 hour. The
reaction was cooled to room temperature, carefully quenched with
aqueous saturated NH.sub.4Cl solution (8 mL), acidified to pH 1-2
with 2 N HCl, and extracted with ethyl acetate (200 mL). The
organic phase was dried over sodium sulfate, filtered and
concentrated to provide
3-(4-hydroxymethyl-2,6-dimethoxyphenyl)-propan-1-ol as a colorless
crystalline solid. Yield: 3.08 g (98.7%).
[0716] To a solution of
3-(4-hydroxymethyl-2,6-dimethoxyphenyl)-propan-1-ol (3.08 g, 13.6
mmol) in ethanol (50 mL) was added activated MnO.sub.2 (4.15 g,
47.6 mmol) and the resulting suspension was stirred at reflux for
16 hours. The reaction mixture was filtered through a celite pad
and the filtrate was concentrated. The residue was purified by
column chromatography (silica gel 230-400 mesh; eluting with 2:1
hexane and ethyl acetate) to give
4-(3-hydroxy-propyl)-3,5-dimethoxybenzaldehyde. Yield: 1.10 g
(36%).
[0717] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.35 g,
1.78 mmol) and 4-(3-hydroxy-propyl)-3,5-dimethylbenzaldehyde (0.40
g, 1.78 mmol) in N,N-dimethylacetamide (8 mL) were added
NaHSO.sub.3 (0.35 g, 1.96 mmol) and p-TSA (34 mg, 0.18 mmol) and
the reaction mixture was heated at 115-120.degree. C. for 5 hours,
then cooled to room temperature. N,N-dimethylacetamide was removed
under reduced pressure. The residue was diluted with water (50 mL)
and the pH was adjusted to 7 by adding sodium bicarbonate solution.
The solid was collected and washed with ether and further mixed
with methanol (30 mL) and stirred for 1 hour, filtered, and dried
under vacuum to give the title compound as a white solid. Yield:
0.25 g (35%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 11.13 (s,
1H), 7.30 (s, 2H), 6.86 (d, J=2.4 Hz, 1H), 6.47 (d, J=2.4 Hz, 1H),
3.98 (s, 6H), 3.95 (s, 3H), 3.94 (s, 3H), 3.52 (m, 2H), 2.86 (t,
J=6.6 Hz 2H), 2.27 (t, J=6.6 Hz, 1H), 1.81 (m, 2H). MS (ES.sup.+)
m/z: 401.49 (M+1).
Example 57. Preparation of
2-[4-(3-hydroxy-propyl)-3-methoxy-phenyl]-5,7-dimethoxy-3H-quinazolin-4-o-
ne
##STR00066##
[0719] To a stirred solution of 4-hydroxy-3-methoxy-benzaldehyde
(5.00 g, 32.8 mmol) in CH.sub.2Cl.sub.2 (50 mL) and pyridine (8 mL)
was added trifluoromethanesulfonic anhydride (10.19 g, 36.1 mmol)
at 0.degree. C. After addition was complete, stirring was continued
for 16 hours at room temperature. The reaction mixture was diluted
with ethyl acetate (200 mL) and washed with water (3.times.100 mL)
and brine (100 mL). The separated organic layer was dried over
anhydrous sodium sulfate, filtered, and concentrated. The crude
product was purified by column chromatography (silica gel 230-400
mesh; 20% ethyl acetate in hexanes as eluent) to give
trifluoromethanesulfonic acid 4-formyl-2-methoxy-phenyl ester.
Yield: 8.00 g, (85%).
[0720] To a stirred solution of trifluoromethanesulfonic acid
4-formyl-2-methoxy-phenyl ester (5.00 g, 17.5 mmol) in anhydrous
DMF (75 mL) under nitrogen at room temperature were sequentially
added triethylamine (3.50 g, 34.5 mmol), ethyl acrylate (17.50 g,
174.7 mmol), 1,3-bis-(diphenylphosphino)-propane (0.40 g, 0.96
mmol), and palladium (II) acetate (0.20 g, 0.87 mmol). The reaction
mixture was stirred at 100.degree. C. for 5 hours. DMF was removed
under reduced pressure, and the residue was taken in ethyl acetate
(200 mL) and washed with 1 N HCl solution (2.times.50 mL), and
saturated sodium bicarbonate solution (100 mL) and brine (100 mL).
The organic phase was dried over sodium sulfate, filtered, and
concentrated. The residue was purified by column chromatography
(silica gel 230-400 mesh; 20% ethyl acetate in hexanes as eluent)
to give 3-(4-formyl-2-methoxy-phenyl)-acrylic acid ethyl ester as a
beige solid. Yield: 3.00 g (73%).
[0721] To a solution of 3-(4-formyl-2-methoxy-phenyl)-acrylic acid
ethyl ester (3.00 g, 13.6 mmol) and N,N-diisopropylethylamine (3.0
mL) in ethanol (100 mL) were added Pd/C (10 wt %, 400 mg). The
suspension was hydrogenated under 25 psi pressure for 5 hours. The
mixture was filtered through a celite pad and the filtrate was
evaporated. The residue was poured into chilled 1 N HCl (200 mL),
the solid was filtered, and further washed with cold water (100 mL)
to give a 3-(4-hydroxymethyl-2-methoxy-phenyl)-propionic acid ethyl
ester as a beige solid. Yield: 2.80 g (93%).
[0722] To a suspension of LiAlH.sub.4 (0.51 g, 26.3 mmol) in
anhydrous THF (100 mL) was added dropwise a solution of
3-(4-hydroxymethyl-2-methoxy-phenyl)-propionic acid ethyl ester
(2.5 g, 11.1 mmol) in THF (10 mL). After the addition was complete,
the reaction mixture was stirred at reflux for 3 hours. Then, the
reaction was cooled to room temperature, carefully quenched with
aqueous saturated NH.sub.4Cl solution (8 mL), acidified to pH
approximately 1-2 with 2 N HCl, and extracted with ethyl acetate
(200 mL). The organic phase was dried over sodium sulfate,
filtered, and concentrated, to provide
3-(4-hydroxymethyl-2-methoxy-phenyl)-propan-1-ol as a colorless
crystalline solid. Yield: 1.80 g (90%).
[0723] To a solution of
3-(4-hydroxymethyl-2-methoxy-phenyl)-propan-1-ol (1.8 g, 9.1 mmol)
in ethanol (50 mL) was added activated MnO.sub.2 (2.79 g, 32.0
mmol) and the resulting suspension was stirred at reflux for 16
hours. The reaction mixture was filtered through celite pad and the
filtrate was concentrated. The residue was purified by column
chromatography (silica gel 230-400 mesh; 2:1 hexane and ethyl
acetate as eluent) to give
4-(3-hydroxy-propyl)-3-methoxy-benzaldehyde. Yield: 1.2 g
(67%).
[0724] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.48 g,
2.44 mmol) and 4-(3-hydroxy-propyl)-3-methoxy-benzaldehyde (0.40 g,
2.05 mmol) in N,N-dimethylacetamide (10 mL) were added NaHSO.sub.3
(58.5 wt %, 0.40 g, 2.25 mmol) and p-toluenesulfonic acid
monohydrate (78 mg, 0.41 mmol) and the reaction mixture was heated
at 115.degree. C. for 16 hours, then cooled to room temperature.
The solvent was removed under reduced pressure. The residue was
diluted with water (50 mL) and the pH was adjusted to approximately
7 by adding sodium bicarbonate solution. The solid was filtered and
washed with water. The crude compound was purified by column
chromatography (silica gel 230-400 mesh; 5% methanol in
dichloromethane as eluent) to give the title compound as an
off-white solid. Yield: 0.35 g (46%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.02 (s, 1H), 7.75-7.73 (m, 2H), 7.28 (d,
J=7.8 Hz, 1H), 6.75 (d, J=2.3 Hz, 1H), 6.53 (d, J=1.9 Hz, 1H), 4.48
(t, J=5.0 Hz, 1H), 3.90 (d, J=4.2 Hz, 6H), 3.85 (s, 3H), 3.44 (q,
J=6.6 Hz, 2H), 2.65 (t, J=7.4 Hz 2H), 1.71-1.67 (m, 2H). MS
(ES.sup.+) m/z: 371.51 (M+1).
Example 58. Preparation of
2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one
##STR00067##
[0726] To a degassed solution of methyl-3-amino-4-iodobenzoate
(2.00 g, 7.22 mmol) in a mixture of 5:1 DMF-triethylamine (30 mL)
were added PdCl.sub.2(PPh.sub.3).sub.2 (0.25 g, 0.36 mmol) and
copper (I) iodide (0.41 g, 2.16 mmol) and the mixture was degassed
again. A degassed solution of 2-(3-butynyloxy)tetrahydro-2H-pyran
(1.7 mL, 10.83 mmol) in a mixture of 5:1 DMF-triethylamine (12 mL)
was added drop-wise at 75.degree. C. over a period of 45 minutes
under nitrogen. Soon after the addition, TLC showed completion of
the reaction. The reaction mixture was cooled to room temperature,
solvent was removed under reduced pressure, and the residue was
diluted with water (75 mL) and extracted with ethyl acetate
(3.times.50 mL). The organic phase was washed with water (50 mL),
brine (50 mL), and dried over anhydrous MgSO.sub.4. The solvent was
evaporated and the crude product was purified by column
chromatography (silica gel 230-400 mesh; 2:1 hexanes and ethyl
acetate as eluent) to obtain
3-amino-4-[4-(tetrahydropyran-2-yloxy)-but-1-ynyl]benzoic acid
methyl ester as a brown solid. Yield: 1.70 g (78%).
[0727] To a stirred solution of
3-amino-4-[4-(tetrahydropyran-2-yloxy)-but-1-ynyl]benzoic acid
methyl ester (1.68 g, 5.55 mmol) in anhydrous pyridine (5 mL) was
added acetyl chloride (0.43 mL, 6.11 mmol) at 0.degree. C. under
nitrogen. Stirring was continued at 0.degree. C. After 30 minutes
TLC showed completion of the reaction. Pyridine was removed under
reduced pressure and the residue was diluted with ethyl acetate
(100 mL). The resulting mixture was washed with aq 2 N HCl (20 mL),
water (2.times.15 mL) and brine (20 mL). After drying over
anhydrous MgSO.sub.4, solvent was removed to obtain
3-acetylamino-4-[4-(tetrahydropyran-2-yloxy)-but-1-ynyl]benzoic
acid methyl ester as a beige solid. Yield: 1.67 g (87%). Crude
product was used in the next step without further purification.
[0728] A 1.0 M solution of tetrabutylammonium fluoride (9.67 mL,
9.67 mmol) in THF was added to a solution of
3-acetylamino-4-[4-(tetrahydropyran-2-yloxy)-but-1-ynyl]benzoic
acid methyl ester (1.67 g, 4.83 mmol) in anhydrous THF (20 mL) at
room temperature. The resulting reddish-brown solution was heated
at reflux for 2 hours and then allowed to cool to room temperature.
The solvent was removed under reduced pressure and the residue was
taken in water (50 mL) and extracted with ethyl acetate (3.times.50
mL). The organic phase was washed with water (25 mL), brine (50
mL), and dried over anhydrous MgSO.sub.4. The solvent was
evaporated and the crude product was purified by column
chromatography on (silica gel 230-400 mesh; dichloromethane as
eluent) to give
2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indole-6-carboxylic acid
methyl ester as a light brown solid. Yield: 1.27 g (87%).
[0729] To a suspension of lithium aluminum hydride (0.32 g, 8.37
mmol) in anhydrous THF (20 mL) was added a solution of
2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indole-6-carboxylic acid
methyl ester (1.27 g, 4.19 mmol) in anhydrous THF (10 mL) at
-30.degree. C. to -20.degree. C. dropwise over a period of 15
minutes under nitrogen. The temperature was allowed to warm to room
temperature and stirring continued for 15 hours. The reaction
mixture was quenched with saturated aqueous ammonium chloride
solution at 0.degree. C., diluted with ethyl acetate (50 mL), and
filtered. The solid was washed with ethyl acetate. The combined
organic phase was dried over anhydrous MgSO.sub.4. The solvent was
evaporated and the crude product was purified by the Simpliflash
system (3:2 ethyl acetate-hexanes as eluent) to give
{2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indol-6-yl}-methanol as a
white solid. Yield: 0.61 g (53%).
[0730] IBX (0.62 g, 2.21 mmol) was added to a solution of
{2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indol-6-yl}-methanol (0.61
g, 2.21 mmol) in DMSO (10 mL). After 30 min, the reaction mixture
became a clear solution. Stirring was continued at room temperature
for 2 hours and during this time, some solid precipitated. Water
(50 mL) was added, the solid was filtered, and washed with ethyl
acetate (50 mL). The filtrate was collected and extracted with
ethyl acetate (3.times.20 mL). The organic phase was washed with
brine (30 mL) and dried over anhydrous MgSO.sub.4. Removal of
solvent gave
2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indole-6-carbaldehyde as a
light brown solid. Yield: 0.60 g (99%).
[0731] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.48 g,
2.42 mmol) and
2-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-indole-6-carbaldehyde (0.60
g, 2.20 mmol) in N,N-dimethylacetamide (20 mL) were added
NaHSO.sub.3 (58.5 wt %, 0.60 g, 3.30 mmol) and p-toluenesulfonic
acid monohydrate (0.17 g, 0.88 mmol). The reaction mixture was
heated at 110.degree. C. for 20 hours and then cooled to room
temperature. N,N-dimethylacetamide was removed under reduced
pressure. The residue was diluted with saturated sodium carbonate
solution (50 mL) and extracted with dichloromethane (4.times.25
mL). The combined organic phase was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was removed and the
crude product was purified by column chromatography (silica gel
230-400 mesh; 7% methanol in dichloromethane as eluent). Yield:
0.45 g (56%). The compound was further purified by preparative HPLC
to give the title compound as an off-white solid. Yield: 123 mg.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.89 (s, 1H), 11.25
(s, 1H), 8.18 (s, 1H), 7.82 (d, J=8.40 Hz, 1H), 7.50 (d, J=8.40 Hz,
1H), 6.73 (d, J=2.4 Hz, 1H), 6.49 (d, J=2.0 Hz, 1H), 6.27 (s, 1H),
4.80 (t, J=5.2 Hz, 1H), 3.90 (s, 3H), 3.85 (s, 3H), 3.78-3.73 (m,
2H), 2.92 (t, J=7.2 Hz, 2H). MS (ES+) m/z 366.54 (100%, M+1).
Example 59. Quantification of hIL-6 mRNA
[0732] In this example, hIL-6 mRNA in tissue culture cells was
quantitated to measure the transcriptional inhibition of hIL-6 when
treated with a compound of the invention.
[0733] A human leukemic monocytic lymphoma cell line (U937) was
plated (3.2.times.10.sup.5 cells per well) in a 96-well plate in
100 .mu.L RPMI 1640+10% FBS, and differentiated into macrophages
with PMA (60 ng/mL) for 3 days prior to the addition of the
compound of interest. The cells were pretreated for 1 h with the
test compound in DMSO prior to stimulation with lipopolysaccharide
from Escherichia coli at 1 .mu.g/mL. The cells were incubated for 3
h before harvest. At the time of harvest, cells were rinsed in 200
.mu.L PBS. Cell lysis solution (70 .mu.L) was added the cells for
10 min, and mRNA was then prepared using the "mRNA Catcher PLUS
plate" (Invitrogen), according to the protocol supplied.
[0734] The eluted mRNA isolated was then used in a one-step
quantitative real-time PCR reaction, using components of the
UltraSense kit together with Applied Biosystems primer-probe mixes.
10 .mu.L of template was amplified with 1.75 .mu.L of IL-6
primer-probe, and 1 .mu.L of hCyclophilin primer probe, and the
reaction was carried out in multiplex. Real-time PCR data was
analyzed, normalizing the Ct values for hIL-6 to hCyclophilin,
prior to determining the fold induction of each unknown sample,
relative to the control.
[0735] In Table 2, an active compound is one that causes a
.gtoreq.20% inhibition in IL-6 mRNA at a concentration less than or
equal to 10 .mu.M.
TABLE-US-00002 TABLE 2 Inhibition of Example IL-6 expression 1
Active 2 Active 3 Active 4 Active 5 Active 6 Active 7 Active 8
Active 9 Active 10 Active 11 Active 12 Active 13 Active 14 Active
15 Active 16 Active 17 Active 18 Active 19 Active 20 Active 21
Active 22 Active 23 Active 24 Active 25 Active 26 Active 27 Active
28 Active 29 Active 30 Active 31 Active 32 Active 33 Active 34
Active 35 Active 36 Active 37 Active 38 Active 39 Active 40 Active
41 Active 42 Active 43 Active 44 Active 45 Active 46 Active 47
Active 48 Active 49 Active 50 Active 51 Active 52 Active 53 Active
54 Active 55 Active 56 Active 57 Active 58 Active
Example 60. Quantification of hVCAM-1 mRNA
[0736] In this example, hVCAM-1 mRNA in tissue culture cells was
quantitated to measure the transcriptional inhibition of hVCAM when
treated with a compound of the invention.
[0737] A human umbilical vein endothelial cell line (HUV-EC-C) was
plated in a 96-well plate (5.0.times.10.sup.3 cells/well) in 100
.mu.L EGM complete media and incubated for 24 h prior to the
addition of the compound of interest. The cells were pretreated for
1 h with the test compound in DMSO prior to stimulation with tumor
necrosis factor-.alpha. (10 ng/mL). The cells were incubated for an
additional 24 h before harvest. At time of harvest, the cells were
rinsed in 200 .mu.L PBS, and cell lysis solution (70 .mu.L) was
then added the cells for 10 min. mRNA was then prepared using the
"mRNA Catcher PLUS plate" (Invitrogen), according to the protocol
supplied.
[0738] The eluted mRNA was then used in a one-step quantitative
real-time PCR reaction, using components of the UltraSense kit
together with Applied Biosystems primer-probe mixes. 10 .mu.L of
template was amplified with 1.75 .mu.L of hVCAM-1 primer-probe, and
1 .mu.L of hCyclophilin primer probe, and the reaction was carried
out in multiplex. Real-time PCR data was analyzed, normalizing the
Ct values for hVCAM-1 to hCyclophilin, prior to determining the
fold induction of each unknown sample, relative to the control.
[0739] In Table 3, an active compound is one that causes a 20%
inhibition in VCAM-1 mRNA at a concentration less than or equal to
10 .mu.M.
TABLE-US-00003 TABLE 3 Inhibition of Example VCAM-1 expression 3
Active 4 Active 5 Active 7 Active 9 Active 10 Active 15 Inactive 17
Inactive 18 Active 20 Active 21 Inactive 22 Active 23 Active 25
Active 26 Active 28 Active 29 Active 30 Inactive 31 Active 32
Active 33 Active 34 Active 35 Active 36 Active 37 Inactive 38
Active 39 Active 40 Active 42 Active 44 Active 47 Active 51 Active
58 Active
* * * * *